EVI1 in Acute Myeloid Leukemia by Lugthart, S. (Sanne)
Sanne Lugthart
E
VI1 in A
cute M
yelo
id L
eukem
ia      S
anne L
ugthart
test
EVI1 in Acute Myeloid Leukemia
EVI1 in Acute Myeloid Leukemia
Sanne Lugthart
EVI1 in Acute Myeloid Leukemia
Copyright © 2010 Sanne Lugthart, Rotterdam, Th e Netherlands.
No part of this thesis may be reproduced, stored in a retrieval system or transmitted in 
any form or by any means without permission from the author or, when appropriate, 
from the publishers of the publications.
ISBN: 978-90-8559-096-5
Cover design: Sanne Lugthart
Layout: Egied Simons
Printing: Optima Grafi sche Communicatie, Rotterdam
Th e work described in this thesis was performed at the Department of Hematology of 
Erasmus University Medical Center, Rotterdam, Th e Netherlands. Th is work was funded 
by ZonMW and European Hematology Association.
Printing of this thesis was fi nancially supported by Merck Sharp & Dome B.V., Janssen-
Cilag, Greiner Bio-One, Celgene, Novartis Oncology, Skyline Diagnostics and Erasmus 
MC University.
EVI1 in Acute Myeloid Leukemia
EVI1 in Acute Myeloïde Leukemie
Proefschrift 
Ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam 
 
op gezag van de rector magnifi cus Prof.dr. H.G. Schmidt
en volgens besluit van het College voor Promoties
De openbare verdediging zal plaatsvinden op
woensdag 22 september 2010 om 9:30 uur
door
Sanne Lugthart
geboren te Rotterdam
PROMOTIECOMMISSIE
Promotor(en):  Prof.dr. B. Löwenberg
   Prof.dr. H.R. Delwel
Overige leden:  Prof.dr. R. Pieters
   Prof.dr. J.A. Foekens
   Prof.dr. R. Fodde
Aan mijn ouders
 
 EVI1 IN ACUTE MYELOID LEUKEMIA 
CONTENTS
1 General introduction 8
Part I
2 Clinical, molecular, and prognostic signifi cance of WHO type inv(3)
(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute 
myeloid leukemia: A study of 6,500 cases of AML
32
Part II
3 High EVI1 levels predict adverse outcome in acute myeloid leukemia; 
revalence of EVI1 overexpression and chromosome 3q26 abnormalities 
underestimated
54
4 EVI1 overexpression in distinct subtypes of pediatric acute myeloid 
leukemia
76
5 High EVI1 expression predicts outcome in younger adult patients with 
acute myeloid leukemia and is associated with distinct cytogenetic 
abnormalities
98
Part III
6 EVI1 positive and EVI1 negative MLL-AF9 rearranged acute myeloid 
leukemias diff er clinically, molecularly, phenotypically and mechanis-
tically
118
Part IV
7 DNA methylation signatures identify biologically distinct subtypes in  
acute myeloid leukemia
146
8 Aberrant DNA hypermethylation signature in acute myeloid leukemia 
directed by EVI1
174
9 Summary and general discussion 198
Nederlandse samenvatting 217
Dankwoord 219
Curriculum vitae 221 
Publications 223
Abbreviations 225
PhD Portfolio 227
Color section 229
CHAPTER1
General introduction

11
Chapter 1
NORMAL HEMATOPOIESIS
Hematopoiesis comes from the greek words for blood (haima) and formation (poiesis). All 
blood cells are derived from haematopoietic stem cells (HSCs), which are at the basis of the 
adult blood cell diff erentiation hierarchy (Figure 1) and provide continuous hematopoeitic 
cell production throughout life(1).
During embryonic development blood cells are fi rst found in the yolk sac and its vasculature. 
Th e HSCs are produced by the aorta-gonad-mesonephros region and yolk sac and placenta 
from where they migrate to the fetal liver, where these cells further expand. Hereaft er, HSCs 
transfer to the bone marrow from where they reside throughout adulthood(1).
Th e HSCs have self-renewal capacity: when HSCs proliferate, at least some of their daughter 
cells remain as HSCs, so the pool of stem cells does not become depleted(2). Th e HSCs are 
pluripotent: they generate progenitor cells or other daughters of HSCs, i.e., myeloid and 
lymphoid progenitor cells, respectively CMPs(3) and CLPs(4), which each can commit to the 
distinct diff erentiation pathways that lead to the production of one or more specifi c blood cell 
types(5). Th ese progenitor cells cannot self-renew, but proliferate and diff erentiate eventually 
to mature blood cells e.g., granulocytes, monocytes, platelets, B- and T-cells, which then enter 
the blood circulation to fulfi ll their function(6). Due to the short life span of the mature cells, 
this cell production process is continuous and tightly regulated by various growth factors(2). 
For instance, a growth stimulus that is important for proliferation and self-renewal of HSCs 
is stem cell factor (SCF). Among other factors, granulocyte-macrophage CSF (GM-CSF), 
granulocyte CSF (G-CSF) and macrophage CSF (M-CSF) stimulate the production of com-
mitted progenitors (Figure 1). Moreover, these latter factors are also important activators of 
functional blood cell formation.
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Figure 1. Hematopoeisis Diagram. 
Th is diagram is originally derived from Reya et al.(2) It shows the development of haematopoietic stem cells (HSC). 
HSCs can be subdivided into long-term selfrenewing HSCs, short-term selfrenewing HSCs and multipotent pro-
genitors. Th ey give rise to common myeloid or lymphoid progenitor (respectively, CMP and CLP). Additionally, a 
selection of growth factors important for diff erentiation are added to each corresponding lineage. GMP; granulocytic 
myeloid progenitor, MEP; megakaryocyte erythrocyte precursor, ErP; erythrocyte precursor, MkP; megakaryocyte 
precursor, NK; natural killer, IL-3/6/7; interleukine 3/6/7, EPO; erythropoietin.
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ACUTE MYELOID LEUKEMIA
AML is characterized by accumulation of immature myeloid cells, which are impaired in their 
ability to diff erentiate towards granulocytes or monocytes(7). Th ese myeloid malignancies 
are heterogenous clonal disorders, with variable underlying genetic, epigenetic, molecular 
abnormalities and with diff erent clinical responses to therapy. 
Incidence
AML is among the most common malignant myeloid disorders in adults. Th e prevalence of 
AML is 3.8 cases per 100,000 individuals and increases with age, i.e., 17.9 cases per 100,000 
adults aged 65 years and older(8). From 2002-2006, the median age at diagnosis for AML 
was 67 years of age. In children, AML comprises about 20% of the acute leukemias. Th e age 
specifi c incidence is in sharp contrast with adults and peaks with 11 cases per million at the 
age of 2 years, and decreases to 7 cases per million throughout the remainder of childhood 
and adolescence(9).
Diagnosis and Classifi cation
Th e primary diagnosis of AML rests on the morphologic identifi cation of leukemic myelo-
blasts in peripheral bone marrow and/or blood. At a morphologic level, the heterogeneity of 
AML is manifested by variability in the degree of  diff erentiation of the cell lineage. AML has 
classically been categorized using the French–American–British (FAB) system(10), which is 
based on cytomorphology and cytochemistry. A recently updated classifi cation model gener-
ated by the World Health Organization (WHO) in 2008, incorporates besides morphology, 
also cytogenetic and molecular data(11, 12). For the diagnosis of AML, a marrow blast count 
of over 20% is required, except for recurrent balanced chromosomal abnormalities t(15;17), 
inv(16) or t(16;16), t(8;21) and some cases of erythroleukemia(11). To identify lineage 
involvement cytochemistry and/or immunophenotyping is used. In case conventional cyto-
genetics is complicated, fl uorescence in situ hybridization (FISH) and molecular diagnostic 
work-up may be needed to classify an AML patient into one of the fi ve subtypes as designated 
by the WHO(11) (Table 1). 
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Table 1: WHO classifi cation of Acute myeloid leukemia (WHO 2008)#.
Acu 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
APL with t(15;17)(q22;q12); PML-RARA
AML with t(9;11)(p22;q23); MLLT3-MLL
AML with t(6;9)(p23;q34); DEK-NUP214
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1
Provisional entity: AML with mutated NPM1
Provisional entity: AML with mutated CEBPA
Acute myeloid leukemia with myelodysplasia-related changes*
>20% blood/marrow blasts AND history of myelodysplastic syndrome, or myelodysplastic/
myeloproliferative neoplasm; myelodysplasia-related cytogenetic abnormality; multilineage 
dysplasia; AND absence of both prior cytotoxic therapy for unrelated disease and recurring genetic 
abnormalities.
Th erapy-related myeloid neoplasms
Cytotoxic agents implicated in therapy-related hematologic neoplasms: alkylating agents; ionizing 
radiation therapy; topoisomerase II inhibitors; others.
Acute myeloid leukemia, not otherwise specifi ed (NOS)
Acute myeloid leukemia with minimal diff erentiation
Acute myeloid leukemia without maturation
Acute myeloid leukemia with maturation
Acute myelomonocytic leukemia
Acute monoblastic/monocytic leukemia
Acute erythroid leukemia
Pure erythroid leukemia
Erythroleukemia, erythroid/myeloid
Acute megakaryoblastic leukemia
Acute basophilic leukemia
Acute panmyelosis with myelofi brosis (syn.: acute myelofi brosis; acute myelosclerosis)
Acute leukemias of ambiguous lineage
Acute undiff erentiated leukemia
Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1
Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged
Mixed phenotype acute leukemia, B/myeloid, NOS
Mixed phenotype acute leukemia, T/myeloid, NOS
Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymphoma
15
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# Adapted from Swerdlow et al.(11) and Döhner et al.(13).
* Cytogenetic abnormalities suffi  cient to diagnose AML with myelodysplasia-related changes are: 
- complex karyotype (defi ned as 3 or more chromosomal abnormalities)
- unbalanced changes: -7 or del(7q); -5 or del(5q); i(17q) or t(17p); -13 or del(13q); del(11q); del(12p) or 
t(12p); del(9q); idic(X)(q13); 
- balanced changes: t(11;16)(q23;p13.3); t(3;21)(q26.2;q22.1); t(1;3)(p36.3;q21.1); t(2;11)(p21;q23); 
t(5;12)(q33;p12); t(5;7)(q33;q11.2); t(5;17)(q33;p13); t(5;10)(q33;q21); t(3;5)(q25;q34)
Th e subgroup “AML with recurrent genetic abnormalities” comprises several primary AML 
entities, i.e., inv(16)(p13.1q22) or t(16;16)(p13;q22), t(8;21)(q22;q22), t(15;17)(q22;q12) and 
t(9;11)(p22;q21). Th ree new cytogenetically defi ned entities have recently been  incorporated, 
i.e., t(6;9)(p23;q34): DEK-NEP214; inv(3)(q21.q26.2) or t(3;3)(q21;q26.2): RPN1-EVI1 and 
t(1;22)(p13;q13): RBM15-MKL1. Foremost, two new entities defi ned by the presence of gene 
mutations were added(13); nucloephosmin (NPM1) and CCAAT/enhancer binding protein 
alpha (CEBPA) (Table 1). Th ese latter two subtypes are among AML patients without any 
recurrent chromosomal abnormality, the cytogenetically normal AML (CN-AML). Th e 
prevalence of recurrent chromosomal aberrations in AML are shown in Figure 2.
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Figure 2. Distribution of Chromosomal Abnormalities in AML. 
Th e percentage of chromosomal abnormalities of 458 AML patients younger than 60 years of age derived from 
various HOVON (the Haemato Oncology Foundation for Adults in the Netherlands) trails studied by 
Gröschel et al.(14), are shown.
Prognosis
Th e treatment response of a patient with AML depends on A) prognostic factors associated 
with treatment-related death; which can be predicted using the performing status(15) (Zu-
brod scale) and B) prognostic factors associated with resistance to therapy; here pre-treatment 
cytogenetic and molecular fi ndings in leukemic blast are the most important predictors(8). 
Around 57% of the AML cases have cytogenetic abnormalities at diagnosis, leaving 43% of 
the leukemias with no cytogenetic abnormalities (CN-AML) (Figure 2). Together with recur-
rent molecular abnormalities (Table 2), response to treatment can be predicted i.e., favorable, 
intermediate or unfavorable risk(13) (Table 3). However, as more studies evolved many 
genetic abnormalities e.g., in NPM1(16-18), EVI1(19) (ecotropic viral integration site 1) 
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or BAALC(20) (brain and acute leukemia gene, cytoplasmic) were identifi ed, each cor-
responding with diff erent survival outcomes(16, 21, 22). Th us, risk classifi cation is changing 
almost on a continuing basis, e.g., recently researchers identifi ed that a monosomal karyotype 
(one or more monosomies and a structural abnormality) had a dismal outcome, more than 
complex karyotype(23). Th e focus of this thesis is on the AML cases in the unfavorable risk 
group highly expressing EVI1 caused by chromosomal abnormalities i.e., inv(3)(q21q26.2) or 
t(3;3)(q21;q26.2) or caused by unknown mechanisms(19).
Table 2: Molecular abnormalities in AML.
AML subgroup Molecular genetic defect#  Prognostic importance Prevalence Reference§
t(8;21)  KIT exon 8 or D816 mutation inferior OS and EFS 2-11% (25, 26)
 FLT3-ITD or D835 mutation  unclear 8% (25, 26)
inv(16)/t(16;16)  KIT exon 8 or D816 mutation inferior OS and RR 8-25% (25-27)
 FLT3-ITD or D835 mutation  unclear 8% (25, 27)
 NRAS mutation  no signifi cant impact 18-26% (27-29)
 KRAS mutation  no signifi cant impact 9-17% (27-29)
CN-AML  FLT3-TKD no signifi cant impact 11-14% (30, 31)
 FLT3-ITD  inferior OS, EFS, DFS, CR rate 28-34% (22, 31-33)
 NPM1 mutation  
no eff ect CR rate, OS, EFS, RFS; 
higher CR rate, longer EFS
48-64% (33-35)
 NPM1 mutant/FLT3-ITD negative longer OS, RFS, DFS, CR rate 48-64% (18, 30)
 CEBPA mutation  longer OS, DFS 10-15% (22, 36)
   double CEBPA mutation longer OS, EFS, DFS 10% (37)
   single CEBPA mutation no signifi cant impact 3% (37)
 MLL1 PTD  OS, EFS, RFS, CR rate 8-11% (38-40)
 NRAS mutation  no signifi cant impact 14% (29)
 KRAS mutation  no signifi cant impact 4% (29)
WT1 mutation inferior OS and DFS 10% (41)
IDH1 mutation unclear 16% (42)
GE↑ BAALC
inferior OS, EFS, DFS, 
CR rate, CIR
† (22, 43)
EVI1* inferior OS, EFS and DFS 10% (20)
MN1 inferior OS, RFS, RR † (44, 45)
ERG inferior OS and CIR † (46, 47)
OS; overall survival, EFS; event-free survival, DFS; disease-free survival, RFS; relapse-free survival, CR; 
complete remission, CIR; cumulative incidence of relapse, CN-AML; normal katyotype, GE; gene overexpression.
#  A complete list of all abbreviations is listed at the Abbreviation Section on page 225.
§   Only a selection of articles is cited per molecular abnormality.
†  Prevalence not determined, since gene expression levels were dichotomized using different criteria; 
*  Intermediate cytogenetic risk subgroup.
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Table 3: Cytogenetic risk groups in AML*.
Favorable
t(8;21)(q22;q22); RUNX1-RUNX1T1
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
Mutated NPM1 without FLT3-ITD (normal karyotype)
Mutated CEBPA (normal karyotype)
Intermediate
t(9;11)(p22;q23); MLLT3-MLL
-Y; del(7q); +8; del(9q); +11; +13; del(20q); +21**
Occurring as sole abnormality, or within a non-complex karyotype
Mutated NPM1 and FLT3-ITD (normal karyotype#)
Wild type NPM1 and FLT3-ITD (normal karyotype#)
Wild type NPM1 without FLT3-ITD (normal karyotype#)
Adverse
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
t(6;9)(p23;q34); DEK-NUP214
t(v;11q23); MLL rearranged
-5 or del(5q); -7; abnl(17p); complex karyotype‡
* Based on Dohner et al.(15); highlighted in gray are the latest molecular criteria..
** Occurring as sole abnormality, or within a non-complex karyotype
# Includes all AMLs with normal karyotype except for those included in the favorable subgroup; most of these 
cases are associated with poor prognosis.
‡ Th ree or more chromosome abnormalities in the absence of one of the WHO designated recurring transloca-
tions or inversions.
Th erapy
AML therapy consists of two phases; induction phase to achieve complete remission and 
consolidation phase, which aims to maintain complete remission and prevent relapse. For 
the past decades, the backbone of induction therapy has been the use of anthracyclines (dau-
norubicin and cytarabine). Patients between 18 and 60 years have three treatment options 
based on their risk classifi cation, response to treatment and donor availability; an allogeneic 
hematopoietic stem cell transplant (allo-SCT) from an HLA-matched donor, an autologous 
SCT (auto-SCT) or chemotherapy(7, 8).
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AML SUBTYPES STUDIED USING NOVEL TECHNIQUES 
New techniques have begun to revolutionize diagnosis, prognosis and classifi cations of 
leukemias. Th e conventional cytogenetics e.g., G-banding is being completed by FISH 
analysis, allowing rapid testing for specifi c chromosomal translocations in metaphase and 
interphase cells. SKY (spectral karyotyping) uses 24 diff erent fl uorescently labeled chromo-
some painting probes to generate automated color display of all chromosomes. Both FISH 
and SKY techniques enhance accuracy and sensitivity of cytogenetic analysis(50). A more 
dense genome-wide technique is array comparative genomic hybridization (Array-CGH), a 
technique that can identify regions of genomic deletions or amplifi cations and subsequently 
disease genes at these loci. Where FISH and SKY are techniques that are being applied on a 
more or less routine basis, Array-CGH is a technology in progress that will most likely enter 
laboratory routine in the upcoming years. 
Over the years, real-time quantitative PCR (Q-PCR) has been used to determine RNA ex-
pression on a gene-by-gene basis, which could have an impact on classifi cation or prognosis 
of diff erent AML subtypes. Molecular diagnosis by Q-PCR for recurring gene fusions, such 
as CBFB-MYH11 (inv(16)/t(16;16)), MLLT3-MLL (t(9;11)) and AML1-ETO (t(8;21)) is being 
applied as a standard diagnostic work-up for AML patients by many laboratories. Th is method 
of detecting cytogenetic rearrangements is especially an option if chromosome morphology 
by standard cytogenetics is of poor quality, or if there is typical bone marrow morphology, 
but the suspected cytogenetic abnormality is not present(13). Classical examples are FAB M4 
AMLs with an inv(16)/t(16;16). Another application for Q-PCR is minimal residual disease 
monitoring which is based on amplifi cation and quantifi cation of disease specifi c fusion 
genes that predict relapse(51). 
Genome-wide approaches, in particular DNA microarray analysis for gene expression 
profi ling (GEP) can delineate AML versus ALL samples based solely on patterns of gene 
expression(52). Within AML known and unknown subtypes with various survival outcomes 
could be identifi ed based on gene expression profi les(53, 54). Molecular subtypes of AML 
could also be predicted using GEP(55). Furthermore, within small subtypes of AML e.g., 
CEBPA mutant AML cases, subgroups could be identifi ed based on diff erences in GEPs(56). 
Th is indicates that, GEP is a valuable tool for classifi cation, subtype discovery, and prediction 
of outcome(57).
More recently, epigenetic analysis by genome-wide methylation profi ling using the HELP 
assay(58) showed that AML and ALL patients could be segregated based on diff erences in 
methylation levels of promoters of a large set of genes(59). Whether these innovative ap-
proaches will be of value for the diagnosis, classifi cation and outcome prediction in AML 
requires further study and is one of the purposes of this thesis.
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LEUKEMIC DISEASE MECHANISMS 
One single mutation is in general believed to be insuffi  cient to cause acute leukemia. Th ere are 
diff erent types of mutations which have been reported to cooperate in leukemogenesis(60). 
Particularly, in the core binding factor (CBF) leukemias, i.e., with inv(16)/t(16;16) or t(8;21) 
chromosomal abnormalities, class I and class II type mutations are frequently discerned. 
Class I mutations are the ones that cause aberrant activation of signal transduction pathways 
resulting in enhanced proliferation and/or survival of leukemia progenitor cells. Among 
these aberrations are mutations leading to activation of the receptor tyrosine kinase FLT3 
and c-KIT or defective RAS signaling. Th e second group, class II mutations, aff ect transcrip-
tion factors or components of the transcriptional co-activation complex(8, 60). Th ese muta-
tions result in impaired diff erentiation and/or aberrant acquisition of self-renewal properties 
by hematopoietic progenitors, i.e., recurrent gene fusions resulting from inv(16)/t(16;16), 
t(8;21), t(15;17), respectively CBFB-MYH11, RUNX-RUNX1T and PML-RARA, as well as 
mutations in CEBPA and MLL and possibly NPM1(8). AML might develop when both muta-
tion classes are present, which is supported by the fi nding that class I and II lesions occur 
together more commonly than each separately(8). Whether this view holds for every type of 
human AML is disputable. 
Th e above mentioned AML subtypes mostly belong to the “favorable risk” leukemias, sug-
gesting that particularly in those subtypes the two-class dogma is representative. In other 
AMLs, in particular the leukemias with a poor treatment response other mechanisms may be 
operational. For instance, the role of epigenetic factors in certain forms of cancer is evident 
and whether these abnormalities fi t into this two class model is not clear. Various tumor 
suppressor genes have been reported to be hypermethylated and therefore silenced in AML. 
One could argue that this permanent hypermethylation is functionally equivalent to a genetic 
mutation(8). As an example, a group of patients has recently been identifi ed with hypermeth-
ylation of the promoter of CEBPA. Based on gene expression profi ling analysis it was evident 
that these cases were highly similar to cases that carried CEBPA mutations(56). Clinically 
however, CEBPA-silenced leukemias behaved diff erently from CEBPA-mutant leukemias. 
Th e latter group appeared to have a favorable response to treatment, whereas this was not 
evidently observed in the CEBPA-hypermethylated group of patients(36). 
MOLECULAR TARGETS TO TACKLE AML
Th e increased knowledge of the genetic and molecular pathogenesis in AML has led to the 
development of molecular targeted therapeutic approaches, using compounds interfering 
with the specifi c function of these abnormalities. 
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Acute promyelocytic leukemia (APL) is associated with t(15;17)(q22;q12) giving rise to the 
PML-RARA fusion. APL is a unique leukemia according to its molecular biology and its sen-
sitivity to all-trans retinoic acid (ATRA), a derivative of vitamin A(61) and arsenic trioxide 
(REF) . Treatment with ATRA causes diff erentiation of the immature leukemic promyelocytes 
into mature granulocytes, thereby restoring normal transcriptional diff erentiation programs. 
ATRA is typically combined with anthracycline based chemotherapy resulting in a clinical 
remission in approximately 90% of patients. Th e exquisite sensitivity of APL to ATRA is a 
successful example of targeted treatment of a specifi c molecularly defi ned subtype of AML 
(13, 61).
Risk adjusted therapeutic strategies and algorithms are also being developed. Th is is done 
according to molecular, cytogenetic and epigenetic abnormalities, mainly in AML subtypes 
that express prognostic signifi cance in AML. For instance cytogenetic data have been fi rmly 
established to predicty treatment outcome. For instance core binding factor abnormalities 
may stratify AML as good risk or lack of cytogenetic abnormalities as intermediate risk. Vari-
ous new molecular biomarkers have been discovered that add to the ability of identifi cation 
of prognostic subtypes of AML. Th is thesis focuses on the AML subgroup highly expressing 
EVI1.
EVI1 AS A MULTIFUNTIONAL TRANSCRIPTIONAL REGULATOR IN NORMAL 
AND MALIGNANT HEMATOPOEISIS
Introduction to EVI1
Th e EVI1 gene (ecotopic viral integration site-1) is localized on human chromosome 3q26.2 
and was originally identifi ed as a common retroviral integration site in murine myeloid 
tumors(64). Th e human gene spans about 100 kb and contains 16 exons with several alterna-
tively spliced transcripts. As an example, a number of fi rst exons for EVI1 has been reported, 
which all splice to exon 2 of EVI1, i.e., 1A, -1B, -1C and 1D (Figure 3A). EVI1 exists also as 
a longer form, called MDS1/EVI1, generated from the in-frame splicing of the small gene 
myelodysplasia syndrome 1 (MDS1) to the second exon of EVI 1(65) (Figure 3A). 
EVI1 is a relatively large protein with an apparent molecular mass of about 145 kDa. EVI1 
contains two zinc fi nger domains, a proximal domain with seven zinc fi ngers and a distal 
domain with three zinc fi ngers. Between the two zinc fi nger domains a repression domain is 
located and a acidic region is at the C-terminus of the protein (Figure 3B)(66).
Th e EVI1 gene encodes a nuclear putative transcriptional regulator and DNA interactions are 
coordinated through the two zinc fi nger domains(67). Multiple functional properties have 
been reported: (1) interaction with CtBP (C-terminal binding protein) and consequently 
acting as a repressor complex for transcription(67, 68); (2) regulation of and interference 
with transcription factors (GATA-2, GATA-1, Pu.1) critical for hematopoiesis and myeloid 
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homeostasis(69-71); (3) interaction with TGF-β-, JNK-, and PI3K-pathways(72-75); (4) and 
interaction with molecules implicated in genomic stability surveillance, through Sox4 by sta-
bilization of the tumor suppressor gene TP53(76, 77). Th e EVI1 interacting proteins and their 
eff ect on cell function are shown in Figure 3B. Recent reports, show that EVI1 also interacts 
with histone methyltransferases, i.e., histone H3 lysine 9-specifi c histone methyltransfer-
ases SUV39H1(78, 79), methyl-CpG binding domain 3(80) (MBD3) and several chromatin 
remodeling proteins(81) such as HDAC1(82), pointing out a role for EVI1 in epigenetic 
regulation of gene expression.Although many functions of EVI1 remain to be elucidated, this 
thesis discusses the function of EVI1, its role in leukemia and new perspective mechanisms.
MDS1 gene
16151412 136542
3
71D1C1B1A 8 9 10 11
3L
∆324 Rp9
EVI1 gene
4
2 3
1A
MDS1/EVI1
60 kb500 kb
ACRD
1st Znf  Domain 2st Znf  Domain
CtBPSmad3PU1GATA1
HDACHMTs
GATA2
HSC
expansion
Cell growth inhibition Cell
proliferation
Erythroid
differentiation Apoptosis
_ TGF- _ signaling _ AP-1 activity_ JNK activity
MBD3
SUV39
Epigentic  regulation
EVI1 protein
A
B
JNK
Myeloid
differentiation
Figure 3. Genomic structure and biochemical properties of EVI1. 
(A) Genomic structure of human EVI1, MDS1 and MDS1/EVI1 gene. Exons are represented by numbered boxes. Th e 
alternative splice variants are indicated by triangular lines. Th e picture is not drawn in scale. (B) EVI1 interacts with 
histone deacetylases (HDAC); HDAC1(74, 83) and HDAC2, histone methyltransferase (HMTs); H3-K9 methyltrans-
ferase SUV39H1(78, 79) (SUV39), methyl-CpG binding domain 3(80) (MBD3), thus through epigenetic regulation 
mediates transcriptional repression. EVI1 upregulates GATA-2 expression and promotes hematopoietic stem cell 
(HSC) expansion(71). EVI1 inhibits c-Jun N-terminal kinase (JNK) activity and prevents apoptosis(84). EVI1 also 
interacts with SMAD3(75, 85) and C-terminal binding protein(74) (CtBP) and through transforming growth fac-
tor(72) (TGF-β) blocks cell growth inhibition. Ac, acidic region; RD, repression domains, Znf; zinc-fi nger. 
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EVI1-related myeloid leukemias 
Th e evolutionarily conserved EVI1 gene has been implicated in a large number of human my-
eloid disorders. Th ere is no question that its inappropriate expression is a dominant cause of 
aggressive human leukemia(66). Over-expression of EVI1 (EVI1+) occurs in approximately 
8% of patients with de novo acute myeloid leukemia (AML)(19). In AML cases carrying 
chromosome inv(3)(q21q26.2) or t(3;3)(q21q26.2) abnormalities, aberrant EVI1 expression 
is caused by a breakpoint in or near the EVI1 locus, i.e., 3q26.2. High levels of EVI1 are 
also found in AML patients without any chromosomal rearrangements in this locus. In both 
groups EVI1 predicts for adverse treatment response. However, EVI1+AMLs without 3q26 
abnormalities represent an even larger and cytogenetically heterogeneous subset of AML(19). 
Accordingly, AMLs with 3q26 rearrangements i.e., inv(3)(q21q26.2) or t(3;3)(q21q26.2), 
oft en display dysplastic multilineage hemopoiesis suggestive of multipotent stem cell in-
volvement(86) and give rise to the 3q21q26 syndrome. Th is syndrome is characterized by 
normal to elevated platelet counts at diagnosis, hyperplasia with dysplasia of megakaryocytes, 
poor treatment response and adverse survival outcome(87). Recently, the 3q21q26 syndrome 
has been associated with diabetes insipidus and T-cell antigen expression(88, 89). Other 
translocation partners and 3q abnormalities are not well characterized and it is unknown if 
the 3q21q26 syndrome is part of a more general 3q syndrome.
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SCOPE OF THE THESIS
Th e work in this thesis focuses on the role of EVI1 in acute myeloid leukemia. Th e thesis 
presents work, which is divided in four parts. 
In the fi rst part of the thesis (chapter 2), we studied a large cohort of AML patients with vari-
ous chromosome 3q abnormalities and compared cytogenetic aberrations, molecular mark-
ers and clinical responses. We wished to investigate 1) whether AMLs with t(3;3)(q21;q26.2) 
or inv(3)(q21q26.2); RPN1-EVI1 are diff erent from AMLs with other chromosome 3q26 or 
3q21 abnormalities, what the role is of EVI1 in the diff erent subgroups of AML and how the 
distinct AMLs groups with 3q aberrations responded to therapy.
In the second part, we asked what the prevalence of diff erent EVI1 5’ splice variants is in a 
cohort of AMLs. Furthermore, we wondered what the prognostic impact is in EVI1 over-
expressing AML. Cytogenetic, molecular and clinical characteristics of the subgroup of AMLs 
with aberrant EVI1 expression were investigated in a large cohort of adult AML (chapter 3) as 
well as in pediatric AML patients (chapter 4). 
Th e large adverse clinical impact on survival of adult EVI1 AMLs, let us to design a new 
quantitative real-time PCR (Q-PCR), in which all fi ve known EVI1 splice variants could be 
measured. Th e aim of this diagnostic assay, which could be applied on a daily basis in the 
diagnostic work-up of AML patients, would be to further investigate the role of EVI1 and its 
eff ect on prognosis. Aft er testing this EVI1 Q-PCR on our previously analyzed adult AML 
cohort, we validated the assay on a larger independent AML patient group. Combining both 
cohorts, we further investigated the prognostic role, possible confounders and the eff ect on 
type of treatment in this poor-risk AML group (chapter 5). 
Th e third part of the thesis (chapter 6) centers on the elucidation of the function of EVI1 in 
a subgroup of AMLs without chromosome 3q26 abnormalities, i.e., AMLs carrying an 11q23 
rearrangement, generating MLL fusion genes. We particularly focused on human AML with 
a translocation t(9;11), giving rise to the MLL-AF9 fusion gene. We hypothesize that EVI1 is a 
target gene of MLL fusion protein. Th e functional correlation between 11q23 rearrangements 
and aberrant EVI1 expression was investigated. 
Lastly, we investigated the role of methylation in leukemogenesis in a genome-wide meth-
ylation study of a large representative cohort of AML patients. In this chapter we addressed 
the question if we could identify new AML subgroups that are clinically and prognostically 
relevant compared to recurrent molecular and cytogenetical abnormalities (chapter 7). Sub-
sequently, we focused on EVI1 AMLs and their methylation profi les in the following chapter. 
Th is study investigates the epigenetic role of EVI1 AMLs and the function that EVI1 may 
have in methylation is discussed (chapter 8).
Finally, the results outlined in this thesis are summarized and discussed in chapter 9. 
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ABSTRACT
Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) [inv(3)/t(3;3)] is 
recognized as a distinctive entity in the WHO classifi cation. Risk assignment, clinical, and 
genetic characterization of AML with chromosome 3q abnormalities other than inv(3)/t(3;3) 
remain largely unresolved. Cytogenetics, molecular genetics, therapy response, and outcome 
analysis were performed in 6,515 newly diagnosed adult AML patients. Patients were treated 
on Dutch-Belgian-Swiss HOVON/SAKK (n=3,501) and German-Austrian AMLSG protocols 
(n=3,014). EVI1 and MDS1/EVI1 expression was determined by real-time quantitative PCR. 
3q abnormalities were detected in 4.4% of AML cases (n=288/6,515). Four distinct groups 
were defi ned: (A) inv(3)/t(3;3) (32%); (B) balanced t(3q26) (18%); (C) balanced t(3q21) (7%); 
and (D) other 3q abnormalities (43%). Monosomy 7 was the most common additional aber-
ration in groups (A) 66%, (B) 31%, and (D) 37%. N-RAS mutations and dissociate EVI1 ver-
sus MDS1/EVI1 overexpression were associated with inv(3)/t(3;3). Patients with inv(3)/t(3;3) 
and balanced t(3q21) at diagnosis presented with higher white blood cell and platelet counts. 
In multivariable analysis, only inv(3)/t(3;3), but not t(3q26) and t(3q21), predicted reduced 
relapse-free survival (HR=2.0, P<0.0001) and overall survival (HR=1.4, P=0.006). Th is ad-
verse prognostic impact of inv(3)/t(3,3) was enhanced by additional monosomy 7. Group 
D 3q aberrant AML also had a very poor outcome, however, related to the co-existence of 
complex and/or monosomal karyotypes and cryptic inv(3)/t(3;3). Various categories of 3q 
abnormalities in AML can be distinguished according to their clinical, hematological, and 
genetic features. AML with inv(3)/t(3;3) represents a distinctive subgroup with unfavorable 
prognosis.
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INTRODUCTION 
Pretreatment cytogenetics is generally accepted as an important prognostic parameter in 
acute myeloid leukemia (AML) and is applied for risk stratifi cation of the disease(1-3). In 
the recent World Health Organization (WHO) classifi cation, AML with inv(3)(q21q26.2) 
or t(3;3)(q21;q26.2); RPN1-EVI1 [inv(3)/t(3;3)] has been incorporated as a new entity in the 
category “AML with recurrent genetic abnormalities”(4). AML with inv(3)/t(3;3) represents 
about 1-2% of AML(5, 6) and has been associated with characteristic morphologic features 
and poor outcome. Other balanced rearrangements involving bands 3q26.2 and 3q21 have 
been identifi ed that occur at even much lower frequencies. Clinico-biologic features and 
prognostic relevance of these abnormalities remain elusive(7). Two such rearrangements, 
i.e., t(1;3)(p36.3;q21.1) and t(3;21)(q26.2;q22.1), are currently grouped among those abnor-
malities suffi  cient to make the diagnosis “AML with myelodysplasia (MDS)-related changes”, 
although their clinical value remains unsettled(8-10). Th e same applies for other rare translo-
cations, such as t(2;3)(p15~23;q26.2)(11) and t(3;12)(q26.2;p13)(12Furthermore, there are a 
number of other balanced and unbalanced 3q abnormalities. Variable risk assignments have 
been proposed for such cases(13). Whereas some risk classifi cations considered any 3q ab-
normality as prognostically unfavorable, in the recent AML recommendations for diagnosis 
and management of AML, only inv(3)/t(3;3) was speci fi ed as unfavorable abnormality(1). 
Th e lack of numerically robust studies probably explains the contradictory fi ndings that have 
been reported about the prognostic value of 3q abnormalities(5-7, 14, 15).
Th e ecotropic viral integration site 1 (EVI1) gene maps to chromosomal band 3q26.2 and 
was fi rst identifi ed to be aberrantly upregulated in almost all AML with t(3;3)(q21;q26.2)
(16) or inv(3)(q21q26.2)(17). Aberrant EVI1 expression (EVI1+) is also found in a majority 
of AML with other 3q26 abnormalities(18-20). Th e association of EVI1 expression and 3q 
abnormalities other than 3q26 remains to be elucidated. Th e fusion gene MDS1/EVI1(21) 
is concurrently overexpressed in many EVI1+AML. In a recent study, we reported a dis-
proportionate pattern of elevated EVI1 and non-elevated MDS1/EVI1 expression in AML 
with inv(3)/t(3;3). High EVI1 expression and complete absence of MDS1/EVI1 expression 
occurred in more than half of these cases(19). Th e incidence and prognostic impact of other 
common molecular markers, e.g., NPM1 (nucleophosmin1) gene mutations and FLT3-ITD 
(internal tandem duplications of the Fms-like tyrosine-kinase-3 gene), across the spectrum 
of 3q aberrant AML remains to be exploredIn this study, we combined data from German-
Austrian AMLSG and Dutch-Belgian-Swiss HOVON/SAKK studies to gain insight into the 
clinical, genetic, and prognostic features of AML with inv(3)/t(3;3), other 3q21 and 3q26 
rearrangements, and remaining 3q abnormalities.
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PATIENTS AND METHODS
Patient samples
A total of 6,515 newly diagnosed AML, of whom complete cytogenetics were available, were 
included in this study; 3,501 patients (15-79 years) enrolled between 1987 and 2008 on Dutch-
Belgian Hemato-Oncology Cooperative Group/Swiss Group for Clinical Cancer Research 
(HOVON/SAKK) phase III trials HO04(A), -29, -42(A), and -43 (available at www.hovon.
nl)(22-25) and 3.014 patients (16-85 years) recruited between 1993 and 2008 on AMLSG 
treatment protocols HD93(26), HD98A/B(27, 28), 06-04 (ClinicalTrials.gov Identifi er 
NCT00151255), and 07-04 (ClinicalTrials.gov Identifi er NCT00151242). Patients with acute 
promyelocytic leukemia were not included. All patients provided written informed consent 
in accordance with the Declaration of Helsinki. All trials were approved by the Institutional 
Review Board of Erasmus University Medical Center and University of Ulm. Cytogenetic and 
molecular analyses are described in the Supplementary methods.
All Supplementary methods, supplementary results, tables and fi gures are not included, but are 
available online at http://jco.ascopubs.org/.
Classifi cation of 3q abnormalities
We defi ned a 3q rearrangement as any cytogenetic abnormality that involved the long arm of 
chromosome 3. AML with 3q abnormalities (n=288) were divided into four groups carrying (A) 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2) (n=94), (B) other balanced 3q26 rearrangements (n=52), 
(C) balanced 3q21 rearrangements (n=19), and (D) remaining 3q abnormalities (n=123).
Due to limitations of G-banding analysis, we included in group A also cases with inv(3)
(q21~q22q26.2) (n=1) or t(3;3)(q21~q22;q26.2) (n=2), in group B cases with balanced ab-
normalities of bands 3q25~3q27 (n=12), and in group C cases with balanced abnormalities 
of bands 3q21~3q22 (n=1). We considered a chromosomal abnormality as recurrent if it was 
present in two or more cases of AML.
Statistics and survival analysis
Patient and cytogenetic characteristics of the 3q groups (A, B, C, D; n=288) were compared 
to a non-3q reference group with abnormal cytogenetics (CA) (n=2,231; excluding core 
binding factor leukemias and isolated losses of gonosomes) using the Wilcoxon-rank-sum 
test (continuous variables) and the Fisher’s exact test (categorical variables). Th ere was no 
signifi cant diff erence in distribution of 3q aberrant AML among the clinical trials (Table S1).
Th e defi nition of complete remission (CR) and overall survival (OS), event-free survival 
(EFS), and relapse-free survival (RFS) endpoints was based on recommended criteria(1). 
Survival analyses were performed in patients aged 15 to 60 years. Medium follow-up time 
was calculated using the method of Korn(29). Univariable survival analysis was performed 
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using the Kaplan-Meier survival analysis and log-rank P value. Cox proportional hazard 
regression models(30) with stratifi cation to account for the two diff erent cohorts (AMLSG 
versus HOVON/SAKK) were used. Th e proportional hazard assumption was tested(31) and 
no indication of non-proportionality was found for the two cohorts. Variable selection was 
not performed and all variables were included in the full Cox regression models, i.e., age (per 
10 years); white blood count (WBC) (log10); platelet count (log10); type of AML(1) (de novo 
AML, secondary-AML [s-AML] or treatment-related AML [t-AML]), monosomy 7, complex 
karyotype, and monosomal karyotype(32). All statistical analyses were performed using SPSS 
15.0 for Windows (SPSS Inc. Chicago, IL, USA).
RESULTS
Frequency of 3q abnormalities and relationship with age
3q abnormalities were present in 288 of 6,515 (4.4%) cases (HOVON/SAKK cohort: 
146/3,501, 4.2% and AMLSG cohort: 142/3,014, 4.7%). Patients less than or equal to 60 years 
of age more frequently presented with 3q abnormalities (231/4,885, 4.7%) compared with 
patients older than 60 years of age (57/1,630, 3.5%).
Type of chromosome 3q abnormalities
Th e distribution of 3q abnormalities among groups A-D was as follows: Group A (n=94; 32%) 
included inv(3)(q21q26.2) (n=67) or t(3;3)(q21;q26.2) (n=27) (Figure 1A, Table S2); group 
B (n=52; 18%) included other balanced 3q26 rearrangements, such as t(2;3)(p15~23;q26.2), 
t(3;12)(q26.2;p13), t(3;21)(q26.2;q22.1) (Figure 1A, Table S3), or rearrangements of 3q26 
with chromosome 3 bands other than 3q21 (n=10); group C (n=19; 7%) included other 
balanced 3q21 rearrangements, such as t(1;3)(p36.3;q21.1) and t(3;5)(q21;q31) (Figure 1A, 
Table S4; distribution of recurrent translocations of group B and C see Figure S1); group 
D (n=123; 43%) where remaining 3q abnormalities, e.g.,, add(3q), del(3q), and ins(3) were 
included (Figure 1A, Table S5). Individual karyotypes are shown in Tables S2-S5.
Recurrent cytogenetic abnormalities coexistent with 3q abnormalities 
In AML with inv(3)/t(3;3), monosomy 7 was present in 62 of 94 (66%) cases; del(5q) (6%) 
and del(7q) (3%) were seen relatively infrequently, there was not a single case of monosomy 
5 (Table 1). Monosomy 7 was also frequently found among groups B (31%) and D (37%), but 
less commonly in group C (5%) (P<0.0001). Complex karyotypes were preferentially found 
in association with group D type 3q abnormalities (74%) and were considerably less frequent 
among groups A (21%), B (17%), C (26%), and the reference CA category (30%) (Table 1). So 
called monosomal karyotypes(32) were found in the majority of AML of groups A (68%) and 
D (72%), and they were considerably less frequent among AML with balanced t(3q26) (group 
B; 35%), balanced t(3q21) (group C; 16%), and the reference CA group (23%) (P<0.0001). 
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Figure 1. Distribution of cytogenetic characteristics and survival according to 3q aberrant AML groups. 
Distribution of 3q abnormalities (all ages, panel A) and overall survival (only 15-60 years of age, panel B) of 3q 
abnormal AML classifi ed as inv(3)/t(3;3) (group A), balanced t(3q26) (group B), balanced t(3q21) (group C), and 
remaining 3q abnormalities (group D). A corresponding log-rank P value per comparison to the non-3q cytogeneti-
cally abnormal (CA) reference group is shown.
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Molecular abnormalities in 3q abnormal AML 
In a subset of cases we had access to material to assess the distribution of various recurrent 
gene mutations (Table S6). Interestingly, AML with inv(3)/t(3;3) (28%) and AML with other 
t(3q26) (25%) frequently carried N-RAS mutations when compared with AML of groups C 
(0%), D (9%), and the reference CA group (7%). NPM1 mutations were detected at a low 
frequency in all 3q categories A-D between 0% and 8%. FLT3-ITD were observed in less than 
20% of cases in any of the four 3q groups and reference CA group (16%). Compared to the 
non-3q CA group (6%), FLT3-TKD (tyrosine kinase domain) mutations were apparent at 
similar frequencies in 3q groups A and D (7% and 8%), absent in group B, but more frequent 
in group C (18%). No MLL-partial tandem duplication (MLL-PTD), c-KIT, and CEBPA 
mutations were detected in any of the four 3q categories. 
Clinical characteristics of 3q abnormal AML
Th ere were no diff erences in gender, French-American-British (FAB) classifi cation, and type 
of AML (s-AML, t-AML or de novo AML) between the four 3q aberrant groups A-D and 
the non-3q reference group (Table 1). Patients in groups A and B were younger at diag-
nosis compared with the reference CA group. AML with inv(3)/t(3;3) (group A) as well as 
those with t(3q21) (group C) presented with 2-fold higher WBC (median 14.8x109/L and 
14.6x109/L, P<0.0001, P=0.54) and higher platelet counts (median 144x109/L and 117x109/L, 
P<0.00 01, P=0.001) compared with non-3q CA cases (Table 1, Figure S2).
Treatment outcome of 3q abnormal AML 
Analysis of treatment response and survival was restricted to patients between 15 and 60 years 
of age, i.e., group A-D and reference CA included 79, 49, 14, 91, and 1,572 cases, respectively. 
Th e median follow-up time for survival was 38.7 months. CR rates were considerably lower 
in patients of groups A (31%, P<0.0001), B (44%, P<0.008), and D (43%, P<0.0001) compared 
with the reference non-3q group (70%). 
Patients with inv(3)/t(3;3) (group A, n=79) had highly unfavorable 5-year survival rates (OS 
5.7%±3, P<0.0001; EFS 0%, P<0.0001; RFS 4.3%±4, P<0.0001) (Figure 1B, Figure S3, Table 1). 
Th ere was no diff erence in survival between patients with inv(3)(q21q26.2) (n=57) and t(3;3)
(q21;q26.2) (n=22) (Figure 2A). OS of patients with inv(3)/t(3;3) and additional monosomy 
7 was even worse compared with those not exhibiting monosomy 7 (P=0.008) (Figure 2B). 
Baseline clinical characteristics did not diff er between the latter subgroups; of note, EVI1 
expression levels were signifi cantly higher in cases with additional monosomy 7 (Table S7). 
AML with t(3q26) (group B) and t(3q21) (group C) had intermediate survival values not 
diff ering from the reference non-3q group, i.e., 5-year OS probabilities of 29.7%±7 (group B, 
P=0.72) and 39.5%±15 (group C, P=0.29) (Table 1, Figure 1B). Although t(3q21) as a group 
had an intermediate survival rate, patients with the most frequent t(1;3)(p36.3;q21.1) had 
very poor outcome (5-year OS, 17.1%±16) (Figure 2C, Table S8).
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AML of group D with various other 3q abnormalities were highly associated with complex 
and monosomal karyotypes and showed very poor 5-year survival values (OS 10.4%±4, EFS 
3%±2, RFS 9%±5).
In a multivariable Cox regression analysis, stratifying for the HOVON/SAKK and AMLSG 
cohorts, we set out to assess the prognostic impact of the four 3q categories in relation to 
other prognostic markers, i.e., age, WBC, platelet counts, s-AML, t-AML, complex karyotype, 
monosomal karyotype, and monosomy 7 (Table 2). Th is analysis revealed that 3q groups A, 
B, and D had independent negative prognostic impact on achievement of CR. With regard to 
survival endpoints, only inv(3)/t(3;3) was found to be an independent prognostic marker for 
OS (HR=1.4, P=0.006), EFS (HR=2.0, P<0.0001), and RFS (HR=2.0, P<0.0001). 
Inv(3)(q21q26.2) vs. t(3;3)(q21;q26.2)
Inv(3)/t(3;3), n=19, 15 events
Inv(3)/t(3;3), -7, n=38, 33 events
Inv(3)(q21q26.2), n=56, 49 events
t(3;3)(q21;q26.2), n=23, 20 events
Inv(3)/t(3;3) with monosomy 7 
vs. Inv(3)/t(3;3) sole
A B
t(3;12)(q26.2;p13), n=8; 5 events
t(1;3)(p36.3;q21.1), n=7; 6 events
t(2;3)(p15~23;q26.2), n=13; 9 events
t(3;21)(q26.2;q22.1), n=7; 2 events
Other recurrent 3q translocations
C
P=.99
non-3q CA reference, n=1572, 1062 events
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Figure 2. Surviva l of AML according to specifi c 3q26 and 3q21 rearrangements. 
Overall survival (panel A) for AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Overall survival (panel B) for 
inv(3)/t(3;3) cases with or without monosomy 7. Overall survival (panel C) for other recurrent 3q26 and 3q21 trans-
locations. A corresponding log-rank P value is shown.
EVI1 and MDS1/EVI1 expression in AML with 3q aberrations
EVI1 and MDS1/EVI1 expression levels are presented in Tables S2-S5, per individual patient 
for each 3q group. 
In group A, EVI1 was highly expressed in 95% (54/57, median expression 5.6) of cases (Table 
3, Figure S5A); measurable levels of MDS1/EVI1 expression were found in 50% (23/46) of 
cases (median expression 0.11) (Table 3, Figure S5B). Pairwise comparison of EVI1 and 
MDS1/EVI1 expression levels revealed that in the majority (40/46, 87%) of cases EVI1 ex-
pression was higher than MDS1/EVI1, i.e., a disproportionate ratio of EVI1 and MDS/EVI1 
transcript levels (Figure 3A).
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Figure 3. Pair-wise comparison of EVI1 and MDS1/EVI1 expression in inv(3)/t(3;3) cases and balanced 3q26 
translocations.
EVI1 and MDS1/EVI1 expression is shown for inv(3)/t(3;3) cases (panel A) and balanced t(3q26) abnormalities 
(panel B). Case 332_HO43 is not shown, due to high MDS1/EVI1 levels (i.e., 154).
Th e relative EVI1 and MDS1/EVI1 expression in the balanced t(3q26) AML (group B) showed 
a diff erent pattern (Figure 3B). In 85% of the cases in this group, EVI1 was highly expressed 
(23/27, median expression of 1.9), and in 57% MDS1/EVI1 expression was above threshold 
(13/25, median expression 0.99) (Table 3). In 12/25 cases of group B, the ratio of EVI1 and 
MDS/EVI1 was reverted with higher MDS1/EVI1 values than EVI1 levels. Only a small subset 
(32%, 8/25) of cases showed a disproportionate ratio of EVI1 and MDS/EVI1 transcript levels 
(Table S3, Figure 3B).
Th e balanced t(3q21) cases of group C infrequently expressed EVI1 (20% of cases) or MDS1/
EVI1 (11% of cases) (Table 3, Figure S5), suggesting that in those patients the RPN1 gene 
located at the 3q21 breakpoint had been translocated to other loci.
In group D, EVI1 expression was found to be high in 13/44 cases (30%), and 6/37 (16%) 
overexpressed MDS1/EVI1 (Table 3, Figure S5). Ten out of thirteen had disproportionate 
EVI1 versus MDS1/EVI1 ratios. Importantly, most of these EVI1 positive cases carried an 
abnormality involving chromosomal band 3q26 or 3q21, i.e., add(3)(q26) (n=1), del(3)(q25), 
or del(3)(q21q26) (n=1), add(3)(q21) (n=4), or del(3)(q21) (n=2) (Table S5), which were not 
found among the cases not expressing EVI1 and MDS1/EVI1 in group D. Th e disproportion-
ate EVI1 versus MDS1/EVI1 ratios suggest cryptic 3q abnormalities, thus we screened three 
of these group D cases [add(3)(q21), n=2; add(3)(q2?7), n=1] using the 3q FISH analysis and 
detected inv(3)(q21q26) in all of them.
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Table 3. Molecular characteristics of the four 3q aberrant AML categories
inv(3)/t(3;3) 
[A]
t(3q26)           
[B]
t(3q21)           
[C]
rest 3q               
[D]
Reference    
non-3q CA
P value#
EVI1
Positive, no. (%) 54 (95%) 23 (85%) 2 (20%) 13 (30%) 87 (17%) < 0.001
Median, Range 5.6 (0-52) 1.9 (0-78) 0.0 (0-5.4) 0.0 (0-16) 0.0 (0-43) < 0.001
   Analyzed 57 27 10 44 504
MDS1/EVI1
Positive, no. (%) 23 (50%) 13 (57%) 1 (11%) 6 (16%) 52 (13%) < 0.001
Median, Range 0.11 (0-9.2) 0.99 (0-154) 0.0 (0-4.2) 0.0 (0-15) 0.0 (0-95) < 0.001
   Analyzed 46 25 9 37 398
# P values were calculated using Wilcoxon-rank-sum test (continuous variables) and the Fisher’s exact test (categori-
cal variables). 
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DISCUSSION
In the current study, we assessed the clinical and genetic features as well as the prognostic 
impact of a large series of AML with chromosome 3q abnormalities (n=288) that were identi-
fi ed among 6,515 cases from the HOVON/SAKK and AMLSG study groups.
We provide further evidence that AML with inv(3)/t(3;3) (designated here as group A) are 
clinically, cytogenetically, and molecularly distinctive, supporting their incorporation as a 
new entity in the current WHO classifi cation. Inv(3)/t(3;3) was associated with younger age 
and higher platelet and WBC counts, and they presented with notably high frequencies of 
monosomy 7 (66%) and N-RAS mutations (28%). Of note, we were able to show that AML 
with inv(3)/t(3;3) and additional monosomy 7 had even worse survival than cases without 
monosomy 7 (Figure 2B). Th ese AML formally fulfi ll the defi nition of the notoriously unfa-
vorable monosomal karyotype(32). Among the four 3q groups, only inv(3)/t(3;3) was found 
to be an independent adverse predictor of overall survival.
AML with inv(3)/t(3;3) commonly expressed high EVI1 levels, whereas MDS1/EVI1 tran-
scripts were low or absent, which is in line with the observation that MDS1/EVI1 expression 
is abrogated, resulting from a breakpoint between the MDS1 and the EVI1 gene(18-20). Th is 
uniformity in the balance of EVI1 versus MDS1/EVI1 mRNA expression was not apparent in 
the other 3q groups.
AML with other t(3q26) (group B) were also associated with younger age, but unlike cases 
with classical inv(3)/t(3;3) did not present with elevated platelet counts. Th ey also had a 
relatively high frequency of additional monosomy 7 (31%), albeit somewhat lower compared 
with inv(3)/t(3;3) cases. In cases with t(3;12)(q26.2;p13) and t(3;21)(q26.2;q22.1), the EVI1 
locus is translocated to ETV6 and RUNX1, respectively(7, 20, 33). Th e high MDS1/EVI1 lev-
els in fi ve t(3;21) cases, but the complete absence of MDS1/EVI1 in two other t(3;21) indicate 
that RUNX1-MDS1/EVI1, as well as RUNX1-EVI1 may be formed, depending on the location 
of the 3q26.2 breakpoint. Th us, RUNX1 or ETV6 may translocate 5’ of MDS1 or 5’ of EVI1. 
Whether the expression of the distinct fusion types is associated with diff erences in treatment 
response cannot be answered and requires an even larger patient cohort. Although in the 
t(3q26) group the CR rate was signifi cantly lower compared with the reference group, there 
was no impact on survival (Figure 1B). Also, in multivariable analysis, t(3q26) had no impact, 
indicating that in terms of outcome these AML are diff erent from classical inv(3)/t(3;3). 
Although the number of abnormalities remained small, we did carry out an exploratory sub-
group analysis for the most frequent recurrent t(3q26) cases, i.e., t(2;3)(p15~23;q26.2), t(3;12)
(q26.2;p13), and t(3;21)(q26.2;q22.1) (Figure 2C, Table S8, and Supplementary results).
AML with balanced t(3q21) (group C) represented a small subset. Similar to cases with 
inv(3)/t(3;3), these AML presented with high platelet counts. In contrast to AML with 
inv(3)/t(3;3) and other t(3q26), there was only a single case with additional monosomy 7. 
Although prognosis of t(3q21) as a group was indistinguishable from the reference group 
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(Figure 1B), the most frequently found t(1;3)(p36.3;q21.1) had a poor outcome (Figure 2C, 
Table S8). AML with t(1;3)(p36.3;q21.1) have been studied molecularly, i.e., the RPN1 locus 
at 3q21, the translocation partner of EVI1 in inv(3)/t(3;3) AML, translocates to PRDM16 
(MEL1; MDS1/EVI1-like-1) at 1p36, that is highly homologous to EVI1 (PRDM3)(8). Th e 
aberrant expression of PRDM16, as well as EVI1 in AML, frequently involves the RPN1 
locus, which points to novel directions of expression regulation of PRDM family members 
via RPN1. Few cases were found with translocations of 3q21 to chromosome bands other 
than 1p36.3. Interestingly, in one patient 3q21 was translocated to band 11p15 that harbors 
PRDM11 (Figure S1C). In group D, one case was observed with a putative translocation be-
tween chromosomes 3q21 and 6q21, the locus that harbors PRDM1 (BLIMP). Together, these 
data suggest that EVI1 homologues might play a role in transforming myeloid progenitors, in 
particular when they come under the control regulatory elements in the RPN1 gene.
Group D constituted a very heterogeneous cohort comprising various other mostly unbal-
anced 3q abnormalities without any specifi c presenting clinical and molecular characteris-
tics. Th is group was associated with a very poor outcome similar to that of patients with 
inv(3)/t(3;3). In a large proportion, these abnormalities were part of a complex and/or a 
monosomal karyotype. In addition, we were able to detect cryptic inv(3) by FISH analysis in 
cases with high EVI1, but low or no MDS1/EVI1 transcript levels, in which enough material 
was available. Th ese cases frequently had del(3)(q21) or add(3)(q21), highly suggestive of the 
existence of a cryptic inversion/translocation involving EVI1 and RPN1. Further molecular 
studies will be necessary to identify biologic subsets of AML among these cases. Th ese obser-
vations indicate the importance of introducing EVI1 and MDS1/EVI1 expression analysis as 
well as FISH analysis as a routine to support cytogenetic practice(34).
In conclusion, the incidence of 3q abnormalities in AML is 4.4%. Th e inv(3)/t(3;3) abnor-
malities are frequently associated with monosomy 7 and N-RAS mutations and confer 
independent prognostic value as regards treatment response and survival. AML with diverse 
other 3q abnormalities, i.e., unbalanced 3q26 or unbalanced 3q21 abnormalities, present with 
monsomal karyotypes and complex karyotypes in the great majority of cases and show dismal 
survival as well. AMLs with cryptic 3q rearrangements, identifi ed according disproportionate 
EVI1 and MDS1/EVI1 expression quotients, in the future, should be included in the WHO 
entity inv(3)/t(3;3).  
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ABSTRACT
Inappropriate expression of EVI1 (ecotropic virus integration-1), in particular splice-form 
EVI1-1D, through chromosome 3q26 lesions or other mechanisms has been implicated in the 
development of high-risk acute myeloid leukemia (AML). To validate the clinical relevance 
of EVI1-1D, as well as of the other EVI1 splice-forms and the related MDS1/EVI1 (ME) gene, 
real-time RQ-PCR was performed in 534 untreated adults with de novo AML. EVI1-1D was 
highly expressed in 6% of cases (n=32) whereas 7.8% were EVI1 positive (n=41) for all splice 
variants. High EVI1 predicted for a distinctly worse event free survival (HR=1.9; P=0.002) 
and disease free survival (HR=2.1, P=0.006) following multivariate analysis. Importantly, we 
distinguished a subset of EVI1 positive cases that lacked expression of ME (EVI1+ME-; n=17) 
from cases that were ME positive (EVI1+ME+; n=24). Th e atypical EVI1+ME- expression 
pattern exhibited cytogenetically detectable chromosomal 3q26 breakpoints in eight cases. 
Fluorescence in situ hybridization revealed seven more EVI1+ME- cases that carried cryptic 
3q26 breakpoints, which were not found in the EVI1+ME+ group. EVI1+ME- expression 
predicts for an extremely poor prognosis distinguishable from the general EVI1+ AML 
patients (OS; P<0.001 and EFS; P=0.002). We argue that EVI1/ME quantitative expression 
analysis should be implemented in the molecular diagnostic procedures of AML.
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INTRODUCTION
Inappropriate expression of EVI1, through chromosome 3q26 lesions, e.g. t(3;3)(q21;q26) 
or inv3(q21q26) has been implicated in the development or progression of high-risk acute 
myeloid leukemia (AML)(1, 2) Importantly, EVI1 is also highly expressed in a subgroup of 
AML without 3q26 rearrangements(3, 4). High expression of EVI1, i.e. splice form EVI1-1D, 
is an independent negative prognostic indicator of survival in AML irrespective of the pres-
ence of 3q26 rearrangements(3). At least four additional splice variants of EVI1 were recently 
identifi ed, i.e. EVI1-1A, -1 B, -1C, and -3L(5), mainly diff ering in their 5’ untranslated regions. 
Since, we previously only determined the relative expression of EVI1-1D(3), it is feasible that 
EVI1 positive AML cases have been underestimated. Th e prognostic value of EVI1 in AML, 
taking into account the distinct EVI1 splice forms has not been evaluated yet.
Myeloid cells may also express MDS1/EVI1 (ME), an EVI1 fusion variant generated through 
intergenic splicing with MDS (6), a gene located ~140 kb upstream of EVI1 with a currently 
unknown function. Among EVI1 positive AML patients, leukemias with selective ME ex-
pression (ME+) can be distinguished from those being ME negative (ME-)(3, 4). Currently, 
it is unclear whether EVI1+ME- and EVI1+ME+ leukemias are clinically and biologically 
diff erent. Normal CD34+ bone marrow cells express EVI1 as well as ME (7, 8), suggesting 
that an EVI1+ME- expression pattern in AML is abnormal. In fact, chromosomal breaks in 
3q26 may occur between MDS1 and EVI1(9) thereby preventing ME fusion but instigating 
transcriptional activation of EVI1 alone. How frequently ME negativity in EVI1+ leukemias 
(EVI1+ME- genotype) is the result of genetic alterations in this locus is unknoIt has also 
remained unexplained why certain leukemias express high levels of EVI1 without carrying 
a 3q26 abnormality. It is conceivable that these AML cells represent normal marrow CD34+ 
precursors, which have been shown to express EVI1 as well as ME(7, 8). Another explanation 
could be that EVI1 and ME expression is the result of defects in other genes, which function 
upstream and cause high EVI1 and ME levels by elevating their transcription. In this study 
we examined another possibility, i.e. whether hidden 3q26 lesions exist in EVI1+ AML cases 
without cytogenetically detectable aberrations in this locus.
We demonstrate in a cohort of 534 AML cases that high EVI1 expression, considering the 
various currently known EVI1 splice variants, is an independent predictor of poor survival. 
Of the EVI1+ AMLs a considerable number of patients could only be identifi ed by RQ-PCR 
detecting alternative EVI1 splice forms, but not EVI1-1D. Th e EVI1+ME- subgroups of AMLs 
oft en carry chromosome 3q26 lesions, some cryptic and only recognizable by fl uorescence in 
situ hybridization. Importantly, among the EVI1 positive AMLs, the EVI1+ME- leukemia 
subtype showed an extremely poor treatment outcome. Finally, the results reveal a positive 
correlation between EVI1+ME+ overexpression and 11q23 chromosomal abnormalities, sug-
gesting a possible role for MLL fusion proteins in the regulation of EVI1 and ME expression.
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PATIENTS AND METHODS
Patients and Molecular analyses
Leukemic blast cells were isolated from bone marrow or blood of 534 patients with AML, en-
rolled in the HOVON-04(10-12), -29, -32, -42 or -43 protocols (available at www.hovon.nl). 
Th e control group contained seven healthy bone marrow specimens. Blasts and mononuclear 
cells form healthy bone marrow specimens and AML samples were purifi ed as previously re-
ported (13). RT-PCR and sequence analyses for mutations in FLT3-ITD, FLT3-TKD, NPM1, 
N-RAS, K-RAS and CEBPA were performed as described previously(14-17). All subjects 
provided written informed consent. Th is research has been approved by the Institutional 
Review Board of Erasmus University Medical Center. 
Real-time quantitative PCR and Northern blot analyses
RNA isolation, cDNA synthesis and real-time quantitative RT-PCR (RQ-PCR) were 
performed as described(3, 5, 13). EVI1-1D splice form and ME expression levels were 
determined using probes(3), whereas the other EVI1 splice variants(5) (-1A, -1B, -1C and 
-3L) were analyzed using SYBR green (Applied Biosystems, Foster City, CA). A systematic 
overview of the EVI1 splice forms and the primer/probe localisations are shown in Figure 1. 
Primer and probe sequences are shown in Table S1. EVI1 expression levels were determined 
using the ΔΔCt method(18). Th e average expression of each EVI1 splice variant and ME in 7 
bone marrow samples from healthy volunteers was used as calibrator. Th e mean Ct values in 
the normal bone marrow samples were 29.6± 1.1 for EVI1-1A, 29.1 ± 0.82 for EVI1-1B, 37.2± 
1.7 for EVI1-1C, 38.6± 1.2 for EVI1-1D, 32.8± 0.92 EVI1-3L and 35.9± 1.9 for ME. Th e Ct 
values obtained were normalized for the internal reference(3), porphobilinogen deaminase 
(PBGD). Th e mean PBGD Ct value for normal bone marrow samples was 27.8 ± 1.0. For 
the ΔΔCt calculation to be valid(18), the absolute value of the slope in the plot of the log 
cDNA dilution versus ΔCt was determined for all primer combinations and was close to zero. 
A sample was considered EVI1 positive if the relative expression was above 30 for one or more 
EVI1 splice variants. All samples were tested in duplicate and the average values were used 
for quantifi cation. Th e amplifi cation effi  ciency of each primer combination using 5 diff erent 
dilutions (equal to 1.25 ng to 20 ng total RNA) was determined using mRNA isolated from 
four EVI1 positive samples. Th e mean amplifi cation effi  ciencies of EVI1-1A, -1B, -1C, -1D, 
-3L and ME were respectively, 1.00, 0.99, 0.90, 1.00, 0.94 and 0.95. Northern blot analyses for 
EVI1 expression was carried out as described previously(3).
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Figure 1. Gene structure and primer/probe locations of EVI1 splice variants -1A, -1B, -1C, -1D, -3L and MDS1/
EVI1 (ME). 
Th e exons, introns and translational starts are depicted in boxes, connective lines and stand-up arrows respectively. 
Th e fi rst exon’s size in base pairs (bp), primers (arrows) and probes (bold line) are shown. Nucleotide sequences of 
primer/probe are presented in Table S1. 
Fluorescence in situ hybridization 
Dual color fl uorescence in situ hybridization (FISH) was performed with BAC clones located 
on chromosome 3q26, the EVI1 and/or the MDS1 locus, RP11-82C9 (EVI1) RP11-672P8 
(EVI1), RP11-141C22 (MDS1) and RP11-250A4 (3q26; MDS1), Furthermore BAC clones 
RP11-456K4 and RP11-912D21 located on chromosome 3q21, the ribophorin I (RPN1) 
locus and RP1-196F4 located on 3q telomere were used. Clone isolation and labeling were 
performed using biotin-16-dUTP and digoxigenin-11-dUTP (Roche Diagnostics Belgium, 
Vilvoorde, Belgium) according to the manufacturer’s protocol. Th e FISH analysis was per-
formed as previously described(19). Each sample was analyzed by two diff erent hybridiza-
tions. Th e evaluation of the hybridization pattern and signal intensity served as a reciprocal 
internal control. A minimum of 100 interphase cells and 10 metaphases were analyzed for 
each probe combination. Th reshold values for true positivity were calculated from the aver-
age percentages, plus three times the standard deviations of nuclei falsely positive for each 
of the aberrant hybridizations patterns in the control group. Th e control group consists of 
four healthy control and fourteen EVI1+ME+ samples who yielded more than 90% normal 
methaphases, i.e two pairs of red and green fusion signals in both hybridizations with BAC 
clones RP11-82C9 plus RP11-141C22 and RP11-672P8 plus RP11-250A4.
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Statistical analysis
Statistical analysis was performed with Stata Statistical Soft ware, Release 9.2 (Stata, College 
Station, TX). Spearman rank test, Fisher-exact test, Chi-square test and Student’s t-test were 
calculated using Excel soft ware (Microsoft , Redmond, WA). All patients received induc-
tion therapy and were included in the survival analysis. Actuarial probabilities of overall 
survival (OS, with death due to any cause), event-free survival (EFS, with failure in case of no 
complete remission at day 1 (CR1) or relapse or death) and disease-free survival (DFS; with 
death in CR1 or relapse) were estimated by the method of Kaplan and Meier (20). Th e Cox 
proportional hazards analysis(21) was applied to determine the association of high total EVI1 
expression (as a binary variable) with OS, EFS, and DFS without and with adjustment for age, 
cytogenetic risk (i.e favorable, intermediate or unfavorable(22)) and FLT3 internal tandem 
duplication (FLT3 ITD) together with known important poor prognostic AML markers i.e 
monosomy 7 and MLL translocations. All tests were two-tailed and a P value of less than 0.05 
was considered statistically signifi cant.
RESULTS
Th e predictive value of EVI1-1D validated in an independent cohort of 272 AML 
patients 
We have previously demonstrated in patients with newly diagnosed AML that high EVI1 
mRNA levels, i.e. splice-form 1D (EVI1-1D) (Figure 1) signifi cantly predict for poor survival 
(3). Here, we show in an independent cohort of 272 cases of newly diagnosed AML (cohort A; 
Table S2) high EVI1-1D levels in 6.2% (n=17) patients (Table 1). Importantly, high EVI1-1D 
expression again correlated with signifi cantly reduced event free survival (EFS) and overall 
survival (OS) (P<0.001, Figure S1). In the following experiments we combined cohort A with 
samples from the previously investigated patient cohort (3) (cohort B (n=262); Table S2). 
Only  patients were included that were treated according to the HOVON cooperative group 
protocols. In cohort B, 5.8% of cases (n=15) were EVI1-1D positive (Table 1). Hence, among 
the combined 534 AMLs 6.0% (n=32) of cases were EVI1-1D positive.
EVI1 positive cases identifi ed by expression analysis of alternative EVI1 splice forms
Four other EVI1 splice forms have been reported, which mainly diff er in their 5’-untranslated 
region, i.e. EVI1-1A, -1B, -1C and -3L (Figure 1). To investigate for the frequency of expres-
sion of each of these EVI1 splice variants in AML and to verify whether EVI1-1D negative 
AMLs might express other EVI1 splice forms, we determined the relative expression by splice 
form specifi c RQ-PCRs (Figure 1). A sample was considered EVI1 positive if the relative ex-
pression was above 30 for one or more EVI1 splice variants. Diff erent cut-off  points i.e. 50, 30, 
20 and 10 were tested based on event-free survival and showed minor diff erences in survival 
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and in EVI1 positive patients respectively 40, 41, 52 and 57. Diff erences in survival between 
EVI1 positive versus EVI1 negative cases appeared to be signifi cant in each situation (data 
not shown). Any cut-off  is arbitrary, but in order to prevent including false positive patients 
we chose the cut-off  level of 30 for further analysis and calculations. Although Spearman 
correlation coeffi  cients comparing expression levels of distinct splice forms were high (Figure 
S2), indicative of frequent co-expression, nine EVI1-1D negative cases were identifi ed that 
were positive for one or more other EVI1 splice forms (Table 1). Th e total EVI1 positive 
fraction (EVI1+) was increased to 7.8% (n=41 cases). EVI1-1A or EVI1-3L were found to be 
most frequently expressed in those cases. Northern blot analysis performed on samples from 
selected patients that expressed distinct EVI1 splice variants (Figure 2), revealed bands of the 
expected size, confi rming the true identity of EVI1.
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Figure 2. EVI1 mRNA expression levels in EVI1-1D+ and EVI1-1D- AML samples in cohort A and B determined 
by Northern blot. 
Human 600 bp EVI1 probe and as control a murine GAPDH fragment was used. Patient I and II represent AML 
samples without EVI1 expression. Th e patient numbers correspond to those in Table 1.
EVI1 expression and clinical characteristics
No diff erences in age and sex distributions, FAB classifi cations, pre-treatment white blood 
cell counts (WBC) or percentages of bone marrow blasts were observed between patients 
with EVI1+ and EVI1- de novo AML. Clinical characteristics of EVI1+ versus EVI1- patients 
within the cohort of 534 AML patients are depicted in Table 2. Chromosomal aberrations in 
the EVI1 locus, i.e. 3q26 abnormalities, were seen in 8 of the 41 (20%) EVI1+ cases, whereas 
only 2/493 (0.4%) EVI1- AMLs showed a 3q26 abnormality (Tables 1 and 2). Possibly, in 
those latter two cases another gene present in the 3q26 locus may have been aff ected. Other 
cytogenetic lesions that are frequently seen in association with EVI1 positivity are -7/7q- dele-
tions and translocations involving 11q23. Deletions -7/7q- were found in 13/41 (38%) EVI1+ 
leukemias and 34/493 (7%) EVI1- cases. Translocations involving 11q23 were observed in 
8/41 (20%) EVI1+ versus 8/493 EVI1- (1.6%) AMLs. Furthermore, an inverse correlation was 
seen between EVI1+ patients and NPM1 mutations (P<0.001). 
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Table 1. Relative expression of EVI1 splice variants (-1D, -1A, -1B, -1C, -3L) and MDS1/EVI1 (ME), a priori karyo-
type and FISH results in EVI1+ patients.
No 1D 1A 1B 1C 3L ME Karyotype (ISCN 2005)              COHORT A FISH
1 850 1634 199 80 819 0,1 45,XY,inv(3)(p12p2?4),-7[16]/46,XY[8] inv(3)
2 540 2159 75 73 157 0,2 45,XY,t(3;3)(q21;q26),-7[20] ND
3 254 1473 42 6 479 0,1 46,XY,t(3;3)(q21;q26)[51] ND
4 265 1405 67 58 76 0,0 45,XX,-7[24] inv(3)
5 352 88 33 4 65 0,5
47,XX,del(5)(q23q34),+del(21)(q21q22)[4]/47,idem, t(2;3)
(p2?2;q2?7)[20]/46,XX[3]
t(2;3)
6 796 943 160 225 131 3 45,XY,inv(3)(q21q26.2),-7[13] ND
7 68 74 47 5 43 8 45,XY,-7[16] inv(3)
8 166 177 42 5 43 25 46,XY[14] NA
9 50 84 21 3 137 89 48,XY,+9,+21[9]/49,idem,+21[14] NA
10 686 408 209 57 361 95 47,XX,del(3)(q25) or del(3)(q21q26),+mar NA
11 54 163 50 1 212 145 46,XX,t(6;11)(q27;q23)[36] NN
12 217 174 73 10 327 224 53,XY,+6,+8,+9,t(11;16)(q23;p13),+13,+14,+19,+21[15] NN
13 227 694 88 3 855 269 46,XX NA
14 120 380 85 6 527 289 46,XX,t(6;11)(q27;q23)[28] NN
15 94 494 119 4 680 437 46,XY[30] NA
16 183 1013 136 30 628 934 47,XY,+?8(9%)/46,XY NA
17 54 3 2 5 2185 1048 46,XY,t(3;21)(q26;q22),del(12)(p12p13)[20] ND
18 13 132 7 0,0 21 0,2 46,XY[38] inv(3)
19 21 89 11 0,5 90 24 46,XY,?der(11)(q2?)[3]/46,XY[18] NN
20 14 67 16 0,5 21 32 46,XY,inv(3)(q21q26)[32] inv(3)
21 26 99 27 1 135 86 46,XY,t(11;19)(q23;p13.1)[15]/46,XY[5] NN
22 7 27 9 2 77 216 NA NA
No 1D 1A 1B 1C 3L ME Karyotype (ISCN 2005)              COHORT B FISH
23 1624 1256 363 59 834 19 45,XX,inv(3)(q22q26),-7[29]/46,XX[1] ND
24 584 417 116 74 37 4 45,XY,inv(3)(q22q26),-7[25] ND
25 506 845 119 37 350 0,2 45,XY,inv(3)(q12q26.2),-7[20] ND
26 700 1121 161 76 244 0,0 45,XX,-7[27]/46,XX[3] inv(3)
27 214 1074 44 9 541 0,1 NA NN
28 173 172 28 10 46 0,0 46,XX[68] inv(3)
29 196 239 69 6 167 0,0 46,XX,t(1;6)(p32;q24~25),del(2)(q34)[33]/46,XX[1] inv(3)
30 829 1258 132 68 333 63 NA NA
31 745 2354 147 23 1309 286 45,XY,-7,t(9;11)(p21;q23)[33] NN
32 315 641 174 9 2532 532 46,XX,t(11;19)(q23;p13)[21] NN
33 207 186 118 5 373 168 46,XY,t(9;22)(q34;q11)[22] NN
34 192 897 112 8 3266 539 46,XX,t(2;9;11)(p13;p22;q23)[20] NA
35 83 306 43 3 517 448 46,XY[40] NN
36 79 67 36 3 204 1065 46,XX,del(7)(q22)[41]/46,XX[1] NN
37 52 157 27 0,9 605 429 46,XY,t(6;11)(q25;q23)[22] NN
38 14 7 6 0,1 95 139 47,XY,+13[11]/46,XY[28] NN
39 16 39 9 0,9 33 223 45,XY,-7,t(7;8)(q22;p11)[21] NN
40 11 6 6 1,7 144 397 47,XX,+13[27]/46,XX[1] NN
41 14 13 5 2,8 234 1830 46,XY,-7,add(12)(p12),+mar[46]/46,XY[54] NN
Relative expression of each of the distinct EVI1 transcripts was determined as explained in the Patients and Methods 
section. A positive EVI1 or ME signal, i.e. >30 is indicated in red. Abbreviations: ME, MDS1/EVI1; FISH, fl uorescent 
in situ hybridization; NN, normal 3q21, 3q26 and 3q telomere locus; inv(3), inversion of chromosomal band 3q21 
and 3q26; NA, not available; ND, not determined.
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Figure 3. High EVI1 expression associates with poor survival outcome in AML. 
Kaplan Meier analysis of (A) overall survival (OS), (B) event-free survival (EFS) and (C) disease-free survival (DFS) 
shows an inferior outcome for EVI1+ patients in comparison to patients without EVI1 overexpression in a total 
cohort of 534 AML patients.
AML cases analyzed were obtained from six diff erent HOVON studies, i.e. HOVON-04, 04A, 
29, 32, 42 and 43. As can be seen from Table 2, EVI1 expressing cases were equally distributed 
among the distinct treatment groups (Table 2 and data not shown). 
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Table 2. Clinical characteristics of EVI1 positive patients in relation to clinical parameters, morphology, cytoge-
netics and molecular characteristics of 534 patients with newly diagnosed AML.
No. of EVI1 negative 
patients (%) 
No. of EVI1 positive 
patients (%)
P value
Sex‡ 0.19
   Male 242 25 (11)
   Female 251 16 (17)
Age (years) ‡ 0.22
   Less than 35 117 14 (11)
   Between 35 and 50 166 12 (15)
   Older than 50 210 15 (15)
HOVON protocol‡
   04A 49 3 (6) > 0.99
   04 40 8 (17) 0.50
   29 203 12 (6) 0.32
   32 5 0 (0) > 0.99
   42 140 11 (7) 0.85
   43 55 7 (11) 0.54
FAB*
   M0 16 2 (11) 0.64
   M1 104 6 (5) 0.42
   M2 123 6 (5) 0.18
   M3 24 1 (4) 0.71
   M4 82 13 (14) 0.11
   M5 104 10 (9) 0.85
   M6 7 1 (12) 0.47
   Mx 33 2 (6) > 0.99
Cytogenetic abnormalities§,‡
   -5/5q- 16 3 (16) 0.23
   -7/7q- 21 13 (38) < 0.001
   3q26 2 8 (80) < 0.001
   t(9;22)(q34;q11) 1 1 (50) 0.17
   t(11q23) 8 8 (50) < 0.001
   t(15;17)(q22;q21) 21 1 (5) 0.71
   t(8;21)(q22;q22) 39 0 (0) 0.039
   inv(16)/t(16;16) 37 0 (0) 0.065
   +8 22 2 (8) 0.71
   +21 3 2 (40) 0.05
   t(6;9)(p23;q34) 6 0 (0) > 0.99
   Complex 20 1 (5) > 0.99
   Other 65 6 (8) > 0.99
   Normal 218 6 (3) < 0.001
   ND 20 2 (9) > 0.99
Cytogenetic risk  
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   Favorable 89 1 (1) 0.23
   Intermediate 347 17 (5) < 0.001
   Unfavorable 57 23 (29) < 0.001
Molecular abnormalities‡
   FLT3-ITD 135 5 (4) 0.027
   FLT3-TKD 43 1 (2) 0.23
   K-RAS 5 0 (0) > 0.99
   N-RAS 40 5 (11) 0.57
   CEBPA 43 1 (2) 0.23
   NPM1 158 2 (1) < 0.001
WBC x 10^9/L‡‡ 0.18
   Mean; SD 52; 63 45; 49
Platelets x 10^9/L‡‡ 0.01
   Mean; SD 72; 101 165; 241
Blast% in BM‡‡ 0.38
   Mean; SD 61; 27 61; 24
Abbreviations: FAB, French-American-British classifi cation; BM, bone marrow; FLT3-ITD, internal 
tandem duplication of the FLT3 gene; FLT3-TKD, a mutation in tyrosine kinase domain of the FLT3 
gene; Mx, FAB not available; ND, not determined; SD, standard deviation.
§All patients with a specifi c abnormality were considered irrespective of the presence of additional 
abnormalities.
‡ P values were calculated using the 2-tailed Chi-square test.
‡‡ P values were calculated using 2-tailed t-test.
High EVI1 expression is an independent prognostic marker in AML
We next investigated the prognostic impact of EVI1 positivity (i.e. EVI1-1A, -1B, -1C, -1D or 
-3L positive) in the total cohort of 534 patients with AML. Patients with EVI1+ AML less oft en 
attained a complete remission (61% v 82%; Chi2 P=0.001) and the probability of relapse was 
considerably higher compared to EVI1- AMLs (51% v 41%; Chi2 P=0.04). Survival analysis 
revealed a severe disadvantage for EVI1+ AML patients regarding the 5 years overall survival 
(OS) (13%±5% v 39%±2%; Figure 3A), event-free survival (EFS) (3%±3% v 29%±2%; Figure 
3B) and disease-free survival (DFS; probability of relapse) (5%±4 v 32%±3%; Figure 3C). 
Table 3 describes the increased hazard ratios for EVI1+ AML for OS, EFS and DFS following 
univariate analysis and multivariate analysis. 
Multivariate analysis established high EVI1 expression as an independent prognostic marker 
in relation to FLT3-ITD mutations and other prognostic cytogenetic abnormalities with haz-
ard ratios for EFS and DFS of 1.88 (95% CI, 1.29-2.76; P=0.002) and 2.14 (95% CI, 1.29-3.54; 
P=0.006) (Table 3), whereas for OS a hazard ratio with a decreasing trend of 1.47 (95% CI, 
0.98-2.21, P=0.073) was established.
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Table 3. Univariate and multivariate analysis of high EVI1 expression as prognostic factor for survival.
EFS DFS OS
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Univariable analysis
   High EVI1 expression# 2.17 (1.55-3.03) <0.001 2.26 (1.46-3.50) <0.001 1.91 (1.34-2.72) <0.001
Multivariable analysis
     Intermediate§ 1.62 (1.17-2.26) 0.004 1.91 (1.30-2.82) 0.001 1.84 (1.27-2.68) 0.001
     Unfavorable§ 2.90 (1.88-4.49) <0.001 3.8 (2.27-6.36) <0.001 3.46 (2.14-5.60) <0.001
   Age 35-50 year 1.03 (0.78-1.35) 0.84 1.10 (0.81-1.52) 0.53 1.22 (0.90-1.65) 0.20
          >50 year 1.23 (0.94-1.60) 0.13 1.17 (0.86-1.60) 0.33 1.48 (1.11-1.98) 0.007
   FLT3-ITD‡ 1.40 (1.11-1.77) 0.005 1.25 (0.93-1.67) 0.13 1.55 (1.21-1.99) <0.001
   Monosomy 7* 1.37 (0.89-2.11) 0.15 1.05 (0.58-1.89) 0.87 1.35 (0.86-2.13) 0.20
   MLL translocation** 0.68 (0.35-1.29) 0.24 0.67 (0.32-1.39) 0.28 0.79 (0.39-1.56) 0.49
   High EVI1 expression# 1.88 (1.29-2.76) 0.002 2.14 (1.29-3.54) 0.006 1.47 (0.98-2.21) 0.072
P values were calculated using the Cox regression model. Abbreviations: HR, hazard ratio with high EVI1 expression; 
CI, confi dence interval; EFS, event free survival; DFS, disease-free survival; OS, overall survival; FLT3 ITD, internal 
tandem duplication of the FLT3 gene. 
#    High EVI1 expression versus no EVI1 expression.   
§    Cytogenetic risk versus favorable cytogenetic risk. 
‡    FLT3 ITD versus no FLT3 ITD.   
*    Monosomy 7 versus no monosomy 7.
**  MLL translocation versus no MLL translocation. 
We performed a Cox regression analysis with expression of EVI1-1A, 1B, 1D and 3L as a 
continuous variable. Th e data were log-transformed to guarantee an equal distribution. Th e 
results shown in Table S3 demonstrate that the relative expression of variants EVI1-1A, 
-1B and -3L, but not EVI1-1D was of signifi cant infl uence in the EFS, DFS and OS of the 
AMLs studied. We also performed a Cox regression analysis where EVI1 expression as a time 
dependent covariate was added to the original multivariate model for OS. High EVI1 expres-
sion as a time dependent covariant was not of signifi cant infl uence in this model (HR=1.0, 
95%CI; 0.98-1.04, P=0.54).
EVI1 positivity and MDS1/EVI1 negativity associate with 3q26 lesions
Since EVI1 is normally co-expressed with the intergenic splice form MDS1/EVI1 (ME) (Fig-
ure 1), we argued that the atypical dissociated expression pattern EVI1+ME- that is noted in 
a proportion of cases of AML(3), might be caused by chromosome 3q26 lesions disrupting 
the MDS1/EVI1 locus. We estimated ME levels in the EVI1+ AML subgroup and observed 
absence of ME expression in 17/41 cases. Six of these (6/17, 36%) carried a cytogenetically 
detectable 3q26 abnormality, while the remaining leukemias carried other cytogenetic aber-
rations or had a normal karyotype (Table 1). ME was co-expressed with EVI1 in 24/41 cases. 
Only 2/24 (8%) EVI1+ME+ cases showed a 3q26 lesion. In fact, in one case (#20) ME expres-
sion levels were border line (Table 1) while in the other case (#17) the translocation t(3;21) 
was apparent, which is known to result in an AML1/MDS1/EVI1 fusions(20, 23).
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Frequent hidden 3q26 lesions in EVI1+ME- AML patients
Th e positive association between EVI1+ME- expression and cytogenetically detectable 3q26 
abnormalities prompted us to investigate whether hidden 3q26 chromosomal lesions might 
be present in the EVI1+ME- subgroup of AML. Dual-color FISH analyses using BAC clones 
covering EVI1 and MDS1 (Figure 4A) were carried out on metaphase spreads of 10 cases 
of EVI1+ME- AML without any a priori cytogenetically detectable 3q26 abnormality. In 
8/10 patients (#1, 4, 5, 7, 18, 26, 28 and 29) split signals were observed in metaphase and 
interphase nuclei, indicating the presence of hidden 3q26 lesions (Figure 4B, Table 1 and Fig-
ure S3A-C). Additionally, the FISH analysis redefi ned the breakpoint of the cytogenetically 
identifi ed t(2;3)(p2?;q2?7) into t(2;3)(p2?;q26) (#5; Figure S3D-E). Next, FISH analysis using 
BAC clones covering RPN1 (3q21) and EVI1 revealed involvement of the RPN1 locus in the 
remaining 7 patients (Figure 4C and Table 1). Th e complete FISH results for each patient 
analyzed are shown in Table 1. FISH experiments using the same BAC clones covering EVI1, 
MDS1 and RPN1 were carried out in EVI1+ME+ leukemias but did not demonstrate the 
existence of inv3(q21q26) or t(3;3)(q21;q26) in any of the 14 cases studied. Other chromo-
some 3 translocations were excluded in these samples by FISH using a BAC clone located 
telomeric on 3q (Figure S3F).
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Figure 4. Fluorescent in situ hybridisation (FISH) of chromosome 3q26 and 3q21 loci reveal hidden 3q26 aber-
rations.
BAC clone localization from centromere (Cen) to telomere (Tel) (A). A metaphase from EVI1+ patient #28 revealed 
a cryptic inv(3)(q21q26) (inv3) and a normal chromosome 3 (nor3) using EVI1 (RP11-82C9) and MDS1 (RP11-
141C22) (B) and RPN1 (RP11-456K4) BAC clones (C).
 Chapter 3  
68
EVI1+ME- and EVI1+ME+ AMLs are cytogenetically and clinically diff erent
No signifi cant diff erences in sex and age distributions, FAB classifi cation, WBC counts, bone 
marrow blast percentages, karyotype risk classifi cation and molecular abnormalities were 
observed between the EVI1+ME- (n=17) and the EVI1+ME+ subsets of patients with AML 
(n=24) (Table S4). Besides the frequent occurrence of 3q26 lesions, patients with EVI1+ME- 
AML also frequently presented a –7/7q- deletion (n=9; P=0.11). Interestingly, the platelet 
count, which was signifi cantly elevated in the total EVI1+ group compared to the EVI1- AML 
patients (Table 1), was only elevated in the EVI1+ME- subgroup but not in the EVI1+ME+ 
subgroup (P=0.024; Table S4). EVI1+ME+ cases frequently carried 11q23 abnormalities 
(n=8, P=0.013). While EVI1+ME+ and EVI1+ME- subgroups both showed a poor treatment 
outcome (Figure 5), EVI1+ME- cases showed an even worse prognosis. Th is was evident 
from the fact that they less oft en achieved complete remission than patients with EVI1+ME+ 
AML (18% v 92%; Chi2 P=0.001) and showed a signifi cantly reduced OS (9%±3% v 24%±6%; 
Figure 5A) and EFS (3%±3% v 29%±2%; Figure 5B) at 1.5 years. In fact, a signifi cantly worse 
OS, EFS and DFS (OS; HR=2.45, P=0.002, EFS; HR=3.21, P<0.001, DFS; HR=2.44, P=0.13) 
for EVI1+ME- cases as compared to EVI1+ME+ AML patients was also evident from mul-
tivariate analysis, although one should keep in mind that patients numbers were relatively 
small for such subdividing and requires further validation in other cohorts. 
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Figure 5. Inferior outcome for EVI1+ME- patients in comparison to EVI1+ME+ patients. 
Kaplan Meier analysis of (A) overall survival (OS) and (B) event-free survival (EFS) shows an inferior outcome for 
EVI1+ME- patients in comparison to EVI1+ME+ patients in the cohort of 41 EVI1+ AML patients.
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DISCUSSION
Molecular markers are of utmost importance in resolving the genetic heterogeneity of AML 
and deriving discriminative prognostic algorithms. Recently, markers such as expression 
levels of EVI1(3), BAALC(24) and ERG(25) have been demonstrated to be powerful indica-
tors of prognostically distinct AML subsets. High expression of EVI1, i.e. in particular splice 
variant EVI1-1D, has been shown to be a strong negative indicator for treatment response 
in AML(3). Here, we confi rmed the adverse prognostic signifi cance of EVI1-1D in an inde-
pendent cohort of 272 AML patients. In addition, we demonstrate in a large cohort of 534 
adults with pre-treatment AML that 41 (7.8%) cases expressed high levels of EVI1 mRNA, 
which signifi cantly predicted for an unfavorable prognosis. Importantly, 22% of these cases 
(9/41) were EVI1-1D negative, but could be designated as EVI1+ when the expression of 
the other recently identifi ed EVI1 splice forms(5) was determined. Our fi ndings inquire for 
the development of a reproducible assay, which discriminates EVI1+ from EVI1- AML for 
diagnostic purposes. 
A diagnostic assay should be rapid and quantitative and it should take into account each of 
the diff erent EVI1 splice forms. A multiplex PCR assay, by which the expression levels of each 
of the diff erent EVI1 splice variants(26, 27) will be determined separately, is feasible but may 
be complicated to interpret.  It may also be possible to develop primer probe combinations, 
which recognize all splice forms in one single EVI1 specifi c Q-PCR.  Such an assay has the 
advantage that “high” versus “low” EVI1 cases may be determined in one easy-to-use test and 
it may provide the possibility to study EVI1 expression level as a continuous- rather than a 
categorical variable. Th is would allow us to study further whether a correlation exists between 
actual EVI1 expression levels and survival time of AML patients. 
Although, a correlation analysis as discussed above would be helpful to further substantiate 
that high EVI1 levels associate with poor treatment response, a diagnostic assay should pro-
vide binary results, which allows a reliable discrimination between EVI1 positive and nega-
tive cases. To avoid the inclusion of false positive cases, we scored patients EVI1 positive with 
expression levels of 30 or higher compared to 6 normal bone marrow controls. Consequently, 
it may be possible that, by choosing such a high cut-off  level, EVI1 positive cases have been 
missed. Since important decisions will be made based on the outcome of a diagnostic EVI1 
assay, it will be very important to include proper reproducible positive and negative controls, 
and develop algorithms by which EVI1 positive cases will be indisputably identifi ed. 
AML with 3q26 lesions are among the most aggressive forms of human leukemia (3)(28). An 
important message of this study is that a large fraction of AML cases that carried a 3q26 aber-
ration were missed by standard karyotyping but was found positive by FISH. Th e abnormal 
pattern of elevated EVI1 levels but absence of MDS1/EVI1 expression (EVI1+ME-) provided 
the clue to these cryptic 3q26 abnormalities. Since EVI1 and ME are normally co-expressed, 
we hypothesized that a cryptic break within the 3q locus between these two closely related 
genes might cause their dissociated expression. EVI1+ME- leukemias that we recognized 
represent the most unfavorable subgroup of AML and they include most of the patients that 
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carry 3q26 lesions. Th is provides another argument to implement an EVI1/ME multiplex 
RQ-PCR in the molecular diagnostic procedures of AML. Applying EVI1/ME RQ-PCR and 
karyotyping in combination with MDS1/EVI1 and RPN1 specifi c FISH on selected cases will 
disclose AMLs that belong to this distinctly unfavorable subgroup. 
In only two EVI1+ME- cases we did not fi nd 3q26 lesions by FISH, suggesting another 
mechanism for aberrant EVI1 expression. BLIMP, an EVI1 homologue, which is a frequent 
target for chromosomal breaks (1p36) in B-cell lymphomas, has been shown to carry 
BLIMP point mutations in certain cases without 1p36 translocations(29), giving rise to short 
BLIMP (like EVI1) forms in favor of the long (like ME) product. Whether within the small 
EVI1+ME- group without major 3q26 lesions mutations at the molecular level have occurred 
in the MDS1/EVI1 locus, remains to be investigated. 
Using FISH we did not detect hidden 3q26 aberrations in EVI1+ME+ AMLs. We carried 
out nucleotide sequencing in all EVI1+ME+ AML patients available but have not found any 
lesions at the molecular level in EVI1 or ME (data not shown). It is possible, that excessive 
EVI1 and ME levels observed in those AML samples are caused by genetic defects in disease 
genes acting upstream of ME and EVI1. Interestingly, in a signifi cant number of EVI1+ME+ 
leukemias, 11q23 chromosomal alterations were found. Kumar and colleagues have reported 
that hematopoietic stem cells from MLL-AF9 knock-in mice express high levels of EVI1(30), 
which may suggest that enforced expression of MLL-fusion genes directly or indirectly aff ect 
EVI1 and ME transcription. Transduction experiments in hematopoietic precursor cells may 
shed light on a putative eff ect of MLL-fusion proteins on transcription of ME and EVI1. An-
other subset of EVI1+ME+ leukemias did not carry cytogenetically identifi able 11q23 lesions. 
We ruled out hidden 11q23 translocations in those patients using Southern blot analyses and 
MLL-specifi c FISH (data not shown). Neither did we observe the existence of MLL-PTD by 
applying genomic PCR on those patients(31) (data not shown), so that for the time being 
there is no suggestive clue as regards possible mechanisms for the excessively high levels of 
EVI1 and ME in this particular patient group. 
Assessment of EVI1/ME does not only provide a useful diagnostic and prognostic marker 
but, at least in ‘EVI1+ME-’ AML with co-existent 3q26 chromosomal lesions, it pinpoints 
AML cases in which EVI1 may be the major disease gene playing a critical role in leukemic 
transformation. It remains a major challenge to unravel the mechanisms of transformation 
by EVI1 protein. EVI1 encodes a nuclear protein, which interacts with several proteins im-
portant in transcriptional control, e.g. CtBp1(32), HDAC(33), SMAD3(34), P/CAF(32) and 
GATA1(35). Studies unraveling how these interactions exactly take place and as to whether 
those associations are crucial in leukemic transformation may provide insight that could be 
valuable for developing tools to specifi cally target EVI1+ leukemia cells.
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ABSTRACT
Overexpression of the EVI1 gene (ecotropic virus integration-1, EVI1+), localized at chro-
mosome 3q26, is associated with adverse outcome in adult acute myeloid leukemia (AML). 
In pediatric AML, 3q26-abnormalities are rare, and the role of EVI1 is unknown. We studied 
228 pediatric AML samples for EVI1+ using gene expression profi ling and RQ-PCR.  EVI1+ 
was found in 20/213 (9%) of children with de novo AML, and in 4/8 with secondary-AML. 
It was predominantly found in MLL-rearranged AML (13/47), monosomy 7 (2/3), or FAB 
M6/7 (6/10), and mutually exclusive with core binding factor AML, t(15;17), and NPM1-
mutations. FISH was performed to detect cryptic 3q26-abnormalities. However, none of 
the EVI1+ patients harbored structural 3q26-alterations. Although signifi cant diff erences in 
4-years pEFS for EVI1+ and EVI1- pediatric AML were observed (28%±11 v 44%±4, P=0.04), 
multivariate analysis did not identify EVI1+ as an independent prognostic factor. We con-
clude that EVI1+ can be found in ~10% of pediatric AML. Although EVI1+ was not an in-
dependent prognostic factor, it was predominantly found in subtypes of pediatric AML that 
are related with an intermediate to unfavorable prognosis. Further research should explain 
the role of EVI1+ in disease biology in these cases. Remarkably, no 3q26-abnormalities were 
identifi ed in EVI1+ pediatric AML.
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INTRODUCTION
In various myeloid malignancies 3q26-rearrangements can be found(1). Th ese abnormalities 
are oft en associated with overexpression of the EVI1 (ecotropic virus integration-1) gene, 
which is localized at 3q26(2). Th e EVI1 gene encodes for a DNA-binding protein with two 
zinc-fi nger domains(3). It has been shown to play an essential role in early development, 
since inactivation of EVI1 in mice embryos is lethal within 8 days aft er conception(4). More 
information on the role of EVI1 in leukemogenesis was gained in murine leukemia studies 
using retroviral insertion(5). Both in mouse and human myeloid progenitors, overexpression 
of EVI1 is suggested to impair granulocytic diff erentiation in hematopoietic stem cells, and 
hence to result in maturation arrest(2). Interestingly, myeloid malignancies associated with 
EVI1 overexpression oft en show dysplastic megakaryopoiesis(1, 6). Although the EVI1 func-
tion is not fully understood, recent studies suggest that this gene is involved in chromatin 
remodeling, through interactions with H3K9 methyltransferases(7, 8). 
Five splice variants of EVI1 have been reported, i.e. EVI1-1A,-1B,-1C,-1D and -3L, as well as 
the MDS1/EVI1 intergenic splice variant(9, 10). Th e MDS1 gene is located upstream of EVI1 
and its function is currently unknown. In the MDS1/EVI1 transcripts the fi rst 2 exons of MDS1 
have been fused to exon 2 of EVI1, resulting in a so-called PR domain containing the EVI1 
protein(10). Th e PR domain is highly correlated to the SET domain, which has been shown 
to play a critical role in chromatin-mediated gene expression histone-methyltransferases(11). 
In cells that express MDS1/EVI1 transcripts, the EVI1 transcripts are normally expressed as 
well. 
In adult acute myeloid leukemia (AML) overexpression of EVI1 is found in particular in 
patients with a 3q26-rearrangement, such as inv(3)(q21q26) or t(3;3)(q21;q26). However, 
high EVI1 levels have also been discovered in a separate subgroup of AML patients without 
3q26-rearrangements(12, 13). In clinical studies in adult AML, overexpression of EVI1 has 
shown to be an independent prognostic factor, irrespective of harboring typical 3q26-rear-
rangements. It was recently shown that high EVI1 expression can also occur in the absence 
of the MDS1/EVI1 transcript in patients with cryptic 3q26-rearrangements involving the 
EVI1 gene(13). In contrast, patients with high expression of both EVI1 and MDS1/EVI1 were 
frequently found in adult MLL-rearranged AML cases(13). 
In  children with AML, 3q26-rearrangements have not been frequently described and the role 
of EVI1 is unknown(14). Th erefore we studied the occurrence and the role of EVI1 overex-
pression in a large cohort of 228 children with AML. 
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PATIENTS AND METHODS
Patients
Viably frozen bone marrow or peripheral blood samples from 221 patients with newly 
diagnosed AML, comprising 213 with de novo and 8 with secondary-AML, were provided 
by the Dutch Childhood Oncology Group (DCOG), the ‘Berlin-Frankfurt-Münster’ AML 
Study Group (AML-BFM-SG), and the Czech Pediatric Hematology (CPH). In addition, 7 
relapse samples (no paired samples were included) of AML patients were included. Informed 
consent was obtained from all patients, aft er Institutional review Board approval according 
to national law and regulations. As a control for EVI1 expression, normal bone marrow of 
2 children and 6 adults with informed consent was available at the Erasmus MC - Sophia 
Children’s Hospital in Rotterdam, Th e Netherlands. Each study group performed central 
review of the morphology, according to the WHO/FAB classifi cation(15). Th ey also provided 
data on the clinical follow-up of these patients. Survival analysis was restricted to a subset of 
198 de novo AML patients who were treated using AML-BFM-98, AML BFM 2004, DCOG-
BFM-87, DCOG 92/94, DCOG 97 protocols. Details of the treatment protocols included in 
the survival analysis and overall outcome data have been previously published, with the excep-
tion of study AML-BFM 2004, which is ongoing(16-18). Due to a selection based on material 
availability, the survival rates of this patient cohort studied for survival analysis (n=198) are 
slightly diff erent from the studies previously published(16-18). Treatment consisted of 4 to 5 
blocks of intensive chemotherapy, using a standard cytarabine and anthracycline backbone.
Leukemic cells were isolated and enriched from these samples as previously described(19). 
All resulting samples contained >80% leukemic cells, as determined morphologically by 
May-Grünwald-Giemsa (Merck, Darmstadt, Germany)-stained cytospins. A minimum of 
5×106 purifi ed leukemic cells were lysed in Trizol reagent (Gibco BRL, Life Technologies, 
Breda, Th e Netherlands) and stored at -80°C. Genomic DNA and total cellular RNA were 
isolated as previously described(20). 
Cytogenetic and molecular analysis
Leukemic samples were routinely investigated for cytogenetic abnormalities by standard 
chromosome-banding analysis, and screened for recurrent non-random genetic abnormali-
ties characteristic for AML, including t(15;17), inv(16), t(8;21) and MLL-rearrangements, 
using either RT-PCR and/or fl uorescent in-situ hybridization (FISH) by each study group. 
NPM1, CEBPα, MLL-PTD, N-RAS, K-RAS, PTPN11, C-KIT, FLT3 mutational screening was 
performed as previously described(21-26). 
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Microarray-based gene expression profi ling
Integrity of total RNA was checked using the Agilent 2100 Bio-analyzer (Agilent, Santa Clara, 
USA). cDNA and biotinylated cRNA was synthesized hybridized and processed on the Af-
fymetrix Human Genome U133 Plus 2.0 Array (Aff ymetrix, Santa Clara, USA) according to 
the manufacturer’s guidelines. Data-acquisition was performed using expresso (Bioconductor 
package Aff y(27)) and probe-set intensities were normalized using the variance stabilization 
normalization (Bioconductor package VSN(28)) in the statistical data analysis environment 
R, version 2.2.0(29). 
Identifi cation of EVI1 overexpression with gene expression profi ling. 
Four probe sets are positioned within the EVI1 gene (Figure S1). Normalized intensities of 
these probe sets were extracted from the complete Supplementary dataset and further clus-
tering analysis was performed with Genemaths XT (Applied Maths, Austin, USA). Of each 
probe set, the standard deviation using the median as cut off  was calculated for all patients. 
Since, the probe sets 243277_x_at and 215851_at were located in introns of the EVI1 gene, 
only the probe sets 221884_at, and 226420_at were used for hierarchical clustering using the 
Euclidean distance. Samples were considered to have an abnormal EVI1 expression (EVI1+) 
based on the hierarchical clustering dendrogram.
Gene expression signatures for EVI1+ cases.
To fi nd gene expression signatures for EVI1 an empirical Bayes linear regression model was 
used (R package limma)(30). Moderated T-statistics P values were corrected for multiple 
testing using the FDR method defi ned by Benjamini and Hochberg(31). Th is was performed 
using models without and with correction for the diff erent cytogenetic subgroups (MLL-
rearranged AML, t(8;21), inv(16), t(15;17), normal-, remaining-, and unknown cytogenetics)
(30). In addition, gene expression signatures were generated for EVI1+ in specifi c subsets of 
AML (i.e. MLL-rearranged AML and non MLL-rearranged 
Real-time quantitative PCR and Fluorescence in situ hybridization (FISH). 
In 179 samples, including 22 samples with EVI1 overexpression based on microarray analy-
sis, the RNA expression could be validated by real-time quantitative RT-PCR (RQ-PCR). 
For the other 49 samples no additional RNA was available to perform RQ-PCR. Th e relative 
expression of the EVI1 transcripts (EVI1-1A, -1B, -1D, and -3L) and MDS1/EVI1 transcript 
was calculated using the comparative cycle time (ΔCt) method, with GAPDH as the house-
keeping gene(32). Primer en probe sequences are shown in Supplementary Table S1. A 
sample was considered EVI1+ with RQ-PCR if the cumulative relative expression EVI1-1A, 
-1B and -3L to GAPDH was above 1.5%. Th is showed the highest correlation with EVI1+ 
cases based on gene expression profi ling and all normal bone marrow samples were below 
this threshold. Interphase cytospins of cases with a high EVI1 expression were screened with 
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FISH for cryptic 3q26 abnormalities with the Poseidon™ Repeat Free™ EVI1 t(3;3), inv(3) 
Break probe (Kreatech, Amsterdam, Th e Netherlands) according to manufacture protocol.
Additional statistical analysis. 
Statistical analysis was performed with SPSS 11.0 (SPSS Inc. Chicago, USA) and SAS (SAS-
PC, version 9.1). Diff erent variables were compared with the Chi-square test or the Mann-
Whitney-U test. Probabilities of overall survival (pOS) and event-free survival (pEFS, events: 
no CR, relapse, secondary malignancy, death from any cause) were estimated by the method 
of Kaplan and Meier. Correlation between microarray gene expression and the RQ-PCR of 
the diff erent transcript of EVI1 was measured with the Spearman correlation coeffi  cient. Th e 
Cox Proportional hazards model analysis was applied to determine the association of EVI1+ 
with pOS, pEFS, adjusted for prognostic factors. All tests were two-tailed and a P value of less 
than 0.05 was considered signifi cant.
RESULTS
EVI1 overexpression in pediatric AML as determined by gene expression profi ling
Four probe sets on the Aff ymetrix Human Genome U133 Plus 2.0 Array were present within 
the EVI1 gene (Figure S1). Th ese probe sets were located in regions common for all isoforms 
of EVI1. However, 243277_x_at was found in intron 2-3 and 215851_at was found partly 
in intron 15-16. Since these short probe sets also showed more random variation of expres-
sion, they were not included in the hierarchical clustering analysis. By means of hierarchical 
clustering of the gene expression profi ling data, 3 separate clusters could be identifi ed. One 
cluster with high expression of EVI1 (cluster 1), one cluster with an intermediate to high 
expression of EVI1 (cluster 2) and one large cluster with low expression of EVI1. Th erefore, 
24 cases in the clusters with intermediate and high expression were considered EVI1+ based 
on the dendrogram (Figure 1). Th ese cases included 19/213 (9%) patients with de novo AML, 
4/8 (50%) patients with secondary AML, and one patient of whom only relapse material was 
available.
Hierarchical clustering of 228 pediatric AML samples with probe sets 221884_at and 
226420_at representing the EVI1 gene. Red represents high expression; black intermediate 
expression; and green low expression for the specifi c probe set. 
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Figure 1. Hierarchical clustering using the gene expression of the 3 probe sets representing EVI1 in 228 pediatric 
AML samples reveals a subclustering of 24 EVI1+ cases. 
Validation of EVI1 expression and 3q26-aberrations by real-time quantitative PCR and 
FISH
Of the 24 patients with a high EVI1 expression, 22 could be investigated for the various EVI1 
and the MDS1/EVI1 transcripts using RQ-PCR. Of 2 patients the amount of available mRNA 
was not suffi  cient. In addition, RQ-PCR was also performed on 150 of the 197 remaining pe-
diatric AML samples for which additional mRNA material was available (Figure 2). Normal 
bone marrow samples of 8 individuals (6 adults and 2 pediatric) were used as a control for 
normal expression of the diff erent transcripts. 
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Figure 2: EVI1 expression in diff erent cytogenetic subgroups. 
Cumulative mRNA expression levels of the EVI1-1A, -1B, -3L, relative to GAPDH (%) for 179 samples in diff er-
ent cytogenetic subgroups in pediatric AML and in 8 normal bone marrow samples (NBM). A cumulative relative 
expression of 1.5% for one of the transcripts was considered positive. 
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Twenty-one of the 22 patients identifi ed by gene expression profi ling had a cumulative 
relative expression to GAPDH of at least 1.5% for one of the EVI1 transcripts (Table 1). 
Th e other patient (#20), whom lacked a cumulative relative expression of at least 1.5%, did 
show overexpression of EVI1-1D and MDS1/EVI1, and was considered EVI1+. In addition, 
one patient with FAB-M7 (#24) whom showed low expression of EVI1 on gene expression 
profi ling, did show abnormal expression of EVI1 with RQ-PCR. All remaining samples did 
not show EVI1 overexpression (Figure 2). Although only 22/23 EVI1+ cases could be identi-
fi ed with gene expression profi ling in comparison with RQ-PCR, still RQ-PCR for these four 
EVI1 isoforms showed high correlation with the gene expression data. Spearman correlation 
coeffi  cients were 0.68 for EVI1-1A, 0.63 for EVI1-1B, 0.52 for EVI1-3L and 0.78 for EVI1-1D. 
Moreover, microarray analysis showed a sensitivity of 95%, a specifi city of 100%, a positive 
predictive value of 100% and a negative predictive value of 99%.
Based on conventional cytogenetics, none of the patients harbored a 3q26 aberration. In 
addition, only three EVI1+ patients lacked the MDS1/EVI1 transcript, which has previously 
shown to be a marker to detect cryptic 3q26 aberrations(13). However, in all EVI1+ cases, 
cryptic 3q26-rearrangements were not detected by FISH (Table 1).  Th us, combining data of 
the gene expression profi ling and RQ-PCR, 25 EVI1+ cases were identifi ed and none of them 
harbored a 3q26-aberration.
Clinical characteristics of EVI1+ in pediatric AML  
EVI1+ pediatric AML was not correlated with sex, white blood cell count or age. When 
studying the relationship between EVI1+ and conventional classifi cation criteria such as 
morphology (FAB classifi cation) and cytogenetic data (Table 2), a higher frequency of EVI1 
overexpression was detected in patients with 1) MLL-rearrangements (n=13/47 cases), in-
cluding all t(6;11) cases (n=4); 2) acute megakaryoblastic leukemia (AML-M7) (n=4/7 cases); 
3) acute erythroblastic leukemia (AML-M6) (n=2/3 cases) and 4) monosomy 7 (n=2/3 cases). 
Th e 6 remaining cases were patients with normal karyotype (n=1), other cytogenetics (n=4) 
or unknown karyotype (n=1), but none of them harbored a 3q26-rearrangement (Table 1 and 
2). Overexpression of EVI1 was not found in the prognostically favorable types of AML, i.e., 
t(8;21), inv(16) and t(15;17). 
We also studied EVI1+ in relation to single-gene mutations. Of interest, 3 patients (#14, #15 
and #22) showed a mutation in the RAS-gene. In addition, one EVI1+ patient (#8) had a 
CEBPα mutation. One EVI1+ patient (#10) had a FLT3-ITD, whereas 40/203 EVI1- patients 
had a FLT3-ITD (respectively 4.0% v 19.7%, P=0.05). EVI1+ was not found in patients with 
NPM1, MLL-PTD and CKIT mutations.
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Table 1: Patients characteristics and expression levels of EVI1 transcripts
RQ-PCR1 EVI1 %
ID
   AML 
   type
Karyotype FAB
MLL 
FISH
-1A -1B -3L -1D ME
inv(3) 
FISH
1 s-AML
46,XX,t(9;11)(p22;q23)[41]/47,XX,
idem,+8[2]
M5 yes 3.44 1.7 0.48 0.02 0.00 neg
2 p-AML 46,X,t(X;6)(p1?2;q2?1) M6 no 3.65 2.46 0.66 0.07 0.25 neg
3 r-AML NA M1 no 1.89 0.76 0.16 0.00 0.00 neg
4 p-AML 46,XY,t(6;11)(q27;q23) M5 yes 35 7.29 13.5 0.07 0.23 neg
5 p-AML 47,XY,+21 M5 no 15.3 7.81 2.73 0.18 0.09 neg
6 p-AML 46,XY,t(9;11)(p22;q23) M7 yes 76.4 48.3 11.9 1.00 1.29 neg
7 p-AML
46,XY,t(9;11)(p22;q23)/48,
idem,+8,+mar
M5 yes 6.94 4.24 3.12 0.03 0.15 neg
8 p-AML 46,XX,t(11;20)(p15;q1?2)[20] M4 no 31.6 7.26 10.3 0.20 0.03 neg
9 p-AML 46,XX,t(6;11)(q27;q23) M4 yes 21.3 8.49 8.42 0.09 1.28 neg
10 p-AML 46,XX,t(11;19)(q23;q11) M2 yes 2.45 1.41 0.84 0.01 0.03 neg
11 s-AML 46,XX,t(11;17;?)(q23;q?21;?) M4 no 6.75 3.57 1.66 0.08 0.00 neg
12 p-AML 46,XX,inv(9)(p11q13),t(11;17)(q23;q12) M5 yes 11.6 3.11 0.89 0.05 0.03 neg
13 s-AML 46,XX,t(9;11)(p22;q23)[4]/46,XX[7] M5 yes 11.6 1.96 2.65 0.04 0.07 neg
14 p-AML
42~44,XY,t(6;11)(q27;q23)[cp2]/ 51,
idem,+X, +der(6)t(6;11)
(q27;q23),+8,+19,+21[5]
M5 yes 31.6 7.26 10.3 0.20 0.03 neg
15 p-AML 46,XX M5 no 9.35 10.7 2.15 0.07 0.05 neg
16 p-AML NA M7 no 2.9 5.55 2.99 0.05 0.09 neg
17 p-AML 46,XY,add(11)(q23),inc M1 yes 5.13 0.87 0.92 0.01 0.10 neg
18 p-AML NA M6 no 2.26 1.99 0.24 0.02 0.00 neg
19 p-AML
46,XX,t(8;13)(q22;q1?4)
[8]/48,idem,+6,+mar[4]/46,XX[8]
M7 no 9.23 8.1 16.5 0.02 0.34 neg
20 s-AML
45,XY,-7[8]/49,XY,-7,+9,+10,+14,
+21[12]
M2 no 0.17 0.2 0.19 0.01 0.13 neg
21 p-AML 46,XX,t(9;11)(p22;q23)[5] M4 yes NA NA NA NA NA neg
22 p-AML 46,XY[20] M5 yes NA NA NA NA NA neg
23 p-AML 45, XX,inv(2)(p24q14),-7 M4 no 0.8 0.85 0.43 0.01 0.01 neg
24 p-AML NA M7 no 1.01 2.47 8.35 0.00 0.02 neg
25 p-AML 46,XY,t(6;11)(q27;q23)[15] M1 yes 7.26 3.48 2.7 0.03 0.53 neg
- normal bone marrow (median expression) - - 0.04 0.09 0.03 0.00 0.00 neg
1Relative expression to GAPDH, 2no material available; NA, not available; neg, negative; ND, not determined; p-AML, 
primary-AML; s-AML, secondary-AML; r-AML, relapsed-AML.
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Table 2: Clinical characteristics of EVI1 positive patients in relation to clinical parameters, morphology and 
cytogenetics.
No. of EVI1 negative 
patients (%) 
No. of EVI1 positive 
patients (%)
P value
Sex 0.181 #
male 119 (58) 11 (44)
female 84 (42) 14 (56)
Age (years, median) 7.2 9.6   0.095 §
< 2 years 30 (15) 6 (24) 0.273 #
2-10 years 77 (38) 11 (44)
> 10 years 96 (47) 8 (32)
WBC x 10^9/L (median) 39.7 42.2 0.772 §
FAB <0.001 #
M0 12 (6) 0 (0)
M1 25 (12) 3 (12)
M2 49 (24) 2 (8)
M3 18 (9) 0 (0)
M4 49 (24) 5 (2)
M5 41 (20) 9 (36)
M6 1 (1) 2 (8)
M7 3 (2) 4 (16)
 other/unknown 5 (3) 0 (0)
Cytogenetic abnormalities <0.001 #
MLL-rearrangements 34 (17) 13 (52)
t(8;21)(q22;q22) 28 (14) 0 (0)
inv(16)(p13q22) 27 (13) 0 (0)
t(15;17)(q22;q21) 16 (8) 0 (0)
t(7;12)(q36;p13) 7 (3) 0 (0)
monosomy 7 1 (0) 2 (8)
normal cytogenetics 41 (20) 1 (4)
others/unknown1 49 (25) 9 (36)
1 See Table 1, # Chi-square test, § Mann-Whitney-U test
Gene expression signature diff erences within EVI1+ cases
In order to get insight into the biology of EVI1+, we analyzed our dataset to identify a spe-
cifi c gene expression signature for EVI1+ pediatric AML. Using an empirical Bayes linear 
regression model (30), 2103 discriminative probe sets for EVI1+ were identifi ed. However, 
within the MLL-rearranged AML subtype a diff erent gene expression signature was observed 
compared to the EVI1+ cases in other AML subtypes (Figure S2). Aft er applying correction 
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for cytogenetic subtype, the amount of discriminating probe sets decreased drastically from 
2103 to 253 and only 88 of these 253 probe sets were detected to be strongly signifi cant in 
both groups, i.e., MLL-rearranged AML and other AML subtypes. Th erefore, these 88 probe 
sets were considered to be highly discriminative for EVI1+ (FDR-corrected P<0.001) inde-
pendent of their cytogenetic background. Th e top 4 probe sets represented overexpression of 
the EVI1 and MDS1 gene themselves. Interestingly, some other probe sets represented genes 
that have been reported to play a role in hematopoiesis and/or the development of leukemias, 
e.g., PBX1 and RUNX2(33, 34) (Table S2).
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Figure 3. Survival outcome for high EVI1 expression in pediatric AML. 
(A) Kaplan-Meier estimates for pEFS in the total cohort between EVI1+ and EVI1- patients. (B) Kaplan-Meier esti-
mates for pOS in the total cohort between EVI1+ and EVI1- patients. (C) Kaplan-Meier estimates for pEFS in the 
cohort of MLL-rearranged AML between EVI1+ and EVI1- patients. (D) Kaplan-Meier estimates for pOS in the 
cohort of MLL-rearranged AML between EVI1+ and EVI1- patients. Per plot a Log-rank P value is depicted. 
Survival analysis and prognosis of EVI1+ in pediatric AML
Survival data were available for 198 patients, including 18 EVI1+ cases. Patients with EVI1 
overexpression had a signifi cantly worse 4 years pEFS (28%±11% v 44%±4%, P=0.04) as 
compared to patients without EVI1 overexpression. However, the overall survival was not 
signifi cantly diff erent between both groups (56%±12% v 64%±4%, P=0.34) (Figure 3A and 
89
Chapter 4 
3B). Within the MLL-rearranged AML group (n=40) no signifi cant diff erence for 4 years pEFS 
(20%±13% v 40%±9%, P=0.44) nor for 4 years pOS (50%±16% v 47%±9%, P=0.68) between 
EVI1+ and EVI1- patient was found (Figure 3C and 3D). Th e fact that EVI1 overexpres-
sion did not infl uence outcome in pediatric AML was confi rmed with multivariate analysis, 
including favorable karyotype, age and WBC, and showed that EVI1+ lacked independent 
prognostic signifi cance for pEFS (HR 1.2, P=0.67) and for pOS (HR 1.0, P=0.97) (Table 3).
Table 3. Multivariate analysis of high EVI1 expression in pediatric AML for event-free survival (EFS) and overall 
survival (OS).
EFS OS
HR (95% CI) P value HR (95% CI) P value
EVI1+ 1.2 (0.6-2.2) 0.67 1.0 (0.5-2.1) 0.97
Favorable karyotype* 0.4 (0.2-0.6) <0.001 0.2 (0.1-0.5) <0.001
WBC > 50 x 109/L 1.0 (0.7-1.5) 0.97 1.3 (0.8-2.1) 0.36
Age older than 10 years 1.0 (0.6-1.4) 0.87 0.8 (0.5-1.3) 0..34
*   t(8;21), inv(16) and t(15;17)
¶   WBC= White blood cell count above 50 x 109/L
§   Children older than 10 years
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DISCUSSION
Evi1 was detected by Morishita et al. as a common integration site by retroviral insertion 
in a murine model system, leading to Evi1 overexpression and leukemia, which suggests a 
role for EVI1 as an oncogene(5). Subsequently, the human EVI1 gene was detected in the 
breakpoint region of chromosome 3q26-rearrangements in diff erent myeloid malignan-
cies(1). Additional evidence that EVI1 may act as on oncogene comes from studies by 
Laricchia-Robbio  et al. and Kilbey et al. who showed that aberrant overexpression of EVI1 
results in loss of cell-cycle control and increased self-renewal(35, 36). Moreover, adult AML 
patients with high EVI1 expression, irrespective of harboring a 3q26 abnormality, have a 
poor prognosis(13). Until now, no information was available on the role of the EVI1 gene 
in pediatric AML, in which cytogenetically detectable 3q26 abnormalities do not seem to 
occur frequently(14). In the present study cohort, without cytogenetically detectable 3q26 
abnormalities, we discovered EVI1 overexpression in 20/213 (9%) of the children with de 
novo AML, and in 4/8 (50%) patients with secondary-AML. Moreover, we showed a strong 
association between EVI1 overexpression and specifi c genetic and morphologic subtypes of 
AML. In contrast to adult AML, we did not fi nd any evidence for chromosome 3q26 ab-
errations, nor for cryptic 3q26 rearrangements in EVI1+ cases. However, we did identify 
EVI1+ in FAB-M6/M7 cases, which has not been reported in adults so far. In addition, we 
identifi ed EVI1+ in subgroups that are considered to have an intermediate or poor prognosis, 
i.e., pediatric AML with MLL-rearrangements and monosomy 7, which included 3 of the 4 
secondary-AML cases. Overexpression of EVI1 was also identifi ed in MLL-rearrangements 
and monosomy 7 in adult AML(14, 37, 38). Interestingly, EVI1 expression was mutually 
exclusive with CBF-AML, t(15;17) and NPM1 mutations which represent favorable types of 
pediatric AML. 
Gilliland et al. hypothesized that the initial development of AML results from both type-I 
and type-II mutations. Type-I mutations induce enhanced proliferation of the hematopoietic 
cells, whereas type-II mutations lead to impaired diff erentiation and maturation arrest(39). 
Non-random associations between specifi c mutations have been shown for various other 
subtypes in AML, such as t(8;21) or inv(16) and c-KIT, supporting the Gilliland hypoth-
esis(40). We found that EVI1 was overexpressed in various morphologic and genetic subtypes 
of childhood AML, and even in homogeneous subgroups EVI1 overexpression was oft en 
only detectable in a subset of patients. Th erefore, we assume that EVI1 overexpression is a 
secondary and not an initiating event that may occur later in leukemogenesis. Moreover, it 
is not clear whether EVI1 is a driver rather than a bystander eff ect in our cases with EVI1+. 
Several fi ndings, however, may support a role for EVI1+ in leukemogenesis in these specifi c 
cases. For instance, all MLL-AF6 and a signifi cant proportion of monosomy 7 cases are clearly 
associated with EVI1+, not only in pediatric but also in adult AML(13). Moreover, in vivo 
studies with an MLL-AF9 mouse-model showed overexpression of Evi1 aft er the leukemic 
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transformation(41). In addition, a recent report in pediatric AML patients with monosomy 
7 showed a higher incidence of 3q26-rearangements, and a role for EVI1 was already sug-
gested by these investigators(37). We know from Fanconi anemia, that patients with 3q26 
aberrations have a higher risk of developing AML and if  monosomy 7 develops, this occurs 
in the 3q26 aberrant clone as a second event(42). Th erefore, and since both MLL-AF6 and 
monosomy 7 are associated with poor outcome in pediatric AML(37, 38, 43), this may un-
derscore that EVI1 plays a role in these leukemias. However, direct evidence demonstrating 
an oncogenic eff ect of EVI1+ overexpression in these types of leukemia could not be derived 
from our study and further evidence is currently lacking. Clearly, further studies need to be 
performed to unravel the exact biological role of EVI1+ in these leukemias.
Th ere is also supporting evidence for a role of EVI1+ in the development of AML FAB-M6 
and -M7. For instance, adult myeloid malignancies with 3q26 abnormalities show increased 
numbers of dysplastic megakaryocytes. Other in vitro studies demonstrate that EVI1 over-
expression leads to impaired erythroid and megakaryocytic diff erentiation by GATA-1 inac-
tivation(44-46). However, in vivo, no abnormalities of erythroid cells were observed in Evi1 
transgenic mice, although they did show a signifi cant reduction in the number of erythroid 
colony-forming units, implying a defect of erythroid hematopoiesis aff ecting erythroid pro-
genitor cells(47). Th erefore overexpression of EVI1 might be involved in the development of 
AML of both acute erythroid and megakaryoblastic leukemia.
Unsupervised cluster analyses (data not shown) did not identify a specifi c cluster for EVI1+ 
cases, as previously reported in adult AML. Th ese cases were oft en split among diff erent 
clusters harboring MLL-rearranged AML (adult and pediatric AML), monosomy 7/3q26 
aberrations (adult AML) or FAB-M6/M7 (pediatric AML)(48). However, by supervised clus-
tering, we found that within the subgroup of MLL-rearranged AML, EVI1+ pediatric patients 
revealed a diff erent gene expression signature as compared to the EVI1+ patients in the other 
cytogenetic subtypes. Interestingly, methylation array profi les in adult AML identifi ed dif-
ferent subgroups within  EVI1+ patients, indicating the heterogeneity of this subgroup(49). 
Although these data strongly suggest diff erences in biology between subgroups of EVI1+, still 
probe sets were identifi ed to be discriminative for EVI1+, independent of their cytogenetic 
or morphologic background aft er multivariate analysis. Th is could indicate a specifi c role for 
EVI1 overexpression in the development of leukemia in these cases, especially since some 
of these probe sets included genes that have been previously been reported to play a role in 
hematopoiesis and/or the development of leukemias, e.g., PBX1 and RUNX2(33, 34). More-
over, recent analysis of the Pbx1 promoter region in mice revealed that Evi1 upregulates Pbx1 
transcription(50). Th is emphasizes that PBX1 is a possible target gene of EVI1 involved in the 
leukemogenesis of EVI1+ patients.
Although diff erences in event-free and overall survival for EVI1+ and EVI1- pediatric AML 
were observed in our study, we showed that EVI1+ has no independent prognostic value for 
pediatric AML, which is in contrast to adult AML(12, 13). Th e latter may mainly be caused 
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by diff erences in frequency of 3q26 abnormalities, but also by diff erences in therapy and 
prognosis between adults and children. 
In this fi rst study on the relevance of EVI1 overexpression in pediatric AML, we conclude that 
EVI1+ is found in 9% of de novo pediatric AML. EVI1 is overexpressed in specifi c cytogenetic 
(MLL-rearrangements and monosomy 7) and morphologic (FAB-M6/7) subtypes. However, 
the typical EVI1+ associated 3q26 aberrations reported in adult AML were not identifi ed, 
indicating that there may be a diff erence for the role of EVI1+ in adult AML as compared to 
pediatric AML. Although EVI1+ was not an independent prognostic factor, it was predomi-
nantly found in types of pediatric AML that are related with an intermediate to unfavorable 
prognosis, e.g., MLL-AF6 and monosomy 7. Th is underscores the need for further studies to 
identify the biological role of EVI1 in the pathogenesis of childhood leukemia.
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ABSTRACT 
Th e aim of this study is to investigate frequency and prognostic signifi cance of high EVI1 
expression in acute myeloid leukemia (AML). A diagnostic assay detecting multiple EVI1 
splice variants was developed to determine the relative EVI1 expression by single real-time 
quantitative PCR in 1,382 newly diagnosed adult AML patients younger than 60 years. 
Patients were treated on four Dutch-Belgian HOVON (n=458) and two German-Austrian 
AMLSG protocols (n=924). Th e EVI1 assay was tested in the HOVON-cohort and validated 
in the AMLSG-cohort. High EVI1 levels (EVI1+) were found with similar frequencies, in 
both cohorts combined with a 10.7% incidence (148/1,382). EVI1+ independently predicted 
low CR rate (OR; 0.54, P=0.002), adverse relapse-free (RFS; HR, 1.32, P=0.05), and event-free 
survival (EFS; HR, 1.46, P=0.0003). Th is adverse prognostic impact was more pronounced in 
the intermediate cytogenetic risk group (EFS; HR, 1.64, P=0.0006; and RFS; HR, 1.55, P=0.02), 
and was also apparent in cytogenetically normal AML (EFS; HR, 1.67, P=0.008). Besides 
inv(3)/t(3;3), EVI1+ was signifi cantly associated with chromosome abnormalities monosomy 
7 and t(11q23), conferring prognostic impact within these two cytogenetic subsets. EVI1+ 
was virtually absent in favorable risk AML and AML with NPM1 mutations. EVI1+ AML 
patients (n=28) who received allogeneic stem cell transplantation in fi rst CR had signifi cantly 
better 5-year RFS (33%±10% versus 0%). EVI1 expression in AML is unequally distributed in 
cytogenetic subtypes. It predicts poor outcome, particularly among intermediate cytogenetic 
risk AML. Patients with EVI1+ AML may benefi t from allogeneic transplantation in fi rst CR. 
Pretreatment EVI1 screening should be included in risk stratifi cation.
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INTRODUCTION
Acute myeloid leukemia (AML) represents a heterogeneous group of neoplasms with vari-
able clinical behavior and diff erent responsiveness to treatment, which can be classifi ed based 
on unique genetic abnormalities(1, 2). Although biological insight of AML has increased in 
the past decade(3), the discovery and validation of novel discriminative biomarkers remains 
of utmost value to improve outcome prediction.
Ecotropic viral integration site 1 (EVI1) was fi rst identifi ed as a common retroviral insertion 
in murine myeloid leukemias(4). Several mouse studies have shown that EVI1 positive mice 
display a myeloid dysplastic condition, including hyperproliferation of bone marrow and 
progressive pancytopenia(5, 6). Clinically, high EVI1 expression (EVI1+) occurs in approxi-
mately 8% of patients with de novo AML.(7) In AML carrying the chromosome abnormalities 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2), aberrant EVI1 expression is caused by a breakpoint 
in or near the EVI1 locus at band 3q26.2. High EVI1 levels are also found in AML without 
chromosome rearrangements in this locus(7). Both groups are prognostically important due 
to poor treatment response. However, EVI1+ AML without 3q26.2 abnormalities represent 
an even larger and cytogenetically heterogeneous subset of AML(8).
Recently, EVI1 has been implicated in a prognostic multi-marker model for cytogeneti-
cally normal AML (CN-AML) cases in a relatively small cohort(9). Th e prognostic value of 
EVI1+ could not be assessed in particular cytogenetic risk categories or genotypic subsets of 
AML due to numerical limitations of previously reported series(8-11). In addition, various 
splice variants of EVI1 have been identifi ed(10). Some have suggested that EVI1+ may not 
be associated with inferior treatment response in any subsets without 3q26.2 abnormalities 
and hence questioned the need of EVI1 screening in routine genetic analysis(12). Due to 
the presence of numerous 5’ EVI1 splice variants, EVI1 screening could only be performed 
using diff erent specifi c 5’ real-time quantitative polymerase chain reaction (RQ-PCR) assays, 
which are time-consuming and thus hamper eff orts to implement EVI1 screening in an ef-
fi cient diagnostic setting(8, 10, 11). Th e clinical impact of EVI1+ on long-term outcome in 
other AML subtypes is also less clear. To date, no study exists in which a large homogeneous 
patient cohort younger than 60 years of age has been explored for EVI1 expression, allowing 
for identifi cation of EVI1+ AML subsets and straightforward risk assessment.We established 
an EVI1 RQ-PCR assay, covering the various EVI1 splice variants. Th is diagnostic assay 
was tested in one AML cohort, and the prognostic signifi cance of EVI1+ was independently 
validated in a second AML cohort. Joint analysis revealed independent signifi cance of EVI1+ 
as a prognostic marker in this large cohort of adult AML patients younger than 60 years of 
age. Furthermore, subgroup analyses identifi ed EVI1+ as an important prognostic factor for 
AML with intermediate cytogenetic risk and separately in AML with 11q23 translocations.
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PATIENTS AND METHODS
Patients and treatment
All patients for this study were recruited within two major leukemia cohorts. AML patients 
from Cohort I (n=458) were enrolled in the Dutch-Belgian Hemato-Oncology Cooperative 
Group (HOVON) -04(A), -29, and -42 trials (available at www.hovon.nl) (13-15). Cohort 
II (n=924) comprised patients who were enrolled in the AML Study Group (AMLSG) trials 
AML HD98A(16) and AMLSG 07/04 (ClinicalTrials.gov Identifi er: NCT00151242). Details 
of the treatment protocols are shown in Figure S1.
Th e proportions of analyzed to recruited patients within the prospective treatment trials 
were: AMLSG trials, 60% (924/1,538); HOVON trials, 17% (458/2,780). No signifi cant diff er-
ences for the endpoints OS (P =.20), EFS (P =.15), and RFS (P=0.36) were found comparing 
the 1,382 analyzed and 2,936 not analyzed patients. 
All adult patients younger than 60 years of age and availability of diagnostic blood or bone 
marrow samples were included. Patient characteristics of both cohorts are shown in Table S1. 
Cytogenetics and molecular analyses were performed as described in the Supplement
All patients provided written informed consent in accordance with the Declaration of 
Helsinki. All trials were approved by the Institutional Review Board of Erasmus University 
Medical Center and University of Ulm.
All Supplementary methods, supplementary results, tables and fi gures are not included, but are 
available online at http://jco.ascopubs.org/.
EVI1 real-time quantitative PCR
RNA isolation technique and conditions used for the EVI1 RQ-PCR are described in the Ap-
pendix. Th e EVI1 and PBGD primer/probe sequences and location are shown in respectively, 
Table S2 and Figure S2A.
Th e 3q26 amplifi ed cell line SKOV3 overexpressing EVI1(17) served as a calibrator for 
quantifi cation. Only standard curves established by serial dilutions of SKOV3 cDNA aliquots 
with correlation coeffi  cients larger than 0.9 were taken into account. Equal amplifi cation 
effi  ciencies of target and reference genes both in EVI1+ samples and SKOV3 at diff erent 
cDNA concentrations were seen. Th e relative EVI1 expression was calculated using the ddCT 
method.(18)
An overview of the EVI1 diagnostic assay validation is shown in Figure S2B. Based on a sepa-
rate cut-off  analysis (Supplementary methods), EVI1 expression levels were dichotomized 
based on a cut-off  of 0.1 relative to SKOV3, i.e., values higher than 0.1 were defi ned as EVI1+ 
(Figure S3).
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Statistical analysis 
Th e defi nition of complete remission (CR) and survival endpoints such as overall survival 
(OS), event-free survival (EFS), and relapse-free survival (RFS) were based on the recom-
mended consensus criteria.(19). OS endpoints were death (failure) and alive at last follow-up 
(censored), as measured from entry onto trial. EFS endpoints were remission induction fail-
ure, disease relapse, or death from any cause, measured from entry onto trial. RFS endpoints, 
measured from the date of fi rst documented CR, were relapse (failure), death in CR (failure), 
and alive in CR at last follow-up (censored). Th e method of Korn was used for assessment of 
the median follow-up for survival.(20) Th e follow-up time of surviving patients ranged from 
0.1 to 18.7 years, including 88% (533/605) with a follow-up time of two years.
Patient characteristics were compared by the Wilcoxon rank sum test (continuous variables) 
and the Fisher’s exact test (categorical variables). Distribution estimations and survival dis-
tributions of OS, EFS, and RFS were calculated by respectively, the Kaplan-Meier method and 
the log-rank test. 95% confi dence intervals (CI) were computed according to the cumulative 
hazard function using Greenwood’s formula for the standard error (SE) estimation (21). 
To determine the prognostic value of EVI1+, Cox proportional hazard regression models(22) 
with stratifi cation to account for the two diff erent cohorts were used. Th e proportional 
hazard assumption was tested(23) and no indication of non-proportionality was found. 
A variable selection was not performed and all variables were included in the fi nal Cox re-
gression models. Besides EVI1+, the prognostic variables used were age (per 10 years); white 
blood count (WBC) (log); platelet count (log); type of AML(19) (de novo AML, secondary 
AML [s-AML] or treatment-related AML [t-AML]); NPM1 mutant/FLT3-internal tandem 
duplication negative status (NPM1mut/FLT3-ITDneg); and cytogenetic risk. Th e cytogenetic 
risk was categorized in three groups, i.e., favorable risk, t(15;17), t(8;21), inv(16)/t(16;16); 
unfavorable risk, inv(3)/t(3;3), t(6;9), t(v;11q23) other than t(9;11), -5/del(5q), -7, abn(17p), 
complex karyotype (three or more abnormalities in the absence of a WHO(2) designated 
recurring chromosome abnormality); and intermediate risk, all chromosome abnormalities 
not classifi ed as favorable or unfavorable. Missing data of covariates were estimated using 50 
multiple imputations by chained equations utilizing predictive mean matching. All statisti-
cal analyses were performed using the statistical soft ware environment R, version 2.4.1, with 
the R package Design, version 2.0-12.
RESULTS
EVI1 diagnostic assay validation
An EVI1 diagnostic RQ-PCR assay was designed (Figure S2) and applied on 458 AML 
samples from Cohort I, on which an EVI1 cut-off  level was determined as described in the 
Supplement. All AML cases previously demonstrated to be EVI1+, using a combination 
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of fi ve diff erent RQ-PCR assays(8), were positive with this single test. EVI1+ was found in 
9.6% (95%-CI 7.2-12.7%) of the 458 AML of Cohort I. Th e EVI1+ incidence was comparable 
(P=0.41) in Cohort II of 924 AML, i.e., 11.3% (95%-CI 9.4-13.5%). In univariable Cox regres-
sion models, the impact of EVI1+ in both cohorts on the major clinical endpoints CR rate 
(Cohort I OR, 0.47, 95%-CI 0.23-0.97; Cohort II OR, 0.31, 95%-CI 0.20-0.48), EFS (Cohort 
I HR, 1.98, 95%-CI 1.42-2.76; Cohort II HR, 2.43, 95%-CI 1.95-3.02), RFS (Cohort I HR, 
2.10, 95%-CI 1.39-3.16; Cohort II HR, 1.75, 95%-CI 1.32-2.34), and OS (Cohort I HR, 1.84, 
95%-CI 1.30-2.61; Cohort II HR, 1.86, 95%-CI 1.46-2.38) was comparable as well. Based on 
these results, both AML cohorts were combined for further analyses.
t(15;17)
1% t(9;11)
8%
t(v;11q23)
12%
inv(3)/t(3;3)
14%
Other 3q26.2 
rearrangements
4%
Normal karyotype**
21%
Trisomy 8*
2%
Monosomy 7*
11%
Complex
karyotype
9%
Other
18%
Figure 1. Distribution of cytogenetic abnormalities among EVI1+ AML (n=148). 
*Occurring in a non-complex karyotype and not associated with inv(3)/t(3;3). **Among the EVI1+ with a normal 
karyotype, 66% of this group carried the NPM1wt/FLT3-ITDneg/CEBPAwt genotype.
Clinical and genetic patient characteristics 
Th e clinical features of the EVI1+ (n=148) compared with EVI1- (n=1,234) AML patients 
are summarized in Table 1. EVI1+ was associated with type of AML, i.e., was found more 
frequently in s-AML and t-AML; and EVI1+ AML tended to have higher platelet counts 
compared with EVI1- AML (P=0.06). No signifi cant diff erences in age, gender, WBC, and 
bone marrow blast percentages were noted between EVI1+ and EVI1- AML.
Expression levels of EVI1 were high in 21 of 23 AML with inv(3)/t(3;3) (P<0.0001). Other 
cytogenetic abnormalities overrepresented among EVI1+ cases included t(9;11) and other 
t(v;11q23), as well as monosomy 7 occurring within a non-complex karyotype and in absence 
of inv(3)/t(3;3) (Table 1 and Figure 1). On the other hand, EVI1+ and favorable risk cyto-
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genetics [t(8;21), inv(16), t(15;17)] were almost exclusive. CN-AML were underrepresented 
among EVI1+ ca ses (P<0.0001). 
Molecular marker analysis revealed an inverse correlation of EVI1+ with NPM1 mutations 
(P<.0001) and FLT3-ITD (P=0.002). In CN-AML, FLT3 tyrosine kinase domain and CEBPA 
mutations were not diff erently distributed among EVI1+ cases. Th e CN-AML genotype 
NPM1wt/FLT3-ITDneg/CEBPAwt was signifi cantly overrepresented and accounted for 66% of 
the EVI1+ CN-AML patients (P<0.0001).
EVI1 as prognostic marker in AML
Th e median follow-up time for survival was 58.9 months. Patients with EVI1+ AML had a 
lower CR rate compared with patients with EVI1- AML (53% v 77%; P<0.0001). Multivariable 
logistic regression analysis revealed EVI1+ as an independent negative prognostic marker for 
achievement of CR (OR, 0.54, P=0.002; Table 2). Survival analyses revealed a signifi cantly 
inferior OS (P<0.0001), EFS (P<0.0001), and RFS (P<0.0001) for patients with EVI1+ AML 
compared with EVI1- AML patients (Figure 2A-C). In multivariable Cox regression models, 
EVI1+ signifi cantly aff ected the endpoints EFS (HR, 1.46, P=0.0003), RFS (HR, 1.32, P=0.05), 
but not OS (HR, 1.17, P=0.18) (Table 2). 
To evaluate the impact of allogeneic hematopoietic stem cell transplantation (HSCT) in 
patients with EVI1+ AML, patients were categorized on an as-treated basis. Univariable 
analysis revealed a signifi cant benefi t in OS (P=0.05) and RFS (P=0.001) for EVI1+ patients 
(n=28) who received allogeneic HSCT in fi rst CR compared with intensive chemotherapy or 
autologous HSCT (Figure 3).
Beside a trend towards a younger age between EVI1+ patients who received an allogeneic 
HSCT and those who did not (median age 41 years and 46 years, respectively, P=0.06), no 
signifi cant diff erence in cytogenetic risk, type of AML, age and WBC counts was found.
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Figure 2. Survival analysis of 1,382 patients with AML according to their EVI1 expression status for overall sur-
vival (A), relapse-free survival (B), and event-free survival (C). 
For each Kaplan Meier plot a corresponding log-rank P value is shown.
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Table 1. Clinical and genetic characteristics according to EVI1 status
 
Characteristics
EVI1 negative
(n = 1234)
EVI1 positive
(n = 148)
P value
Age, years 0.91
Median (range) 46 (15 – 60) 46 (15 - 60)
Sex, no. (%) 0.26
Male 629 (51) 68 (46)
Female 605 (49) 80 (54)
WBC, × 109/L 0.73
Median (range)
missing
21.4 (0.2 – 427)
n=18 
19.3 (0.5 – 532)
n=2 
Platelets, × 109/L 0.06
Median (range)
missing
51 (2 – 933)
n=21
64 (4 – 998)
n=2
Bone marrow blasts, % 0.31
Median (range)
missing
73  (0 – 100)
n=83
69.5 (12 – 100)
n=10
Type of AML, no. (%) 0.02
de novo AML 1152 (94) 129 (87)
M0 60 (5.5) 13 (11)
M1 190 (17.5) 24 (20)
M2 257 (23.5) 26 (22)
M3 82 (7.5) 2 (2)
M4 267 (24) 29 (24)
M5 180 (16.5) 16 (13)
M6 23 (2) 0 (0)
M7 4 (0.5) 1 (1)
Unclassifi ed 31 (3) 9 (7)
missing n=58 n=9
s-AML 21 (2) 6 (4)
t-AML 54 (4) 13 (9)
missing n=7 n=0
Cytogenetic characteristics, no. (%)*
t(8;21) 82 (7.0) 0 (0) 0.0001
inv(16)/t(16;16) 104 (8.9) 0 (0) <0.0001
t(15;17) 77 (6.6) 1 (0.7) 0.003
t(6;9) 11 (1.0) 0 (0) 0.61
t(9;11) 18 (1.6) 12 (8.8) <0.0001
t(v;11q23) 15 (1.3) 18 (13.2) <0.0001
inv(3)/t(3;3) 2 (0.2) 21 (15.4) <0.0001
Normal karyotype 559 (48.1) 31 (22.3) <0.0001
-7 within non-complex karyotype 5 (0.5) 33 (27.5) <0.0001
+8 within non-complex karyotype 66 (6.2) 3 (2.5) 0.011
Complex karyotype 97 (8.3) 18 (13) 0.08
Other 128 (10.4) 26 (17.6) 0.02
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Cytogenetic risk, no. (%)** 0.001
Favorable 262 (23) 1 (1)
Intermediate 774 (67) 62 (46)
Unfavorable 118 (10) 73 (53)
missing n=80 n=12
Molecular abnormalities, no. (%)
FLT3-ITD 325 (27) 22 (15) 0.002
missing n=18 n=2
FLT3-TKD 125 (11) 9 (6) 0.14
 missing n=49 n=7
NPM1-mutated 386 (32) 4 (3) <0.0001
missing n=19 n=6
NPM1mut/FLT3-ITDneg 199 (14) 2(1) <0.0001
 missing n=16 n=5
CEBPA-mutated CN-AML 76 (14) 2 (7) 0.41
missing n=19 n=2
NPM1wt/FLT3-ITDneg/CEBPAwt  
CN-AML
132 (22) 19(66) <0.0001
missing n=22 n=2
Abbreviations: AML, acute myeloid leukemia; WBC: white blood cell count; FLT3-ITD, FLT3 internal tandem 
duplication; FLT3-TKD, FLT3 tyrosine kinase domain; CEBPA, CCAAT/enhancer binding protein alpha; NPM1, 
nucleophosmin 1; Subheadings under “de novo AML” refer to French American British classifi cation subtypes; wt, 
wild-type; neg, negative.
*     Patients may be counted more than once owing to the coexistence of more than one cytogenetic abnormality in 
the leukemic clone.
**   Favorable risk, t(15;17), t(8;21), inv(16)/t(16;16); unfavorable risk, inv(3) or t(3;3), t(6;9), t(v;11q23) other than 
t(9;11), -5 or del(5q), -7, abn(17p), complex karyotype (three or more abnormalities in the absence of a WHO(2) 
designated recurring chromosome abnormality); and intermediate risk, all chromosome abnormalities not classi-
fi ed as favorable or unfavorable.
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Table 2. Multivariable analysis of EVI1 as a prognostic marker for survival
Achievement of CR OR 95%-CI P value
EVI1+ 0.54 (0.36-0.80) 0.002
NPM1mut/FLT3-ITDneg 2.35 (1.52-3.65) 0.0001
Cytogenetic unfavorable risk 0.49 (0.34-0.71) 0.0001
Cytogenetic favorable risk 1.62 (1.07-2.44) 0.02
Age (diff erence of 10 years) 0.79 (0.70-0.89) 0.0007
Log10(WBC) 0.63 (0.52-0.78) <0.0001
Overall Survival HR 95%-CI P value
EVI1+ 1.17 (0.93-1.46) 0.18
NPM1mut/FLT3-ITDneg 0.52 (0.41-0.65) <0.0001
Cytogenetic unfavorable risk 1.96 (1.60-2.40) <0.0001
Cytogenetic favorable risk 0.49 (0.39-0.62) <0.0001
Age (diff erence of 10 years) 1.40 (1.27-1.54) <0.0001
Log10(WBC) 1.52 (1.35-1.70) <0.0001
Event-free Survival HR 95%-CI P value
EVI1+ 1.46 1.19-1.87) 0.0003
NPM1mut/FLT3-ITDneg 0.43 (0.35-0.54) <0.0001
Cytogenetic unfavorable risk 1.68 (1.38-2.04) <0.0001
Cytogenetic favorable risk 0.48 (0.39-0.59) <0.0001
Age (diff erence of 10 years) 1.12 (1.05-1.19) 0.0007
Log10(WBC) 1.35 (1.22-1.50) <0.0001
Relapse-free Survival HR 95%-CI P value
EVI1+ 1.32 (0.99-1.76) 0.05
NPM1mut/FLT3-ITDneg 0.47 (0.37-0.61) <0.0001
Cytogenetic unfavorable risk 1.67 (1.29-2.17) <0.0001
Cytogenetic favorable risk 0.48 (0.37-0.61) <0.0001
Age (diff erence of 10 years) 1.12 (1.03-1.21) 0.005
Log10(WBC) 1.43 (1.25-1.64) <0.0001
Abbreviations: WBC, white blood cell count; FLT3-ITD; FLT3 internal tandem duplication; FLT3-TKD, FLT3 tyro-
sine kinase domain; NPM1, nucleophosmin 1. Cytogenetic risk, unfavorable and favorable risk defi ned as described 
in Patients and Methods section. *Th e non-signifi cant prognostic markers used in the Cox model, i.e. type of AML 
and platelet count are not shown.
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Figure 3. Overall survival (A) and relapse-free survival (B) of EVI1+ patients aft er allogeneic hematopoietic 
stem cell transplantation (HSCT) or aft er chemotherapy or autologous HSCT in fi rst complete remission (CR). 
For each survival plot a corresponding log-rank P value is shown.
EVI1 expression in relation to cytogenetic risk categories 
Given the extremely low frequency of EVI1+ in favorable cytogenetic risk AML, EVI1+ does 
not have a role in prognostication in this AML subset. Forty-six percent of EVI1+ AML had 
intermediate risk cytogenetics (Table 1). Patients with EVI1+ AML and intermediate risk cy-
togenetics had a slightly lower CR rate compared with EVI1- AML patients in this risk group 
(71% v 78%; P<0.27). In univariable analysis, EVI1+ predicted inferior EFS (P<0.0001), RFS 
(P=0.006), and OS (P=0.05) (Figure 4A and Figure S4; top panel). In multivariable models, 
EVI1+ also was an independent adverse factor for EFS (HR, 1.64, P=0.0006), RFS (HR, 1.55, 
P=0.02), and in trend OS (HR, 1.34, P=0.07). A separate subset analysis focusing on CN-
AML is presented in the Supplementary Results and Figure S5, showing that EVI1 was an 
independent adverse prognostic marker for EFS (HR, 1.67, P=0.008).
Relationship of EVI1 expression with t(11q23) and -7 chromosome abnormalities
EVI1+ was associated with specifi c recurrent chromosome abnormalities, including 
inv(3)/t(3;3), monosomy 7 (occurring as sole abnormality or within a non-complex karyo-
type), and 11q23 translocations.
Of 64 cases with 11q23 translocations, 30 were EVI1+; 12 of the 30 cases carried a t(9;11), in-
cluding 7 de novo and 5 t-AML. Subtype analysis in the AML cases carrying 11q23 transloca-
tion revealed that EVI1+ patients showed an adverse survival rate with signifi cant diff erences 
in RFS (P=0.0006), but not OS (P=0.20) (Figure 4B and Figure S4; middle panel) 
Th irty-eight AML cases had monosomy 7 (-7) occurring either as sole abnormality (n=8) or 
within a non-complex karyotype (n=30). Of these 38 cases, 33 (87%) were EVI1+. Th e vast 
majority (31/33) of patients with -7/EVI1+ AML failed to achieve CR aft er fi rst induction, 
and 31 patients died aft er a median of 8.6 months (95%-CI 5.3-14.4 months), the remaining 
2 patients with -7/EVI1+ AML survived aft er 3 years. 
In the -7/EVI1+ subset, 18 of 33 cases carried an inv(3)/t(3;3), 4 of 33 had another 3q26.2 
chromosome rearrangement, whereas in 8 of the 11 remaining cases monosomy 7 was the 
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sole chromosome abnormality. Importantly, all patients with -7/EVI1+ AML had a dismal 
survival (2-year RFS 0%; 2-year OS 0%), irrespective of the presence or absence of inv(3)/t(3;3) 
(Figure 4C and Figure S4; lower panel).
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Figure 4. Relapse-free survival of patients with intermediate cytogenetic risk AML (A) and AML with t(11q23) 
(B) according to EVI1 status. 
Panel C shows the overall survival of AML cases with EVI1+ and monosomy 7, according to the presence (n=18) or 
absence (n=11) of inv(3)/t(3;3).
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DISCUSSION 
High EVI1 mRNA expression has initially been proposed as a negative prognostic marker in 
a study led by investigators of this report, and, more recently, in a multimarker model of CN-
AML(7, 9). To our knowledge, these results have not yet been validated in an independent 
cohort. Furthermore, due to limitations in sample size of these studies, identifi cation of other 
EVI1+ AML subsets remained unresolved. Here we assessed the incidence and prognostic 
impact of EVI1+ in a cohort of 924 adult AML patients less than 60 years of age treated 
within prospective multi-center trials of the German-Austrian AMLSG. Joint analysis with 
combined trial cohorts of the Dutch-Belgian HOVON Study Group and German-Austrian 
AML Study Group allowed us to assess the prognostic value of EVI1+ in a total of 1,382 
patients and identifi ed novel subgroups of EVI1+ AML.
Previously described EVI1 assays necessitate multiple PCR reactions to account for diff erent 
5’ splice variants, rendering EVI1 screening hardly feasible in a routine setting(10). We show 
that by using a single RQ-PCR assay, screening for EVI1 expression is feasible in a routine 
diagnostic work-up. EVI1 overexpression was identifi ed in 148 of 1,382 (10.7%) AML pa-
tients, consistent with previous results(7, 8). Within the EVI1+ AML cohort, there was over-
representation of specifi c chromosome abnormalities including inv(3)/t(3;3), monosomy 7, 
t(11q23), and among CN-AML there was overrepresentation of the triple negative genotype 
(NPM1wt/FLT3-ITDneg/CEBPAwt). AML with inv(3)/t(3;3) in fact represent a subgroup within 
the EVI1+ AML, as opposed to EVI1+ being a mere surrogate marker for this specifi c chro-
mosome alteration. Furthermore, EVI1+ was virtually absent in favorable cytogenetic risk 
AML and also in AML with NPM1 mutations.
EVI1+ independently predicted a reduced CR rate (53%), EFS, and RFS, but not OS. In view 
of the poor response to induction therapy and the reduced remission duration, alternative 
consolidation therapies need to be investigated. Due to diff erences in treatment protocols 
among trials and the long recruitment phase, this analysis had to be carried out retrospec-
tively and on an as-treated basis. Nonetheless, our data suggest that allogeneic HSCT from 
a matched related or unrelated donor in fi rst CR may be benefi cial for patients with EVI1+ 
AML with regards to OS and RFS. Allogeneic HSCT may represent a viable treatment option 
while targeted therapies are not yet available for this patient cohort.
Th e high number of patients in this study enabled us to evaluate the prognostic impact of 
EVI1+ in cytogenetic risk categories, in particular the intermediate risk group and also the 
subset of CN-AML. In multivariable analysis, EVI1+ predicted inferior EFS, RFS, and in 
trend also OS in intermediate risk AML, and inferior EFS in CN-AML. Molecular genotyping 
showed that NPM1 mutations were highly underrepresented in EVI1+ CN-AML, especially 
the favorable genotype NPM1mut/FLT3-ITDneg(24). Th is observation, together with the fact 
that EVI1+ predominantly associates with high risk cytogenetics, might explain why OS 
was not signifi cantly aff ected by EVI1+ in multivariable analysis in the total cohort and the 
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CN-AML subset. In case of relapse, chances of achievement of a durable second CR are very 
low for both groups independently of other molecular or clinical features(24-26). Th erefore, 
the eff ect of EVI1+ as a surrogate for both groups is outweighed when adjusting for these 
genotypic features in multivariable models.
Another interesting aspect relates to the fi nding of the association of EVI1+ with monosomy 7. 
On the one hand, monosomy 7 is the most frequent secondary chromosome change in AML 
with inv(3)/t(3;3) (found in ~50% of cases), and virtually all these cases show deregulated 
EVI1 expression by chromosomal rearrangement of the EVI1 locus at 3q26.2. On the other 
hand, of the 16 monosomy 7 cases without 3q26.2 rearrangement in our study, 11 were also 
EVI1+. Of note, outcome of patients with -7/EVI1+ AML was dismal irrespective of whether 
inv(3)/t(3;3) was present or not (Figure 4C), thus pointing to an alternative mechanism of 
EVI1 deregulation in monosomy 7 AML. How EVI1 overexpression contributes to an ag-
gressive course or chemotherapy unresponsiveness remains speculative. Notwithstanding, 
the interaction of EVI1 with several epigenetic regulators, such as methytransferases(27), 
could also defi ne EVI1 as a new target for treatment with hypomethylating agents of EVI1+ 
AML associated with monosomy 7. It has been reported that myelodysplastic syndromes 
(MDS) with monosomy 7 potentially benefi t from therapy with hypomethylating agents(28). 
Whether EVI1+ AML patients may benefi t from treatment with hypomethylating agents 
needs to be evaluated in future trials, which may open a new therapeutic door with regards 
to the biologic role of EVI1+ in MDS or AML(5, 29). More functional studies elucidating the 
biological role of EVI1 are needed to determine whether in human AML the deregulation of 
PU.1 through disruption of the c-Jun interaction impairs myelopoiesis(30). 
Another subgroup in this study negatively aff ected by high EVI1 expression was AML with 
t(11q23). Recently, prognostic factors for t(11q23) i.e., MLL-rearranged AML were described, 
upon which a risk stratifi cation model was presented(31). Th ese mainly included clinical 
parameters and the presence or absence of t(9;11) and t(6;11). Here, we show that by rapid 
testing for EVI1+, a new molecular screening target for 11q23 rearranged AML conducive for 
an accurate risk assessment becomes available, which has not been reported before.
Th is study shows that aberrant EVI1 expression is a strong prognostic marker for therapy 
response and survival in patients with AML. Pretreatment screening for EVI1+ should 
therefore be considered in newly diagnosed AML patients to better guide risk assessment 
and therapeutic approaches. In patients with EVI1+ AML who achieve CR, it seems justifi ed 
to prospectively evaluate the impact of allogeneic HSCT from a matched related or unrelated 
donor.
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ABSTRACT
Aberrant expression of EVI1 occurs in acute myeloid leukemia (AML) with chromosome 
3q26 abnormalities, the locus where the gene resides, but may also occur in AMLs with 
MLL rearrangements caused by 11q23 translocations. Applying EVI1 quantitative PCR, 
we observed EVI1 over-expression in 39/83 MLL-rearranged AMLs. High EVI1 levels were 
observed in 11/13 MLL-AF6, 17/42 MLL-AF9 and 7/14 MLL-ENL AML patients. In the 
present study, we investigated the relationship between EVI1 expression and MLL-AF9 in 
11q23 rearranged leukemias. MLL-AF9 leukemias expressing EVI1 showed a signifi cant 
adverse outcome compared to MLL-AF9 EVI1 non-expressors, which were mainly of the 
FAB-M5 subtype. MLL -AF9 transfection into murine bone marrow (mBM) cells resulted 
in high Evi1 levels in pooled primary colonies. Upon replating, 17% of the single colonies 
showed high Evi1 levels (Evi1+). More than 60% were Evi1-. We compared Evi1+ with Evi1- 
transformed clones and found that in the Evi1+ clones the immature common myeloid 
progenitors (CMPs) were present. Evi1- MLL-AF9 transformed cells only contained the 
more mature granulocyte-macrophage progenitors (GMPs). In Evi1+ transformed clones 
we observed immunophenotypically mature cells that aberrantly expressed Evi1. Th ese data 
are in line with sorting experiments of MLL-rearranged AMLs in which aberrantly high 
EVI1 levels were found in CD34-/CD38+ or CD34-/CD38- cells. In normal marrow these 
cells are EVI1-. Evi1 knockdown in Evi1+ MLL-AF9 mouse bone marrow cells resulted 
in a signifi cant decrease in colony growth aft er the fi rst replating. Th is study identifi es a 
new AML MLL-AF9 subtype over-expressing EVI1 and demonstrates a role for EVI1 in 
initiation of MLL-AF9 leukemia.
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INTRODUCTION 
Aberrant expression of EVI1 (ecotropic viral integration site-1) occurs in approximately 
6-8% of human acute myeloid leukemias (AML) and has been shown to be associated with 
poor treatment outcome(1-3). Th e EVI1 gene is located on chromosome 3 band q26 and is 
particularly highly expressed in patients with chromosome translocations involving the 3q26 
region(4). EVI1 encodes a nuclear protein with two zinc fi nger domains, each capable of bind-
ing DNA in a nucleotide specifi c manner(5, 6). In addition, it has been demonstrated that the 
protein can interact with a number of transcriptional and epigenetic regulators, such as Ct-
BPs(7), HDACs(8), MBD3(9) or histone-methyltranferases(10). Diff erent eff ects of aberrant 
EVI1 expression on cellular responses have been reported(11, 12). Aberrant expression of 
EVI1 associates with myelodysplatic syndrome (MDS), both in vitro and in vivo(13-15). EVI1 
blocks myeloid diff erentiation when over-expressed in transformed myeloid progenitors and 
it may provide proliferative advantage under certain circumstances(16-18). Although it is at 
present unclear why diff erent eff ects may be evoked by EVI1, its role in leukemia develop-
ment is indisputable and the particular interest of the present studyHigh expression of EVI1 
was also observed in both adult and pediatric AMLs without  chromosomal abnormalities 
within the EVI1 locus, especially in AMLs with MLL-gene rearrangements(1, 2, 19, 20). Th e 
prevalence within specifi c MLL-gene rearrangements remains unknown. Since multiple 
genetic events are required to obtain AML, both in humans and in murine leukemia mod-
els(21), it is possible that the observed Evi1 up-regulation in MLL-rearranged leukemia is a 
secondary phenomenon, acquired via additional genetic or epigenetic changes rather than 
a direct eff ect of the MLL-fusion gene induced transformation. High expression of Evi1 was 
found in the pre-leukemic stem and progenitor cells of knock-in MLL-AF9 mice compared to 
their corresponding wild type cells(22). Th e knock-in MLL-AF9 mice recapitulate the human 
disease by developing AML. Importantly, among the various MLL-AF9 hematopoietic stem 
and progenitor cells a direct correlation was observed between the level of Evi1 expression 
and the level of transformation, with the highest Evi1 expressing Lin-/Sca1+/c-Kit+ (LSK) 
cells inducing leukemia with the highest effi  ciency in transplant recipients(22). Th ese results 
suggest that at least in the murine MLL-AF9 model, Evi1 up-regulation is a downstream 
eff ect of the fusion oncogene rather than a random, acquired secondary eff ect. A putative 
role for EVI1 in myeloid transformation has recently been reported for MLL-ENL fusion 
oncogene(23).
In the present study, we sought to defi ne the relationship between EVI1 and the various 
MLL-fusion genes by studying a large cohort (n=83) of 11q23 rearranged leukemias. We 
demonstrate that EVI1 expression is associated with MLL-AF6, MLL-AF9 and MLL-ENL 
transformed human AMLs. However, in both subgroups a signifi cant number of AML cases 
are EVI1 negative. Based on clinical, morphological, immunological, in vitro proliferation 
and gene expression profi ling data the EVI1+ cases are clearly diff erent from the EVI1- 
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AMLs. Experiments with MLL-AF9 transduced mouse bone marrow cells demonstrate that 
the intermittent expression of EVI1 in human MLL-AF9 AMLs can be reproduced in murine 
models. Furthermore, we show that the EVI1 expression pattern in human AML as well as in 
MLL-AF9 transduced murine bone marrow cells is aberrant, since Evi1 is highly expressed in 
cells that are normally Evi1 negative. Knockdown of Evi1 in MLL-AF9 transformed cells in 
vitro point to a role of EVI1 in the pathogenesis of the EVI1 expressing MLL-AF9 leukemias. 
PATIENTS AND METHODS
Patient samples
Leukemic blast cells isolated at initial diagnosis from bone marrow or blood of 83 patients 
with 11q23 rearranged (MLL-rearranged) acute myeloid leukemia (AML) were purifi ed as 
previously reported(24, 25). All patients provided written informed consent in accordance 
with the Declaration of Helsinki. Th e study have been approved by the Institutional Review 
Board of Erasmus University Medical Center and Ulm University. 
Real-time quantitative PCR human EVI1 
RNA isolation and cDNA synthesis were performed as previously described(24). Real-time 
quantitative PCR (Q-PCR) to determine relative expression of EVI1 was performed as 
described(25). In summary, using human EVI1 forward primer 5’-AGTGCCCTGGAGAT-
GAGTTG-3’, EVI1 reverse primer 5’-TTTGAGGCTATCTGTGAAGTGC-3’ and EVI1 probe 
FAM- CCCCAGTGAGGTATAAAGAGGA using the ΔΔCt method(1, 2) with the human 
EVI1 over-expressing SKOV3 cell line(26) as reference and the PBGD gene (porphobilino-
gen deaminase) as calibrator (Ct values > 30.5 were discarded), the EVI1 relative expression 
was calculated. Th e patient samples with EVI1 relative expression above 0.1xSKOV3 were 
dichotomized as EVI1+ and cases below this threshold were EVI1-(25).
Statistical analysis
Fisher’s Exact test was performed to determine the distribution of French-American-British 
classifi cation (FAB) among the MLL-rearrranged AMLs. Survival analysis for overall survival 
(OS), event-free survival (EFS) and relapse-free survival (RFS) were performed according to 
recommended guidelines(27). Kaplan Meier analysis and log-rank P values were calculated 
for AML patients younger than 60 years of age with a t(9;11)(p22;q23) (MLL-AF9) based on 
EVI1 status, i.e. EVI1+ versus EVI1-.
Clustering analysis of the gene expression profi les (Gene Expression Omnibus GSE6891) 
from 12 EVI1- MLL-AF9 and 8 EVI1+ MLL-AF9 cases was performed using Omniviz soft -
ware as previously described(24, 28). 
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Real-time quantitative PCR of murine genes
RNA isolation of the cells obtained from the colony assays and cDNA synthesized was 
carried out as previously described(24, 29). Q-PCR for murine Evi1 was performed using 
forward primer 5’-CCAATCTTGACAGACACCTTGAA-3’ and reverse primer 5’- GGTT-
GCTGTTCCCGATGAAATT-3’ using SYBR Green (Applied Biosystems) according to 
manufacture’s protocol. Th e reference gene Hprt (hypoxanthine-guanine phosphoribosyl-
transferase), with forward primer 5’-AGCCTAAGATGAGCGCAAGT-3’ and reverse primer 
5’-GGGTACCCACGCGAATCAC-3’, was used with the empty vector (EV) as a calibrator
Meis1 Q-PCR was performed as previously described(22, 30).
Retroviral transduction 
pMSCV vectors containing MLL-AF9 puromycin and E2A-PBX puromycin were published 
previously(31, 32). A pMSCV-eGFP vector was used as a negative control (EV). 293T cells 
were co-transfected with each construct separately and pCL-Eco using FUGENE6 transfec-
tion reagent (Roche, Mannheim, Germany) according to manufacture’s protocol. Viral su-
pernatants were collected 48 hours aft er transfection, fi ltered, and used for transduction. One 
milliliter viral supernatant was added to 12 μg/ml Retronectin (Lonza, Basel, Switzerland) 
coated tissue culture dishes and incubated for four hours. Next, 2x106 C57BL/6 mouse bone 
marrow cells separated by Ficoll (Axis Shield, Rodelokka, Oslo, Norway), were added to the 
Retronectin coated dishes. Th e viral transduction procedure was repeated aft er twenty-four 
hours. Forty-eight hours post-infection, cells were harvested and placed in colony assays. 
Colony assays, in vitro cultures (Greiner Bio-One) and fl ow cytometry analysis were per-
formed as described previously(22).
Western blot analysis
In human AML samples nuclear extracts were generated according to manufacture’s proto-
col (NePer, Th ermo Scientifi c, Rockford, USA). In 40 μg nuclear protein lysate human EVI1 
protein levels were determined using an anti-human EVI1 antibody (Cell Signaling, Danvers, 
MA). 
Murine cells were lysed using a buff er containing 20 mM Tris-HCL, 137 mM NaCl, 10 mM 
EDTA, 50 mM NaF, 1% Triton, 10% glycerol and protease inhibitors. EVI1 protein level was 
determined in 40 μg protein lysate from transfected mouse bone marrow cells with EVI1 
antibodies directed against the N-terminal part(5) of the protein. 
For the western blot analysis performed on the MLL-AF9 leukemia cell line 4166, 3 0 μg 
protein lysate was used with antibodies against respectively, EVI1 (Santa Cruz Biotech., 
Santa Cruz, CA), Caspase-3, -8, -9, -12, PARP (Cell Signaling, Danvers, MA), HSP90 (BD 
Biosciences, San Jose, CA) or Actin (Sigma-Aldrich, St. Louis, MO).
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Knock down experiments using lentiviral shRNAs
Lentiviral short hairpin RNA (shRNA) clones were obtained from Open-Biosystems (Hunts-
ville, AL). Th e shRNAs include a hairpin with a 21 base-pair sense and antisense stem and a 
6 base-pair loop and were cloned into the pLKO.1 lentiviral vector that carried a blasticidine 
or neomycine resistance marker. A total of three EVI1 shRNAs were screened for eff ective-
ness of Evi1 knockdown. ShRNAs E95 (Clone ID: TRCN0000096095) and E97 (clone ID: 
TRCN0000096097) were found most eff ective. Lentivirus was produced by co-transfecting 
lentivirus expression vectors with the packaging plasmids pMDG and pCMVR 8.91 into 
293T cells using LT1 transfection reagent according to the manufacturer’s protocol (Roche, 
Indianapolis, IN). Culture supernatants containing lentivirus were harvested 48 to 72 hours 
post-transfection. Viral titers were determined by transducing NIH3T3 cells using diluted 
culture supernatants and determining the number of viable cells aft er fi ve days of culturing in 
the presence or absence of puromycin (1.5 μg/ml). To transduce target cells, lentivirus con-
taining culture supernatants were fi ltered through a 0.45 μ fi lter (Millipore Bedford, MA) and 
concentrated by ultracentrifugationm 12,000 x g) for 2 hours. Th e pellets were resuspended 
in serum-free IMDM. Unless specifi ed, a multiplicity of infection (MOI) of 10-20 was used in 
subsequent experiments by spin transduction..
RESULTS
EVI1 is frequently expressed in MLL-rearranged human AML 
Expression of EVI1 transcripts was studied in 83 AML patient samples with MLL-rearrange-
ments using a 3’ specifi c EVI1 Q-PCR(25). High EVI1 levels (EVI1+) were found in 39/83 of 
the MLL-rearranged cases (47%). Clinical characteristics of the MLL-rearranged AMLs and 
their EVI1 relative expression values are shown in Table S1. EVI1 expression was found in 
11/13 MLL-AF6 cases (85%), 17/42 MLL-AF9 (41%) and 7/14 MLL-ENL cases (50%) (Figure 
1A). EVI1 western blot analysis revealed the presence of EVI1 protein in three selected AML 
samples with MLL-AF6, MLL-AF9 or MLL-ENL rearrangements and with high EVI1 mRNA 
levels (Figure 1B). As expected, in a control AML sample with a 3q rearrangement, high 
EVI1 protein levels were detected, whereas EVI1 protein was absent in an AML that did not 
express EVI1 mRNA (EVI1-) (Figure 1B).
Abnormal EVI1 expression pattern in EVI1+ MLL-rearranged AMLs
In normal bone marrow samples EVI1 is expressed in primitive CD34+/CD38- fractions 
(Figure 2A ). Th e levels of EVI1 transcripts decrease strongly with normal diff erentiation, i.e. 
markedly lower expression is found in CD34+/CD38+, CD34+/CD38++ or CD34- cells com-
pared to cells from the CD34+/CD38- fraction (Figure 2A). To address the question whether 
EVI1 expression pattern in immunophenotypically defi ned subfractions of MLL-rearranged 
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AML was abnormal, we determined EVI1 levels in sorted fractions of two MLL-rearranged 
(MLL-AF6) AML samples. In one case (#5351) comparable numbers of cells were present 
in CD34+/CD38-, CD34+/CD38+, CD34-/CD38+ and CD34-/CD38- fractions, which were 
all equally EVI1 positive (Figure 2B, left  panel). Patient cells from case #2207 were mainly 
CD34+/CD38+ or CD34-/CD38+. High levels of EVI1 were found in both fractions (Figure 
2B, right panel). Th us, our data point to lineage infi delity of EVI1 expression in EVI1+ MLL-
rearranged AMLs..
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Figure 1. EVI1 is frequently expressed in MLL-rearranged AMLs. (A) Th e relative expression of EVI1 is shown 
for patients with diff erent 11q23 translocations corresponding to MLL-fusion genes, i.e. MLL-AF4, MLL-AF6, 
MLL-AF9, MLL-AF10, MLL-ENL and other MLL fusions. Per MLL-fusion patient group the percentage of EVI1 
positive (EVI1+) patients iwnindicated. (B) An EVI1 western blot analysis of three MLL-rearranged EVI1+ cases, 
one EVI1 negative (EVI1-) case and one 3q26-rearranged case is shown. High EVI1 protein levels were seen in 
three MLL-rearranged cases. Western blot staining using an actin antibody was applied to show comparable protein 
loading. *EVI1 protein (140 kD) was detected using increased exposure to the higher mass band (not shown).
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Figure 2. EVI1 expression in CD34 and CD38 fractions in normal bone marrow (A) and 11q23 rearranged 
AML (B). 
Bone marrow cells from a healthy individual and from two MLL-rearranged AML patients were stained with CD34 
and CD38 and diff erent fractions were isolated by fl owcytometric sorting. Marrow cells from the second MLL-AF6 
AML patient only containd CD34+/CD38+ and CD34-/CD38+ cells. Relative expression of EVI1 was calculated 
using PBGD as reference gene. Each measurement was carried out in triplicate and standard deviation is shown per 
measurement. EVI1 expression was determined in diff erent fractions and unsorted bone marrow.
EVI1+ and EVI1- MLL-rearranged AMLs diff er clinically and molecularly
MLL-rearranged EVI1+ versus EVI1- cases showed a signifi cant adverse survival outcome 
for OS, EFS and RFS of EVI1+ cases(25). Two other data sets revealed that MLL-rearranged 
AMLs can be subdivided into two distinct subtypes that are respectively, EVI1+ and EVI1-. 
A correlation view of an unsupervised gene expression profi ling analysis of a subset of MLL-
rearranged AMLs revealed that samples that were EVI1- clustered separately from the EVI1+ 
samples (Figure S1A). Secondly, EVI1- MLL-AF6, MLL-AF9 and MLL-ENL patients were al-
most exclusively of the morphologic subclass FAB-M5 (26/30), whereas EVI1+ cases with the 
same fusions were found among all FAB-categories (Fisher’s Exact test P<0.0001) (Table S1). 
We next wondered whether in the EVI1- MLL-rearranged FAB-M5 cases, mainly consisting 
of monoblasts, the minor fraction of CD34+ cells did express EVI1. Since MLL-AF9 cases 
formed the major fraction of MLL-rearranged AMLs (51%), we focused for the remaining 
of our study on this subtype only. Survival analysis within the MLL-AF9 population showed 
the same signifi cant adverse survival outcome for OS, EFS and RFS of EVI1+ cases (Figure 
S2). EVI1- MLL-AF9 AMLs were also mainly of the FAB-M5 (21/25) morphological class 
as well (Fisher’s Exact test P<0.0001). Th e percentages of sorted CD34+/CD38- or CD34+/
CD38+ cells in 9 samples as indicated in Table S2 were low and importantly these cells did 
not express EVI1 (Figure S3). Th us these MLL-AF9 AMLs are really EVI1-.
High Evi1 expression in MLL fusion gene transduced mouse marrow cells
We next investigated whether there is a causal relationship between the presence of MLL-AF9 
fusion genes in mouse bone marrow cells and Evi1 expression (Figure 3A). Ficoll separated 
mouse bone marrow cells were transduced with MLL-AF9, E2A-PBX or empty vector under 
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puromycin selection. Comparable primary colony numbers were found at day 7 in methyl-
cellulose colony assays for each construct (Figure 3B). Upon replating, secondary and tertiary 
colonies were formed with the MLL-AF9 and E2A-PBX but not with empty vector transduced 
marrow cells (Figure 3B). High levels of Evi1 and control Meis1 transcripts were observed 
in collected primary colonies of MLL-AF9 transformed marrow cells, but not in primary 
colonies of vector control or E2A-PBX transduced cells (Figure 3C, day 7 panel). Aft er the 
second replating, Evi1 and Meis1 mRNA levels increased in MLL-AF9 transformed colony 
cells (Figure 3C, day 14 panel). In accordance with the mRNA expression data, western blot-
ting of the cell lysates of collected colonies revealed expression of EVI1 protein in MLL-AF9 
at day 7 and day 14, but not in the E2A-PBX transformed cells (Figure 3D).
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Figure 3. High Evi1 expression in MLL-AF9 fusion transformed murine bone marrow progenitors. 
(A) Schematic illustration of the experimental approach to study the in vitro eff ects of MLL-AF9-fusion intro-
duced in normal murine bone marrow cells and the correlation of Evi1 expression to the leukemogenic potential of 
MLL-AF9. (B) Colony formation of murine mononucleated hematopoietic cells was observed aft er viral transduction 
of MLL-AF9. E2A-PBX and empty vector (EV). Note that, colony numbers at day 7 are calculated per number of 
plated retrovirus exposed cells. As puromycin selection occurred during this fi rst week of culture, these colony num-
bers represent CFUs relative to virus infected and virus non-infected cells. Colonies formed aft er replating represent 
numbers of CFUs per virus infected cells. All constructs, except the empty vector derived coloniet were replatable. 
(C) Evi1 and Meis1 relative expression was determined compared to EV from mRNA obtained from colonies at day 
7 or day 14, i.e. aft er the fi rst replating. (D) EVI1 protein was detected by Western blot analysis. Lysates were derived 
from pooled colonies at day 7 and 14. Th ree experiments were performed, one representative experiment is shown.
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MLL-AF9 transformed bone marrow cells generate Evi1+ and Evi1- colonies
Th e experiments from Figure 3 demonstrate that Evi1 expression is high in pooled myeloid 
progenitors when transduced with MLL-AF9, but does not answer the question whether 
Evi1 expression is activated in every MLL-AF9 transformed progenitor cell. To address this 
question we picked 100 single primary MLL-AF9 transduced colonies that were subsequently 
replated (Figure S4A). Seventy fi ve of those picked colonies formed new colonies and re-
mained indefi nitely replatabley Messenger RNA was isolated from those 75 replated cultures 
and analyzed for Evi1 mRNA expression. In 13/75 (17%) clones Evi1 was highly expressed 
(Figure S4B). In another 13 replates, Evi1 was expressed at intermediate levels and i4952/75 
secundary colonies Evi1 was negative, i.e. relative expression of Evi1 less than 1 (Figure S4B). 
Evi1+ versus Evi1- transformed cells showed equal replating capacity (Figure S5A) and in 
liquid cultures the growth rates werl similar as well (Figure S5A). In subsequent replatings, 
Evi1+ colonies remained positive, whereas Evi1- colonies remained negative (Figure S5B). 
Th ere was no clear diff erence in cell type distribution and growth rate between Evi1+ and Evi1- 
colonies (Figure S5C and D). Together these experiments demonstrate that, the intermittent 
expression of EVI1 in human MLL-AF9 AMLs, can be reproduced in murine bone marrow 
transformation assays. 
Evi1 expression in MLL-AF9 transformed murine bone marrow cells is abnormal 
Detailed fl owcytometric analysis of MLL-AF9 transformed marrow cells revealed a clear 
diff erence between Evi1+ versus Evi1- MLL-AF9 transformed clones. In Evi1- MLL-AF9 trans-
formed cell fractions only granulocyte/macrophage progenitors (GMPs) were detectable, 
whereas GMPs as well as the more immature common myeloid progenitors (CMPs) were 
found in Evi1+ MLL-AF9 cells (Figure 4A and B). No Lin-/Sca1+/c-Kit+ (LSK) cells, represent-
ing hematopoietic stem cells, were present in clones frin both groups. Th is is remarkable, 
since Q-PCR on mRNA obtained from sorted normal mouse bone marrow progenitor 
fractions revealed high Evi1 levels particularly in LSK fractions, whereas in normal CMP, 
GMP or MEP (megakaryocytic/erythroid progenitors) compartments Evi1 expression is 
lower or absent (Figure 4C). We next addressed the question whether Evi1 was expressed 
in mature cells of Evi1+ clones. Q-PCR on lineage positive cells sorted from Evi1+ MLL-AF9 
transformed clones showed high Evi1 levels (Figure 4D). Th us, Evi1 expression pattern in 
MLL-AF9 transformed clones is abnormal and mirrors the lineage infi delity observed in hu-
man EVI1+ MLL-rearranged AMLs. 
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Figure 4. Enrichment of common myeloid progenitors in Evi1 positive single MLL-AF9 clones. 
(A) Strategy of  fl ow cytometrical analysis performed on Evi1 positive and Evi1 negative single MLL-AF9 clones. 
Forward scatter (FSC) and side scatter were used for cell size and shape, 7-AAD for separating living cells and lineage 
marker negativity (Lin neg) was used to select immature cells. Monoclonal antibodies for CD16, CD32, and CD34 
were used to diff erentiate between granulocytic myeloid progenitor (GMP), megakaryocyte erythrocyte precursor 
(MEP) and common myeloid progenitors (CMP). (B) Th e percentages of CMP, GMP and MEP relative to the total 
numbers of progenitors are shown for each clone. (C) Evi1 expression in diff erent cell fractions of normal bone 
marrow. Relative expression of Evi1 was determined in diff erent cell fractions, LSK, CMP, GMP and MEP, as posi-
tive control the MLL-AF9 cell line 4166 was used. Th ree experiments were carried out and the standard deviation is 
depicted. (D) Relative Evi1 levels determined in lineage positive subfraction of MLL-AF9 clones. Th e expression of 
Evi1 was calculated relative to the lineage negative fraction of MLL-AF9 clone #1. Th ree experiments were carried 
out and the standard deviation is depicted.
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Evi1 knock down inhibits proliferation of MLL-AF9 transformed marrow cells in vitro
To study the role of Evi1 in MLL-AF9 transformation we carried out shRNA knock down 
experiments in Evi1+ and Evi1- MLL-AF9 clones. In cells treated with Evi1 specifi c shRNA, 
Evi1 expression declined (Figure 5A) and the number of colonies at day 7 decreased signifi -
cantly aft er replating (Figure 5B). Control shRNA did not aff ect Evi1 expression levels nor 
did colonies numbers decline. No eff ect on replating ability with any of the shRNAs was 
observed in Evi1- MLL-AF9 transformed cells (data not shown).
Recently, a MLL-AF9 knock-in leukemia cell line 4166, was generated(30). Th is knock-in 
model of MLL-AF9 closely mimics the conditions in human disease, because each cell 
contains only one copy of MLL-AF9, expressed under the control of the endogenous MLL 
promoter(33). Th is leukemia cell line model highly expresses Evi1(22) mRNA and EVI1 
protein. Evi1 mRNA levels as well as EVI1 protein were prominently reduced by the shRNA 
construct E95 and E96 but not by E94 (Figure 6A and 6D). Evi1 knockdown (E95) in 4166 
cells showed a signifi cant reduction of colony growth (Figure 6C). Based on these knock 
down experiments in transduced bone marrow cells and the 4166 cell line, we conclude that 
Evi1 plays a critical role in MLL-AF9 transformation when over express
EVI1
0
0.2
0.4
0.6
0.8
1
1 3 14
EV
I1
 F
ol
d 
ch
an
ge
0
10
20
30
40
50
60
70
1 3 14
C
ol
on
y 
nu
m
be
r /
 1
00
0 
ce
lls
 
SHC
EVI1 knockdown
n.s P=0.02
P=0.03
Clone
Evi1 negative Evi1 positive
Undet .
Clone
Evi1 negative Evi1 positive
BA P=0.023 P=0.034
Fo
ld
 c
ha
ng
e 
E
vi
1
EV
I1
 F
ol
d 
ch
an
ge
Fo
ld
 c
ha
ng
e 
E
vi
1 
Figure 5. Evi1 knockdown in MLL-AF9 clones results in decreased colony formation. 
(A) Evi1 shRNA E95 and short hairpin control (SHC) were transduced in two MLL-AF9 Evi1 positive clones and 
one Evi1 negative clone. Evi1 fold change was determined by comparing the relative Evi1 expression of the SHC to 
the relative expression of the Evi1 knockdown per clone. (B) Colony assays show that Evi1 knockdown results in 
decreased colony formation compared to SHC. One experiment was performed in duplo.
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Figure 6. Lentiviral shRNA mediated Evi1 knockdown in MLL-AF9 cell-line 4166 inhibits cell growth, reduces 
cell self-renewal and induces apoptosis.
4166 cells were transduced with three lentiviral constructs or a control virus and cultured for 5 days under puromy-
cin selection. (A) Relative expression of Evi1 in shRNA transduced 4166 cells. Gapdh was used as a reference gene 
and the expression was calculated relative to the virus control. Th e vector control is set to 100%. One representative 
experiment out of three is shown. (B) Percentage of alive cells, i.e., tryptan blue negative cells 5 days aft er shRNA 
transduction is depicted. One representative experiment is shown. (C) Methylcellulose colony assay of transduced 
4166 cells with virus control and Evi1 shRNA (EVI1 KD E95) under puromycine selection showed signifi cant reduc-
tion of colony formation in the Evi1 knockdown 4166 cells. Th e error bars represent 2SD (2 times standard devia-
tion), the t-test P value is shown. (D) Western blot analysis shows knockdown of Evi1 using EVI1 KD E95 construct. 
Antibodies against actin and Hsp90 were used to show, comparable protein loading and cell viability, respectively. 
Th e eff ect on apoptosis on Evi1 knockdown is shown by the protein levels of several full length and cleaved caspases 
and PARP. (E) Th e 4166 cells were transduced with EVI1 KD E95 or control virus and cultured for 48 hours with-
out puromycine. Nuclei were isolated and stained with PI (top panel). Analysis of DNA content by fl ow cytometry 
showed no increase in the proportion of G0/G1 nuclei (left  peak) in the KD-transduced cells compared with control 
virus. Increased uptake of the pan activated caspase maker CaspaTag in the KD-transduced cells indicate increased 
apoptosis in these Evi1 knockdown 4166 cells (bottom panel).
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Loss of Evi1 induces apoptosis without aff ecting cell cycle distribution
To discern by which mechanism Evi1 knockdown leads to reduced cell growth we performed 
cell cycle and apoptosis analysis. Flow cytometric analysis of PI-stained nuclei showed that 
Evi1 knockdown did not lead to drastic changes in the proportions of cells in G0/G1, S or 
G2/M phase of the cell cycle (Figure 6E, upper panel). Trypan blue staining of the transduced 
cells revealed that Evi1 knockdown resulted in increased cell death (Figure 6B). Moreover, 
Evi1 knockdown did result in increased apoptosis compared to the control group, evidenced 
by the increase in activated caspatag staining in E95-transduced cells as compared to vector 
control treated 4166 cells, respectively 32% versus 13% (Figure 6E, lower panel). Western 
blotting also revealed the presence of a strong increase of cleaved forms of Caspase -3, -8 
and -12 as well as cleaved PARP in 4166 cells in which Evi1 expression was reduced (Figure 
6D). Th ese experiments demonstrate that interfering with Evi1 expression in MLL-AF9 
transformed cells causes inhibition of proliferation through induction of apoptosis without 
aff ecting the cell cycle. 
DISCUSSION 
Th is study included a large cohort of AML patients carrying several diff erent 11q23 (MLL) 
translocations. We showed high EVI1 expression in approximately 40% of MLL-rearranged 
leukemias. Although the level of EVI1 expression was in general lower than that seen in 
AMLs with 3q26-rearrangements(25), the expression was signifi cant and MLL-rearranged 
leukemias were the only AMLs with recurrent translocations analyzed showing EVI1 expres-
sion. We did not observe any clear correlation between the MLL-fusion partner and EVI1 
expression. Th e preponderance of FAB M5 AMLs in the EVI1-negative cases suggests that 
the EVI1 expression might be infl uenced by the phenotype of the leukemic cell. Our sorting 
experiments in these patients showed that the minor fraction of CD34+/CD38- or CD34+/
CD38+ cells are also EVI1 negative. Th us MLL-rearranged AML can truly be subdivided into 
EVI1- versus EVI1+ patients. EVI1+ MLL-AF9 AMLs show a worse response to therapy than 
the EVI1- cases. Transplantation experiments that we are currently conducting might give us 
insight into whether Evi1+ MLL-AF9 transformed marrow cells are indeed more aggressive in 
vivo. Although we particularly focused on MLL-AF9, which is the most frequently occurring 
MLL-rearrangement in human AML, we hypothesize that our conclusions drawn from this 
study may be equally valid to the other EVI1+ MLL-fusion transformed AMLs (Figure 1, 
Figure S1). 
It is unclear, why certain MLL-AF9 leukemias are EVI1+, where as others with the same trans-
location do not express this oncogene. One explanation could be that in these leukemias, 
subsequent to the MLL-rearrangements additional mutations occur, which lead to aberrant 
EVI1 expression. It is also possible that the cell of transformation diff ers among patients, 
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such that the EVI1+ leukemias could have originated in cells that were EVI1+ to begin with. 
Th is second explanation would fi t with the fi nding that in normal marrow precursors EVI1 
positivity is particularly found in the most immature fraction, i.e. CD34+/CD38- in humans 
and LSKs in mice. Although this may indeed explain our fi ndings, this does not explain the 
aberrant EVI1 expression pattern, i.e. in both human and in experimental mouse bone mar-
row studies, EVI1 expression was observed in immunologically defi ned mature cell subsets, 
that are normally EVI1-. We hypothesize that in the EVI1+ cases, MLL-AF9 (co-)activates 
EVI1 mRNA transcription in cells that were initially already EVI1+. In cells that were EVI1-, 
MLL-AF9 and other MLL-fusions were not capable of activating transcription of this gene. 
Chromatin immunoprecipitation (ChIP) followed by promoter chip hybridization (ChIP-
Chip) or deep sequencing (ChIP-Seq), combined with studies using reporter assays, should 
clarify whether EVI1 is indeed a selective downstream target for MLL-AF9. 
Loss of Evi1 expression led to a decrease in colony formation of MLL-AF9 leukemia cells in 
vitro, suggesting that Evi1 plays a role in the maintenance of MLL-AF9 leukemia. We hy-
pothesize that in EVI1- MLL-AF9 AMLs, another mutated or aberrantly expressed oncogene 
is responsible for leukemic maintenance. We found that the growth inhibitory eff ects of Evi1 
knockdown were mediated by increased apoptosis without any eff ect on cell cycling. In the 
same 4166 cell line, these results are in contrast to the eff ects of Meis1 knockdown, a known 
down-stream target of MLL-fusion proteins(30). In this cell line, it was found that Meis1 
inhibition caused 4166 cells to arrest at the G0/G1 phase of the cell cycle. Additionally, while 
both Meis1 and Evi1 knockdown resulted in reduced colony growth in methylcellulose colony 
assays, Meis1 inhibition led to an increase in the proportion of  the more diff erentiated type 
II and type III colonies, while the undiff erentiated type I colony proportion was reduced(30). 
Th ese results suggest that while both MEIS1 and EVI1 are required for growth of certain 
MLL-AF9 leukemias, they are not part of the same biologic pathway, but rather complement 
each other. In a recent report, Jin et al. showed that Evi1 accelerated leukemia caused by over-
expression of Hoxa9 and Meis1(14). Th us, EVI1 and MEIS1, both activated by MLL-fusion 
proteins, might cooperate in the pathogenesis of leukemia. An important question to be ad-
dressed is, whether knocking down Evi1 in MLL-AF9 transformed cells interferes with in vivo 
leukemia growth. Our in vitro Evi1 knock down experiments and studies previously reported 
by Goyama et al.(23) showing that MLL-ENL induced tumor formation is greatly reduced in 
Evi1-/- bone marrow cells, suggest a critical role for EVI1 in MLL-fusion induced leukemia 
development. Targeting the EVI1 function might be considered as therapeutic option in the 
poor responding MLL-rearranged AMLs
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SUPPLEMENTARY TABLES
Table S1. Patient characteristics of 83 MLL-rearranged AML patients. Per patient, age, sex, FAB type, karyotype, 
MLL-rearranged fusion gene, relative expression (RE) of EVI1 and EVI1 over-expression (+) or no EVI1 expres-
sion (-) are shown. Th e karyotyping was performed according to the International System for Human Cytogenetic 
Nomenclature (2008) for each patient.
Sample Age Sex FAB  G-banding MLL-fusion RE EVI1 EVI1+
642 48 M M1 46,XY,t(10;11)(q22;q23) MLL-AF10 0.44 +
114 30 M M4
46,XY,t(10;11)(q11;q23)[8]/45,XY,add(1)(p36), 
t(10;11)(q11;q23),der(12)t(12;18)(p11;q11),-18[11]
MLL-AF10 0.45 +
292 50 F
47,XX,add(7)(p22),inv(8)(p23p13),+8,del(10)
(p11), der(11)t(11;10;7)(pter->11q23::?->?::q23-
>pter),del(19)(q13)
MLL-AF10 0.0 -
336 37 M M4
46,XY,ins(10;11)(p13;q23q13)[12]/48,XY,+8, 
ins(10;11)(p13;q23q13),+19[7]/46,XY[1]
MLL-AF10 0.05 -
582 31 M M5 46,XY,ins(10;11)(p13;q13q23) MLL-AF10 0.01 -
2255 45 M M1 46,XY,t(4;11)(q21;q23)[18] MLL-AF4 0.0 -
524 38 F
46,XX,t(4;11)(q21;q23),del(20)(q13)
[7]/46,XX,t(4;11)(q21;q23), del(5)(q31q33),del(12)
(p11),del(20)(q13)[19]
MLL-AF4 0.0 -
15017 34 M M4 46,XY,t(4;11)(q21;q23)[21] MLL-AF4 0.0 -
818 60 F M0 48,XX,t(6;11)(q27;q23),+21,+21[9] MLL-AF6 2.22 +
590 59 F M1 46,XX,t(6;11)(q27;q23) MLL-AF6 0.67 +
675 58 F M4 46,XX,t(6;11)(q27;q23) MLL-AF6 3.75 +
18 41 F M1 46,XX,t(6;11)(q26;q23) MLL-AF6 1.92 +
964 34 F M4 46,XX,t(6;11)(q27;q23) MLL-AF6 0.5 +
2207 31 M M1 46,XY,t(6;11)(q25;q23) MLL-AF6 0.7 +
6238 30 F M4 46,XX,t(6;11)(q27;q23)[28] MLL-AF6 1.1 +
15018 30 M M4 46,XY,t(6;11)(q27;q23) MLL-AF6 6.5 +
549 28 F M0 46,XX,t(6;11)(q27;q23) MLL-AF6 0.42 +
14294 19 M M5 46,XY,t(6;11)(q26;q22) MLL-AF6 0.6 +
5351 67 F M4 46,XX,t(6;11)(q27;q23)[36] MLL-AF6 0.39 +
15015 40 M M5 46,XY[35],46,XY,t(6;11)(q26orq27;q23)[6] MLL-AF6 0.0 -
889 22 F M5 45,XX,t(6;11)(q27;q23),-8,+2x i(8)(q10) MLL-AF6 0.0 -
14454 72 F
45,XX,add(1)(p?),der(2)t(2;6)(p16;q13)t(2;6)
(q32;p12), add(5)(q21),der(5)t(5;18)(q31;?),?inv(7)
(q31q35), der(9)t(9;11)(q22~31;q13),del(12)
(q13q23),-17,-18,+mar
MLL-AF9 0.1 +
14290 62 F M1 46,XX,t(9;11)(p22;q23)[16] MLL-AF9 0.7 +
14456 61 F Sec 46,XX,t(9;11)(p22;q23)[21] MLL-AF9 2.6 +
7072 61 M M4
46,XY,der(11)(q2?)[3]/46,XY[18] .ish t(9;11)
(p22;q23)
MLL-AF9 0.1 +
464 60 F 46,XX,t(9;11)(p22;q23) MLL-AF9 4.38 +
2682 57 F M4 46,XX,t(2;9;11)(p13;p22;q23) MLL-AF9 1.0 +
14457 51 M 46,XY,t(9;11)(p22;q23)[18] MLL-AF9 0.7 +
709 51 M M4 46,XY,t(4;11;9)(q27;q23;p22) MLL-AF9 4.6 +
1055 46 M M4 46,XY,t(9;11)(p22;q23) MLL-AF9 8.15 +
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Sample Age Sex FAB  G-banding MLL-fusion RE EVI1 EVI1+
485 45 F
46,XX,t(9;11)(p22;q23)[13]/47,XX,t(9;11)
(p22;q23),+19[2]
MLL-AF9 6.52 +
716 43 F M0 46,XX,t(9;11)(p22;q23) MLL-AF9 4.46 +
587 34 M M4 46,XY,t(9;11)(p22;q23) MLL-AF9 4.32 +
589 32 F M5
46,XX,t(9;11)(p22;q23)[3]/47,XX,t(9;11)
(p22;q23),+13[8]
MLL-AF9 2.13 +
2288 31 M M4 45,XY,-7,t(9;11)(p21;q23)[33] MLL-AF9 1.7 +
375 23 M M5 46,XY,t(9;11)(p22;q23) MLL-AF9 1.42 +
261 23 F M5 46,XX,t(9;11)(p22;q23) MLL-AF9 6.95 +
15014 17 F 47,XX,t(9;11)(p22;q23),+der(9)t(9;11)(p22;q23) MLL-AF9 2.0 +
14293 66 F M5
51-52,XX,+4[2],+8,t(9;11)(p22;q23)
[3],+13,+16[2],+21[2], +22[2][cp4]/46,XX[3]
MLL-AF9 0.0 -
14289 59 M M5 46,X,-Y,+8,t(9;11)(p21;q23),t(18;20)(q21;p12)[13] MLL-AF9 0.0 -
2541 57 F M5 45,XX,-7[3]/45,idem,t(9;11)(p21;q23)[20]/46,XX[3] MLL-AF9 0.0 -
799 56 M M5
47,XY,+8,t(9;11)(p22;q23),inv(16)(p13q22),del(17)
(p11)
MLL-AF9 0.0 -
210 53 F M5 47,XX,+8,t(9;11)(p22;q23) MLL-AF9 0.0 -
649 52 F M5
46,XX,t(9;11)(p22;q23)[10]/47,XX,t(9;11)
(p22;q23),+8[4]
MLL-AF9 0.01 -
944 50 M M5 46,XY,t(9;11)(p22;q23) MLL-AF9 0.0 -
6364 49 M M5 46,XY,t(9;11)(p22;q23)[19] MLL-AF9 0.0 -
65 48 M M5 46,XY,t(9;11)(p22;q23) MLL-AF9 0.0 -
274 48 F M5 46,XX,t(9;11)(p21;q23) MLL-AF9 0.0 -
2694 46 M M5 46,XY,t(9;11)(p22;q23) MLL-AF9 0.0 -
7166 44 F M5 46,XX,t(9;11)(q22;q23)[11]/46,XX[4] MLL-AF9 0.0 -
3316 44 F M5 46,XX,t(9;11)(p22;q23),t(10;12)(q21;q24)[22] MLL-AF9 0.0 -
5358 40 F M5 46,XX,add(6)(q2?5),t(9;11)(p22;q23)[20]/ MLL-AF9 0.0 -
350 37 F M5 46,XX,t(9;11)(p22;q23) MLL-AF9 0.0 -
413 36 F 47,XX,t(9;11)(p21;q23),+21 MLL-AF9 0.01 -
14288 35 M M5 46,XY,inv(2)(q1?1q35),t(9;11)(p22;q23)[38] MLL-AF9 0.0 -
1083 35 F 46,XX,t(9;11)(p21;q23) MLL-AF9 0.01 -
348 34 F M5 47,XX,+8,t(9;11)(p22;q23)[9]/46,XX[2] MLL-AF9 0.0 -
14295 30 M M5 47,XY,+8,t(9;11)(p22;q23)[22] MLL-AF9 0.0 -
15013 30 M M3 47,XY,+8,der(9)t(9;11)(q;q),t(15;17)(q22;q21) MLL-AF9 0.0 -
15019 29 M M5 50,XY,+5,+6,t(9;11)(p21;q23),+19,+22[4] MLL-AF9 0.0 -
691 28 M M5
46,XY,t(9;11)(p22;q23)[10]/47,XY,+8,t(9;11)
(p22;q23)[5]
MLL-AF9 0.02 -
14453 28 M
46,XY,der(9)ins(9;?)(q12;?)del(9)(q12;q2?2),t(9;11)
(p22;q23)[16]
MLL-AF9 0.0 -
2285 18 F M5 46,XX,t(9;11)(p21~22;q23)[57] MLL-AF9 0.0 -
15016 64 M NA 46,XY,t(11;19)(q23;p13) MLL-ENL 4.3 +
14460 57 F NA 46,XX,t(11;19)(q23;p13)[29] MLL-ENL 0.3 +
360 55 F 46,XX,t(11;19)(q23;p13) MLL-ENL 0.11 +
60 52 F 46,XX,t(11;19)(q23;p13) MLL-ENL 0.31 +
7306 51 M M5 46,XY,t(11;19)(q23;p13.1)[15]/46,XY[5] MLL-ENL 0.3 +
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Sample Age Sex FAB  G-banding MLL-fusion RE EVI1 EVI1+
126 48 F M4 46,XX,t(11;19)(q23;p13)[9]/46,XX[1] MLL-ENL 3.02 +
3328 41 F M5 46,XX,t(11;19)(q23;p13)[21] MLL-ENL 0.8 +
14459 75 F M4 46,XX,t(11;19)(q23;p13)[5] MLL-ENL 0.0 -
465 45 M M5 46,XY,t(11;19)(q23;p13) MLL-ENL 0.0 -
572 39 M M5 45,X,-Y,t(11;19)(q23;p13) MLL-ENL 0.0 -
143 39 M M1
46,XY,t(2;8)(p12;q24),add(7)(q32),?t(10;11;19)
(p13;q23;p13)
MLL-ENL 0.0 -
14291 38 F 47,XX,+X,t(11;19)(q23;p13)[23] MLL-ENL 0.0 -
3322 35 F M5 47,XX,+8,t(11;19)(q23;p13)[25] MLL-ENL 0.0 -
14462 34 F M5 47,XX,+8,t(11;19)(q23;p13)[25] MLL-ENL 0.0 -
374 49 M M4 46,XY,t(11;17)(q23;q21) Other 0.12 +
247 47 F M2 46,XX,t(7;11)(p11;q23) Other 0.29 +
363 56 F M4 46,XX,t(11;22)(q23;q13)[18]/46,XX[3] Other 0.0 -
1102 55 M 46,XY,t(11;21)(q23;q11) Other 0.0 -
613 47 F M4 46,XX,t(1;11)(q21;q23),del(20)(q11)[4]/46,XX[2] Other 0.05 -
7307 40 F M1
46,X,ins(X;11)(q13;q23q22)
[1]/48,idem,+6,+19[33]/46,XX[7]
Other 0.0 -
Table S2. Percentages of the CD14 negative population and the percentages of the CD34+CD38+ and CD34+CD38- 
populations within the CD14 negative population.
Sample CD14- (%) CD34+CD38+ (%) CD34+CD38- (%)
2747 14.7 79.3 10.97
2275 22.1 9.09 2.97
2220 26.5 0.43 0.16
3221 10.5 0.13 0.47
2261 6.5 0.52 0.48
14288 73.5 5.11 0.85
2285 50.1 0.20 0.01
5358 21.8 0.02 0.00
14293 28.5 23.33 56.88
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SUPPLEMENTARY FIGURES
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Figure S1. Acute myeloid leukemia patients carrying an 11q23 translocation expressing EVI1 (EVI1+) and not 
expressing EVI1 (EVI1-) show a distinct mRNA gene expression pattern. In the Pearson’s correlation clustering 
1455 probe sets (standard deviation > 4) where used. Th e colors correspond to high correlation (red) and low cor-
relation (blue) between mRNA expression of genes in patient samples. 
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Figure S2. MLL-AF9 leukemias with EVI1 expression show an adverse outcome compared to MLL-AF9 leuke-
mias not expressing EVI1. Overall survival (A), event-free survival (B) and relapse-free survival (C) for MLL-AF9 
cases with EVI1 expression (EVI1+) and cases not expressing EVI1 (EVI1-) were compared. Only patients between 15 
and 60 years of age were included. Per Kaplan-Meier analysis a corresponding log-rank P value is shown. 
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Figure S3. Th e hematopoietic stem and progenitor cells in FAB M5 leukemia are not expressing EVI1. (A) Gating 
strategy for sorting. Th e leukemic cells of AML samples (FAB M5) were sorted for CD34+/CD38- (corresponding 
to immature stem cells) and CD34+/CD38+ (corresponding progenitor cells). As a initial step, dead cell and debris 
were excluded based of forward- and side scatter properties (A panel), any residual dead cells were removed in by 
exlusion of DAPI positive cells (B panel) aft er which the CD14 negative cells were selected (C panel). From these 
CD14-negative cells the CD34+CD38+ and CD34+CD38low/- cells were sorted according to the gates depicted in 
the D panel. (B) Th e EVI1 expression of samples carrying an MLL-AF9 fusion was compared to cases that do not 
carry this fusion. An AML sample carrying a 3q26 abnormality was used as positive control. Th e relative expression 
of EVI1 was measured in duplo and relative to the SKOV3 cell line. 
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Figure S4. Nearly 20% of the single colonies picked from MLL-AF9 transduced murine bone marrow cells aft er 
the fi rst replating (day 14) show high Evi1 expression. (A) Representative colonies aft er fi rst replating (day 14) of 
MLL-AF9 and E2A-PBX transduced murine bone marrow cells As a reference, representative colonies of murine 
bone marrow cells transfected with empty vector (EV) were taken at day 7. All pictures were taken using a 50x 
magnifi cation. (B) Evi1 expression was determined in 72 single colonies. High Evi1 expression was defi ned as larger 
than 35, intermediate expression between 35 and 1, low or no expression of Evi1 with levels smaller than 1. A relative 
expression Evi1 of 1 represents equal Evi1 levels compared to the reference murine bone marrow transfected with 
empty vector.
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Figure S5. MLL-AF9 single colonies with Evi1 expression show no diff erence in self-renewal, morphology and 
growth compared to Evi1 negative MLL-AF9 colonies. (A) Colony numbers of MLL-AF9 single colonies (Evi1 
positive and Evi1 negative) aft er fi rst and second replating (respectively, day 7 and 14) in methylcellulose assays. 
Experiment was carried out in duplo, average colony numbers are shown. (B) Relative expression of Evi1 per single 
colony aft er 7, 14 and 21 days in methylcellulose assays. Experiment was carried out in duplo, average relative expres-
sion of Evi1 is shown. (C) Cell morphology of MLL-AF9 single colonies. 100 cells were scored twice, the average 
percentage of bandforms, myeloblasts or metablasts and blasts or promyelocytes is shown. (D) A 10-day growth 
curve of Evi1 positive and Evi1 negative MLL-AF9 single colonies.
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ABSTRACT
We hypothesized that DNA methylation distributes into specifi c patterns in cancer cells, 
which refl ect critical biological diff erences. We therefore examined the methylation profi les of 
344 patients with acute myeloid leukemia (AML). Clustering of these patients by methylation 
data segregated patients into 16 groups. Five of these groups defi ned new AML subtypes that 
shared no other known feature. In addition, DNA methylation profi les segregated patients 
with CEBPA aberrations from other subtypes of leukemia, defi ned four epigenetically distinct 
forms of AML with NPM1 mutations, and showed that established AML1-ETO, CBFB-
MYH11 and PML-RARA leukemia entities are associated with specifi c methylation profi les. 
We report a 15-gene methylation classifi er predictive of overall survival in an independent 
patient cohort (P<0.001, adjusted for known covariates). 
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INTRODUCTION
Acute myeloid leukemia (AML) is a highly heterogeneous disease from the biological and 
clinical standpoint. Th is remains a signifi cant barrier towards the development of accurate 
clinical classifi cation, risk stratifi cation and targeted therapy of this disease. Epigenetic con-
trol of gene expression has been suggested to play a pivotal role in determining the biological 
behavior of cells.  One such epigenetic mechanism is DNA cytosine methylation, which can 
alter gene expression by creating new binding sites for methylation dependent repressor 
proteins(1, 2), or by disrupting the ability of transcription factors to bind to their target 
sequences(3, 4). In normal development the proper distribution of DNA methylation plays a 
critical role in tissue diff erentiation and homeostasis(5, 6). Disruption of normal DNA meth-
ylation distribution is a hallmark of cancer and can play critical roles in initiation, progres-
sion and maintenance of the malignant phenotype. For example, aberrant hypermethylation 
and silencing of certain tumor suppressor genes such as p15CDKN2B has been widely reported in 
leukemias and other myeloid neoplasms(7-10).  We recently showed that hypermethylation 
and silencing of the master regulatory transcription factor CEBPA was associated with a 
leukemia entity with T-cell/myeloid features, hypermethylation of a number of additional 
transcriptional regulators, and distinctive biological features(11, 12). 
Based on these data we hypothesized that DNA methylation distributes into specifi c patterns 
in cancer, and that these methylation profi les impose and refl ect critical biological diff er-
ences with practical clinical and therapeutic implications. In order to test this hypothesis we 
performed a comprehensive exploration of DNA patterning in human a disease, focusing on 
a well-characterized cohort of 344 patients with AML. 
PATIENTS AND METHODS
Patient samples
We made use of 344 AML cases collected at Erasmus University Medical Center (Rotterdam) 
between 1990-2008 for which suffi  cient patient material was available(13, 14). Patients had 
been treated on study protocols of the Dutch-Belgian Hemato-Oncology Cooperative Group 
(HOVON) (available at http://www.hovon.nl). Patients in the HO04/A, HO29 and HO42 
trials received standard backbone AML treatment and no signifi cant survival diff erence has 
been found between these slightly diff erent treatments. Th e HO43 therapy protocol included 
patients over 60 years of age and showed a more adverse outcome with increasing age as a 
prognostic confounder and for this reason we have included age as a covariable in our sta-
tistical analyses. Samples were processed as previously described(13, 14). 165 of the patients 
in this study were included in the 285-patient cohort studied by gene expression by Valk et 
al(13), and the methylation status of 16 patients was previously reported in a publication by 
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our group(12). Median follow-up time based on survivors was 71 months (range: 7 months, 
215 months). Table 1 summarizes patients’ characteristics, Table S1 shows detailed informa-
tion for each patient, and Table S2 summarizes treatment information for each cluster. Eight 
normal bone marrow CD34+ cell specimens were obtained from the Translational Trials 
Development and Support Laboratory, Cincinnati Children’s Hospital (Cincinnati, OH) and 
Allcells (Emeryville, CA). Th is research was approved by the institutional review boards at 
Weill Cornell Medical College and Erasmus University Medical Center, and written donor 
informed consent was obtained in accordance with the Declaration of Helsinki.
DNA methylation microarrays
High-molecular-weight DNA was isolated from mononuclear cell fractions consisting of 
>90% blasts using a standard high salt procedure. Th e HELP (HpaII tiny fragment enrich-
ment by ligation-mediated PCR) assay was carried out as previously described(15),(16) and 
samples were hybridized onto a custom human promoter array covering 25,626 HpaII am-
plifi able fragments (>50,000 CpGs), annotated to ~14,000 genes (Roche NimbleGen, Design 
name: 2006-10-26_HG17_HELP_Promoter, Design ID: 4802). HpaII amplifi able fragments 
(HAF) are defi ned as genomic regions contained between two fl anking HpaII restriction sites 
that are found between 200 and 2000 bp apart. HAF were fi rst re-aligned to the HG18 build 
of the human genome and then annotated to the nearest transcription start site (TSS), allow-
ing for a maximum distance of 5 kb from the TSS. Hybridization and normalization steps 
are described as Supplementary methods. All microarray data are available from the GEO 
repository(17) (accession number GSE18700).
Gene expression microarrays
Gene expression data for these patients had been previously published by Verhaak et al.(14) 
(GEO accession number: GSE6891). Briefl y, gene expression data were obtained using Af-
fymetrix Human Genome 133 Plus2.0 GeneChips. mRNA isolation, labeling, hybridization 
and quality control were carried out as described previously(13). Raw data were processed 
using the GC-RMA package (version 2.16.0) from BioConductor(18). 
Microarray data analysis 
Statistical analysis was performed using R 2.8.1(19) and BioConductor(20). Unsupervised 
hierarchical clustering of HELP data was performed using the subset of probe sets (n=3745) 
with standard deviation > 1 across all cases. We used 1- Pearson correlation distance, fol-
lowed by a Lingoes transformation of the distance matrix to a Euclidean one(21) and sub-
sequent clustering using Ward’s method. Clusters were considered to be representative of a 
given molecular or cytogenetic fi nding when > 50% of cases were positive and a two-sided 
Fisher’s test was signifi cant at p < 0.05 aft er adjusting for multiple testing using the Bon-
ferroni method. Identifi cation of the aberrant DNA methylation signature for each cluster 
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was performed using an ANOVA test, with correction for multiple testing according to the 
Benjamini-Hochberg method, followed by Dunnett’s post hoc test using the normal CD34+ 
samples as the reference group(22). Only genes with adjusted P values < 0.05 and an absolute 
diff erence in log2(HpaII/MspI) ratios > 2 (which corresponds to at least 35% diff erence in 
DNA methylation) were selected for each cluster. 
Quantitative DNA methylation sequencing by MassARRAY EpiTYPER
Validation of HELP data was performed by MALDI-TOF mass spectrometry using Epi-
TYPER by MassARRAY (Sequenom, San Diego, CA) on bisulfi te-converted DNA as previ-
ously described(23). MassARRAY primers were designed as previously described(12) (See 
Supplementary methods).
Pathway analysis
Ingenuity Pathway Analysis soft ware (Redwood City, CA) was used to perform pathway 
analysis of relevant gene signatures. Th e top scoring networks were identifi ed for the gene 
expression signatures of the epigenetically defi ned clusters. A comparative analysis of the 
canonical pathways deregulated in each of the clusters, as captured by the integration of 
the DNA methylation and gene expression signatures was also performed. Enrichment 
for specifi c pathways was determined relative to the ingenuity knowledge database using a 
Benjamini-Hochberg adjusted Fisher’s test, at a signifi cance level of adjusted P value <0.05. 
Survival analysis
Kaplan-Meier survival analysis for overall survival was performed to compare survival 
diff erences between diff erent groups of clusters. A multivariate Cox proportional hazards 
regression model was constructed for the including age, cytogenetic risk, NPM1 mutation 
status, FLT3-ITD mutation status and cluster membership as the variables to be tested. 
Detailed description of the model is found as Supplementary methods. All survival analyses 
were performed in SAS Version 9.2 (SAS Institute, Inc., Cary, NC, and Stata Version 10.0 
(StataCorp, College Station, TX).
Development of an epigenetic predictive model for overall survival in AML 
In order to develop a prognostic biomarker model predictive of AML overall survival we 
used the supervised principal components (SuperPC) algorithm developed by Bair and Tib-
shirani(24). Th e data set was randomly divided into three groups: a training set (n=200), a 
test set (n=95) and the remaining 49-patient cohort to be used as the independent validation 
set. Table S6 summarizes the patient characteristics for each of the three groups. Table S8 
shows the clinical outcome for each patient in the cohort. A detailed description of the model 
training, testing and independent validation procedures, as well as the R script used can be 
found as Supplementary methods.
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RESULTS
AML is composed of epigenetically distinct diseases
Since the molecular heterogeneity of AML remains only partially resolved, the fi rst goal 
of our study was to determine whether DNA methylation profi ling could identify new 
clinically and biologically relevant disease subtypes. For that purpose, blast cells of 344 newly 
diagnosed AML patients were subjected to DNA methylation profi ling of over 50,000 CpG 
dinucleotides contained within ~14,000 unique gene loci using the HELP (HpaII tiny frag-
ment enrichment by ligation-mediated PCR) method(15, 16). Table 1 summarizes patients’ 
characteristics. DNA methylation measured by HELP was highly concordant with a quan-
titative single locus DNA methylation validation assay (correlation coeffi  cient r= -0.88) in 
these AML patients (Figure S1A). An unsupervised analysis using hierarchical clustering (1 
- Pearson correlation distance and Ward’s clustering method. showed that leukemias could 
be distinctly grouped according to their methylation profi les.  A cut-off  of 16 clusters was 
selected for further analysis since this segregation most accurately overlapped with the cur-
rently known molecular subtypes of AML while at the same time revealing the existence of 
additional epigenetic diff erences among the remaining patients. Th e stability of these clusters 
was verifi ed by performing comparison of multiple cluster analyses using a decreasing num-
ber of probe sets (based on alternative cutoff s of across-patient standard deviation, Figures 
S1B-S1E). Table 2 shows the clinical, cytogenetic and molecular features of each of the 16 
clusters. Th ree of these patient clusters correspond to AML subtypes defi ned by the WHO 
classifi cation(25)(Figure 1), another eight clusters were enriched for cases harboring specifi c 
genetic or epigenetic lesions, and the remaining fi ve clusters could not be explained by any 
known morphologic, cytogenetic or molecular feature. 
Each of these DNA methylation-defi ned AML subtypes displayed a unique epigenetic sig-
nature when compared to normal bone marrow CD34+ cells (Figure 2 and Tables S3A-3P). 
Taken together these data indicate that DNA methylation is not randomly distributed in 
AML blasts but rather is organized into highly coordinated and well-defi ned patterns. In most 
cases the AML subgroups showed a very strong hypermethylation signature as compared 
to normal marrow CD34+ cells. In contrast, a few of the clusters were hypomethylated in 
comparison to normal controls. Th is distinctive patterning is highly suggestive of a biologi-
cally signifi cant role for altered DNA methylation in these diff erent AML subtypes. Th e data 
also suggest that the most prevalent tumor-associated abnormality in gene promoter DNA 
methylation abundance is not always hypermethylation but can also be hypomethylation.      
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Figure 1. DNA methylation segregates AML patients into 16 groups. 
Heatmap representation of a correlation matrix in which each patient’s DNA methylation profi le is correlated with 
that of the other patients in the dataset. Patients are ordered according to the unsupervised analysis (hierarchical 
clustering) results, so that highly correlated patients are located next to each other. Parallel bars on the right of the 
heatmap have been used to indicate the principal cytogenetic and molecular fi ndings for each patient. Cluster mem-
bership and cluster feature summaries are described on the left  of the heatmap.  
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Table 1: Patient characteristics. 
Characteristic Group Total (%)
Gender Male 188 (54)
Female 156 (46)
Age < 60 years 294 (85%)
> 60 years 50 (15%)
Median years 48 (15-77)
FAB M0 12 (3.5%)
M1 75 (21.8%)
M2 82 (23.8%)
M3 9 (2.6%)
M4 65 (18.9%)
M5 70 (20.3%)
M6 3 (0.87%)
NA* 28 (8.1%)
Cytogenetics inv(16)/t(16;16) 30 (9%)
t(8;21) 24 (7%)
t(15;17) 10 (3%)
t(9;22) 2 (0.6%)
t(6;9) 3 (0.9%)
t(v;11q23) 13 (3.8%)
3q abnormalities 2 (0.6%)
del5(q)/del7(q) 19 (5.5%)
Trisomy 8 14 (4%)
del9q 8 (2.3%)
Complex 8 (2.3%)
Normal 152 (44%)
Other 43 (12.5%)
NA*/Failure 13 (3.8%)
Cytogenetic risk Favorable 53 (15%)
Intermediate 231 (67%)
Unfavorable 47 (14%)
NA* 14 (4%)
CEBPA Double mutation 24 (7%)
Single mutation 11 (3.1%)
Silenced 8 (2.4%)
NPM1 105 (30.5%)
FLT3-ITD 96 (28%)
EVI1 27 (8%)
*NA = not available
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Cytogenetically defi ned AML subtypes have unique epigenetic signatures
Th e WHO classifi cation of AML defi nes cases with t(8;21), inv(16) and t(15;17) transloca-
tions or the presence of the relevant fusion genes as separate entities indicative of a favorable 
clinical prognosis(26-28). All three of these AML subtypes presented with a unique methyla-
tion profi le. Methylation cluster 1 (n=26) consisted entirely of cases carrying either inv(16) 
or t(16;16) (22/26 cases), or the CBFB-MYH11 fusion gene (4/26). Methylation cluster 3 was 
signifi cantly enriched for cases positive for t(8;21) (22/31 cases, Fisher’s exact test P value 
<1.85e-25), and all cases in methylation cluster 6 carried the t(15;17) or the PML-RARA fu-
sion gene (8/8 cases). Patients in the two core binding factor clusters did not further segregate 
according to c-KIT mutation status, indicating that the presence of this mutation does not 
result in a specifi c DNA methylation pattern. Supervised analysis comparing each of these 
clusters to a cohort of normal CD34+ cells from healthy donors revealed that they all ex-
hibited a unique signature, with a strong shift  towards genes being methylated in the AML 
subtypes compared to CD34+ normal marrow blasts. (Figure 2 and Table S3). Th e data are 
consistent with a scenario whereby each of these fusion oncoproteins can drive epigenetic 
patterning in hematopoietic cells, and/or cooperate to drive leukemogenesis when specifi c 
sets of complementary genes are deregulated through aberrant DNA methylation. 
Cluster 3 included nine cases that did not present with the t(8;21) or AML1-ETO fusion gene, 
yet the survival curves of these patients were indistinguishable from the 22 t(8;21) positive 
patients in cluster 3 (log-rank test, P value =0.83). Th is fi nding refl ects the ability of DNA 
methylation profi les to identify a subset of patients with comparable risk and epigenetic pat-
terning to that of t(8;21) patients despite their lack of the aberrant AML1-ETO fusion gene. 
Even though the number of patients is small, the robustness of this common epigenetic profi le 
is refl ected in the fact that these patients all continue to cluster together even when diff erent 
numbers of probe sets are used in the analysis (Figure S1B-1E). Furthermore, unsupervised 
analysis of these patients using gene expression data failed to segregate them according to the 
presence or absence of the t(8;21). (Figure S1F)
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Figure 2. Distinct DNA methylation signatures defi ne each of the 16 clusters. 
Heatmap representation of the aberrant DNA methylation signatures of specifi c clusters compared to a cohort of 
normal CD34+ hematopoietic cells obtained from healthy donors. Each row of the heatmap represents one probe 
set of the HELP array, and each column represents an AML patient (denoted by light brown bars) or a healthy donor 
(denoted by dark brown bars). (A) DNA methylation signatures for clusters with recurrent translocations, (B) DNA 
methylation signatures associated with abnormalities of CEBPA, (C) DNA methylation signatures for clusters pre-
senting NPM1 mutations, (D) DNA methylation signatures for the 5 epigenetically defi ned clusters. 
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Table 2. Summary of clinical, cytogenetic and molecular features of the 16 DNA methylation clusters.
For complete cytogenetic and molecular information for each patient see Tables S1 and S2. Also, see Figure S2 for 
CEBPA methylation status of case 5630, which is in cluster 10.
CLUSTER # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Total
N 26 55 31 14 34 8 31 24 9 6 9 12 45 18 12 10 344
Clinical markers
Gender
Male 12 36 22 8 19 4 17 12 5 4 5 6 25 6 4 3 188
Female 14 19 9 6 15 4 14 12 4 2 4 6 20 12 8 7 156
Age
<60 yr 24 37 29 13 27 8 25 20 8 6 9 11 43 16 10 8 294
>60 yr 2 18 2 1 7 0 6 4 1 0 0 1 2 2 2 2 50
FAB
0 0 6 0 0 3 0 0 0 0 2 0 0 0 0 0 1 12
1 0 9 6 10 6 0 21 4 2 3 0 5 2 4 2 1 75
2 0 13 20 3 11 0 5 6 2 0 0 6 6 3 5 2 82
3 0 0 1 0 1 7 0 0 0 0 0 0 0 0 0 0 9
4 23 8 3 1 2 1 1 7 1 0 0 0 8 4 3 3 65
5 3 6 1 0 7 0 4 3 0 0 9 1 26 6 2 2 70
6 0 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 3
NA 0 12 0 0 4 0 0 4 4 1 0 0 2 0 0 1 28
Cytogenetic markers
Cytogenetic class
    inv(16)/t(16;16) 26* 2 1 0 1 0 0 0 0 0 0 0 0 0 0 0 30
    t(8;21) 0 0 22 0 0 0 1 0 0 0 0 0 0 1 0 0 24
    t(15;17) 0 0 1 0 1 8# 0 0 0 0 0 0 0 0 0 0 10
    t(9;22) 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 2
    t(6;9) 0 0 0 0 0 0 0 2 0 0 0 0 1 0 0 0 3
   t(v;11q23) 0 0 0 0 0 0 0 5 0 0 6 1 0 1 0 0 13
    3q 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 2
   del5(q)/del7(q) 0 12 1 0 1 0 1 1 0 1 0 0 0 0 1 1 19
    tri8 0 1 0 0 0 0 2 2 1 0 1 0 5 1 0 1 14
    del9q 0 1 0 3 2 0 1 0 1 0 0 0 0 0 0 0 8
    Complex 0 3 1 0 1 0 0 1 0 2 0 0 0 0 0 0 8
    Normal 0 17 4 10 19 0 17 10 6 1 1 7 33 11 8 8 155
    Other 0 13 0 1 5 0 7 3 0 2 0 3 2 4 3 0 43
    NA/Failure 0 0 1 0 3 0 1 1 1 0 1 1 4 0 0 0 13
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CLUSTER # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Total
Cytogenetic risk
Favorable 20 1 24 0 2 5 1 0 0 0 0 0 0 0 0 0 53
Intermediate 6 32 4 14 25 3 27 15 8 3 6 10 41 17 11 9 231
Unfavorable 0 22 2 0 3 0 2 8 0 3 2 1 1 1 1 1 47
Molecular Markers
CEBPA
Double mutant 0 0 2 14 0 0 0 0 5 0 0 0 0 0 3 0 24
Single mutant 0 3 1 0 1 0 2 0 2 0 0 0 1 1 0 0 11
Silenced 0 3 0 0 0 0 0 0 0 6 0 0 0 0 0 0 9
Wild-type 26 49 28 0 33 8 29 24 2 0 9 12 44 17 9 10 300
NPM1
Wild-type 26 54 30 14 26 8 17 13 7 6 9 2 8 7 9 3 239
Mutated 0 1 1 0 8 0 14 11 2 0 0 10 37 11 3 7 105
FLT3-ITD
Negative 26 45 28 12 28 4 18 15 7 6 9 4 21 11 9 5 248
Positive 0 10 3 2 6 4 13 9 2 0 0 8 24 7 3 5 96
EVI1
Negative 26 42 31 14 31 8 30 17 9 6 8 12 45 16 12 10 317
Positive 0 13 0 0 3 0 1 7 0 0 1 0 0 2 0 0 27
Cytogenetic class is defi ned in order of importance according to the 1999 WHO classifi cation(34): t(8;21), inv(16), 
t(15;17), Complex (>3 clonal abnormalities), del5(q)/del7(q), 3q= any abnormality involving 3q, t(6;9), t(9;22), 
11q23= any abnormality involving 11q23, tri8=trisomy 8, del9q, NN= no abnormalities in karyotype, Other= does 
not classify in any other group. NA= not available.
*  including four inv(16) cases detected by CBFB-MYH11 fusion gene PCR, 
#    including three t(15;17) cases detected by PML-RARA fusion gene PCR.
Epigenetic diff erences defi ne NPM1-mutated, CEBPA-mutant and CEBPA-silenced AMLs 
Methylation profi ling defi ned 13 additional AML subtypes. Four of those methylation clus-
ters (clusters #12, 13, 14 and 16) were all signifi cantly enriched for cases carrying NPM1 
mutations (Bonferroni adjusted Fisher’s exact test P values: <0.0008, <9.4e-14, <0.02 and 
<0.048, respectively). Mutations in exon 12 of the NPM1 gene which result in aberrant cy-
toplasmic localization of the protein constitute an independent favorable prognostic marker 
in AML(29). However, when this mutation occurs in the context of an associated FLT3-ITD, 
then this favorable prognostic impact is lost(30). Th e NPM1-mutant clusters 12 and 13 were 
enriched for characteristic morphological subtypes, i.e., FAB M1/M2 (11/12) and M4/M5 
(34/45), respectively. Th e variety of NPM1 methylation clusters could not be explained solely 
by the presence or absence of concurrent FLT3-ITD (Table 2). While the four clusters were all 
enriched for NPM1 mutations, they still presented enough unique characteristics to separate 
into 4 methylation clusters, each of them with a specifi c aberrant DNA methylation signature 
(Figure 2 and Table S3). Diff erential methylation in cluster 12 consisted almost entirely of 
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hypermethylated genes, while DNA methylation in the remaining NPM1 clusters was more 
evenly distributed when compared to normal controls. Th ese data support the notion that 
NPM1 mutations play a dominant role in defi ning AML biology, but can be modifi ed to a 
signifi cant extent by additional alterations in epigenetic or unidentifi ed genetic factors. A 
signifi cant diff erence in overall survival was observed for the NPM1 clusters 12, 13, 14, and 16 
(log-rank test, P value =0.02), when compared to clusters 1, 3 and 4, which contained patients 
with inv(16), t(8;21) and CEBPA double mutations (CEBPA-dm) respectively (Figure 3A). 
Th ese diff erences in survival remained signifi cant aft er adjustment for age, cytogenetic risk, 
NPM1 mutation and FLT3-ITD mutation status following multivariate analysis (Figure 3B). 
Figure 3. DNA methylation captures clinically signifi cant diff erences among AML patients. 
(A) Left : Kaplan-Meier curves for overall survival for the favorable risk clusters 1 (inv(16)) and 4 (CEBPA-dm), 
and the novel epigenetically defi ned clusters. For plotting simplicity curves for clusters 3 (t(8;21)), cluster 5 and 
cluster 15 were not included in the plot. Figure S3 shows a Kaplan-Meier plot including all the clusters in the overall 
survival analysis.  Right: Kaplan-Meier curves for overall survival for the favorable risk clusters 1 (inv(16)) and 4 
(CEBPA-dm), and the NPM1 clusters. For plotting simplicity curves for clusters 3 (t(8;21)), and NPM1 cluster 14 
were not included in the plot. Figure S3 shows a Kaplan-Meier plot including all the clusters in the overall survival 
analysis. (B) Kaplan-Meier curves for overall survival (left ) for the fi ve novel clusters. On the right: Table summa-
rizing the multivariate Cox proportional hazards regression model, using cluster 1 (inv(16)) as the referent cluster. 
Additional Kaplan Meier plots are shown in Figure S3. 
Th e CEBPA transcription factor is a critical mediator of hematopoietic cell diff erentiation(31), 
and CEBPA-dm AMLs are associated with a favorable clinical prognosis(32). Th ese cases split 
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into two distinct subtypes with diff erent methylation signatures. Methylation cluster 4 dis-
played a markedly hypermethylated profi le and consisted entirely of CEBPA-dm cases (n=14; 
Fisher’s exact test P value <6.88 e-19). Th e clinical outcome of cluster 4 patients was even 
better than the known favorable risk core-binding factor leukemias, i.e. t(18;21) and inv(16) 
(2-year overall survival ± standard error [SE]; 78.6%±11.0%) (Figure 3A). DNA methylation 
cluster 9 was also signifi cantly enriched for CEBPA mutant cases (n=7/9, Fisher’s exact test 
P value <0.000009), most of which (5/7) harbored CEBPA double mutations. However, the 
cluster 9 signature was predominantly hypomethylated vs. controls, suggesting that these 
CEBPA-related leukemias are biologically distinct from the CEBPA-dm cluster 4. Cluster 9 
contained insuffi  cient numbers to allow for a comparative survival estimate. 
Five out of the six patients in cluster 10 had previously been shown to display a phenotype 
featuring CEBPA hypermethylation and silencing (CEBPAsil), a hypermethylated gene profi le, 
but with hypomethylation of certain T-cell genes, T-cell lineage infi delity, and poor clinical 
outcome(11, 12). Th e remaining patient in this cluster 10 had not previously been recognized 
as a CEBPAsil leukemia (case 5360), but was demonstrated upon further investigation in this 
study to indeed display all the characteristic features of CEBPAsil leukemias (Figure S2 and 
data not shown). Mutations or silencing of CEBPA thus appear to result in or to be associated 
with three epigenetically distinct forms of leukemia. 
Unique epigenetic diff erences independent of (cyto)genetically defi ned AML subtypes
Methylation clusters 2, 5, 7, 8, and 15 were defi ned solely by their DNA methylation profi le 
and could not be explained by the enrichment of any currently known recurrent cytogenetic, 
molecular or clinical feature (Table 2). Each of these AML subtypes displays a unique and 
signifi cant epigenetic signature vs. normal CD34+ controls (Table S3). Normal cytogenet-
ics AML cases were distributed among all 5 clusters, and although 5/24 cases in cluster 8 
harbored 11q23 abnormalities this was not a defi ning feature since it represented only 20.8% 
of the cases. Gene expression profi les of each of these epigenetically defi ned clusters were 
obtained in a supervised analysis comparing them to a set of normal CD34+ controls. Each 
of the 5 clusters presented with a distinct gene expression profi le. Figure 4A shows the top 
scoring networks associated with each of these expression signatures. 
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Cluster #2: NFkB-CD79A Cluster #5: PDGF BB
Cluster #5: EGFR-CDH1 Cluster #15: ESR1-CBX5
Cluster #7: Jnk
Figure 4. Pathway analysis for the epigenetically defi ned clusters. 
(A) Top scoring aberrantly expressed gene networks for each of the 5 epigenetically defi ned clusters. Genes over-
expressed compared to normal CD34+ cells are colored in red, while downregulated genes appear in green. (B) 
Comparative analysis of the most signifi cantly deregulated canonical pathways of the 5 epigenetically defi ned clusters 
as captured by an integration of the aberrant epigenetic and gene expression signatures.  
Aberrantly expressed genes far exceeded and only partially overlapped with the aberrantly 
methylated genes in each cluster, which suggests that even relatively small changes in epi-
genetic patterns can have a signifi cant biological impact in the cell. In order to determine 
the biological impact of this epigenetic deregulation, we performed an integrative pathway 
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analysis of the combined aberrantly methylated and aberrantly expressed genes. Th is analysis 
revealed that each of these clusters resulted in deregulation of diff erent canonical pathways. 
Cluster 5 showed deregulation of immunity related pathways, involving immunodefi ciency 
signaling, cytotoxic T-cell mediated apoptosis and T cell receptor signaling. Cluster 2, on the 
other hand, was the only one that signifi cantly deregulated p53-signaling. Clusters 8 and 15 
showed predominant deregulation of pathways involved in molecular mechanisms of cancer, 
deregulating genes in the DNA damage repair mechanism such as ATM, CHK1, MDM2 and 
FANCD2, genes involved in cell cycle regulation such as CDK4, and CYCLIN D, as well as 
genes from the AKT signaling pathway (Figure 4B). Most notably, a signifi cant diff erence 
in survival was observed between these novel AML subtypes. For instance, clusters 5 and 7 
correlated with an evidently better outcome (2-year overall survival ± SE; 58.8%±8.4% and 
45.2%±8.9% for clusters 5 and 7, respectively, vs. 23.6%±5.7%, 26.4%±9.2% and 33.3%±13.6%, 
for clusters 2, 8 and 15, respectively) (log-rank test, P value=0.04). Aft er adjustment for age, 
cytogenetic risk, NPM1 mutation, and FLT3-ITD mutation status in a multivariate Cox 
proportional hazards regression model including all the clusters with at least 10 patients, 4 of 
the 5 novel clusters presented a statistically signifi cant increased hazard ratio with respect to 
the favorable risk inv(16) cluster, while cluster 5 did not reach statistical signifi cance (Figure 
3B). Epigenetic profi ling thus identifi ed a clinically relevant and signifi cant diff erence among 
AML subtypes not captured by other methodologies. 
AMLs present a common epigenetic signature of consistently aberrantly methylated genes
While the above studies were geared towards fi nding the unique signatures of epigenetically 
defi ned AML subtypes, we also wondered whether a set of genes could be defi ned whose 
DNA methylation was consistently deregulated across all the AML subtypes. We indeed 
identifi ed a common aberrant DNA methylation signature consisting of 45 genes, most 
of them hypermethylated, that was consistently detected in at least 10 of the 16 clusters’ 
methylation signatures and aff ecting at least 70% of the cases studied (Figure 5A). Genes 
in this signature are likely to be part of a common epigenetic pathway involved in leukemic 
transformation of hematopoietic cells. Among these genes we found the tumor suppressor 
PDZD2, transcriptional regulators (ZNF667, ZNF582, PIAS2, CDK8), nuclear import recep-
tors (TNPO3, IPO8), and CSDA, a repressor of GM-CSF. A complete list of the genes in this 
common signature is found in Table S4. 
We next looked at the gene expression levels of these genes on Aff ymetrix HGU133 Plus 2.0 
microarrays performed on the same patients(14), and compared them to those of a cohort 
of normal CD34+ bone marrow cells. 8/45 genes had to be excluded from the analysis due to 
failure of the gene expression probe sets (n=6) or because of lack of representation of the tran-
script of interest on the expression arrays (n=2). For the remaining 37 genes, in all but 5 we 
found either complete silencing or downregulation of the corresponding transcript. Eighteen 
of these showed the expected diff erential gene expression when compared to normal CD34+ 
164
 Chapter 7
cells (ANOVA followed by Dunnett’s test P value < 0.05) (Figure 5B). Four bidirectional 
promoters showed silencing of one transcript with high expression of the transcript from 
the opposite strand. Th e remaining genes were silenced in both the AMLs and the normal 
CD34+ cells. Th e latter might be explained, as we have previously shown, by the relative 
insensitivity of gene expression microarrays to detect diff erential gene expression of low 
abundance transcripts, which can be overcome by looking at the more sensitive epigenetic 
marks(33). Alternatively, this fi nding could refl ect the establishment of a more irreversible 
state of silencing of these genes in the AML blasts compared to the normal CD34+ cells.
Figure 5. 45 genes are consistently aberrantly methylated in AML. 
(A) Heatmap representation of the common 45-gene signature consistently aberrantly methylated in AML. Each row 
represents a probe set from the HELP microarray and each column represents a sample. (B) Boxplots of gene expres-
sion levels in 4 representative genes from the 45-gene common epigenetic signature demonstrating downregulation 
of expression in the AML samples compared to normal CD34+ cells  Th e list of genes is shown in Table S4. 
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A DNA methylation classifi er predicts clinical outcome in AML
Th e fact that aberrant DNA methylation of gene promoters represents an epigenetic modifi -
cation that is stably transmitted among leukemic blasts and that this is done in an organized 
pattern that correlates with disease subtypes led us to explore its potential as predictor of 
important clinical features. Moreover, since DNA is relatively stable in clinical samples and 
DNA methylation is easy to measure, it is very likely that small sets of methylated genes could 
readily be harnessed as clinically useful biomarkers. Th erefore, in order to determine whether 
we could identify and validate methylation biomarkers of independent prognostic value in 
AML we applied a three-step approach of model development and validation. Th e complete 
patient cohort was randomly divided into a training set (n=200), a test set (n=95) and an 
independent validation set (n=49). Cluster membership was not taken into consideration for 
this part of the analysis. Using the supervised principal components (SuperPC) method of 
Bair and Tibshirani(24), a Cox proportional hazards regression model for overall survival was 
trained with data in the training set (see Supplementary methods). Parameters of the model 
were chosen so that they maximized performance, as estimated by 10 fold cross-validation 
on the training set. Th e model resulting from the maximum cross-validation performance 
estimate was tested on the test set, found predictive, and used to predict survival status on the 
independent validation set (Figure 6A). Th is model included 18 probe sets, corresponding to 
15 genes. Th e predictor model included transcription factors (E2F1, ZFP161, BTBD3), genes 
related to protein metabolism (USP50, SRR, PRMT7, GALNT5), regulation of telomeres 
(SMG6) and signaling (CXCR5, LCK) (see Table S5 for the complete list of features used 
in this model). Th e predictive performance of this model was validated on the 49-patient 
independent validation set both for overall survival (Hazard ratio: 1.39, 95% CI = 1.10-1.75; P 
value <0.005; SuperPC score range= -5 to 5) (Figure 6B) and event-free survival (Hazard ratio: 
1.53, 95% CI = 1.21-1.93; P value <0.0002; SuperPC score range= -5 to 5) (Figure 6C). Aft er 
controlling for clinical and other known predictors, i.e., age, cytogenetic risk, CEBPA status, 
NPM1 mutations and FLT3-ITD; the model was still found informative (multivariate Cox 
proportional hazards model, Hazard ratio: 1.29, 95% CI: 1.11-1.49; P value < 0.001) (Figure 
6D and 6E). In order to confi rm the robustness of DNA methylation markers as predictors 
of clinical outcome, we performed 30 additional random splits of the data set into a training 
set of 200 patients and a test set of 144 and ran the SuperPC algorithm with a common 
set of parameters for all 30 runs. Under these stringent conditions in which the parameters 
were not individually selected for the optimal threshold in each run, 26 out of the 30 runs 
validated with a signifi cant P value of <0.05 in a Cox proportional hazards regression model 
(Table S7). Th ese results demonstrate that DNA methylation status of individual patients 
can help predict the future survival of the AML patient, and suggest that DNA methylation 
biomarkers should be evaluated alongside other predictors in future model development and 
evaluation studies. 
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Figure 6. A DNA methylation classifi er predicts clinical outcome in AML patients. 
(A) Outline describing the steps for building the DNA methylation classifi er. In a fi rst step, 200 randomly selected 
patients were used to identify HELP probe sets that best predicted survival. Th e model was then tested on a diff erent 
cohort of 95 patients (test set). Once the fi nal model was selected, its performance in predicting survival was tested 
in an independent validation set consisting of 49 randomly selected cases. (B) Kaplan-Meier curves for overall sur-
vival for the predicted groups in the independent validation set. Overall survival was compared between patients in 
an independent validation set that were predicted either alive or deceased by the DNA methylation classifi er. (Cox 
Proportional hazards P value <0.005, hazard ratio= 1.39, 95% CI =1.10, 1.75) (C) Kaplan-Meier curves for even-
free survival for the predicted groups in the independent validation set. Event-free survival was compared between 
patients in an independent validation set that were predicted either alive or deceased by the DNA methylation classi-
fi er (Cox Proportional hazards P value <0.0002, Hazard ratio: 1.53, 95% CI =1.21, 1.93) (D) Kaplan-Meier curves for 
overall survival for the predicted groups in the combined test and independent validation sets. Overall survival was 
compared between patients in the combined test and independent validation sets that were predicted either alive or 
deceased by the DNA methylation classifi er. (Cox Proportional hazards P value <0.000003, Hazard ratio: 1.34, 95% 
CI =1.18, 1.51). (E) Multivariate Cox proportional hazards regression model for the DNA methylation predictor, age, 
cytogenetic risk, NPM1 mutation, FLT3-ITD and CEBPA mutations.  For additional information please see Tables S5, 
S6, S7 and S8, as well as Supplementary R scripts. 
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DISCUSSION
Th is comprehensive and large-scale study of DNA methylation profi les associated with 
~14.000 genes in a human disease demonstrates that epigenetic patterning distributes into 
signatures of biological and clinical signifi cance and that DNA methylation classifi ers can be 
derived from population studies with clinical predictive power. From the biological stand-
point these data off er an opportunity to better understand the mechanisms through which 
hematopoietic cells undergo leukemogenesis. Much eff ort has been invested in identifying 
genetic lesions that cooperate with known recurrent translocations such as t(8;21), t(15;17) 
and inv(16) or in patients with normal karyotype leukemia.  While this eff ort has led to the 
identifi cation of bona fi de leukemogenic mutations such as those in CEBPA, FLT3 and NPM1, 
it now appears that recurrent genetic lesions insuffi  ciently explain the biological diversity of 
clinical AML. In contrast, our data show that epigenetic lesions are abundant and common, 
raising the possibility that a number of the oncogenic lesions in AML could be epigenetic in 
nature. Th us, further research exploring the contribution of genes aff ected by aberrant DNA 
methylation seems warranted.  
Th e clinical signifi cance of DNA methylation profi les is underlined by the fact that it con-
tributes to identifying groups of patients that share a common clinical outcome, in some 
cases even beyond what their cytogenetic class is, such as the case of cluster 3 leukemias. 
Th is cluster, which was enriched for t(8;21) patients, included others without this cytogenetic 
marker, however, there was no diff erence in survival between the two subgroups. While some 
of the patients negative for the t(8;21) presented other cytogenetic and molecular indicators 
of favorable risk, this fi nding refl ects the existence of a common DNA methylation profi le 
for these patients. Th is epigenetic signature aggregated these leukemias together beyond the 
presence of other molecular and cytogenetic markers, and in addition identifi ed additional 
cases that did not present with any favorable risk indicator. Similarly, a hypermethylated 
gene signature defi nes a subset of leukemias with CEBPA silencing due to hypermethylation, 
T-cell lineage infi delity, resistance to myeloid growth factors and a poor prognosis(12). Th ese 
cases formed cluster 10 in this cohort. AMLs with mutations on both CEBPA alleles or with 
homozygous mutations were recently shown to have a highly favorable prognosis(32) and 
these cases also presented with a defi ning DNA methylation profi le. Taken together, these 
data warrant considering both of these subtypes as distinct leukemia diseases that should 
be assigned to risk stratifi ed therapy regimens and explored for the development of specifi c 
targeted therapy. 
NPM1 mutations distributed to four related but slightly distinct signatures. Th ese epigenetic 
variations cannot be explained by the presence or absence of a concurrent FLT3-ITD, sug-
gesting that other as yet unrecognized mechanisms might be at play in determining these dif-
ferent epigenetic groups. We were unable to identify a DNA methylation signature associated 
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with FLT3 lesions, indicating that mutations of this gene do not exert their eff ects in AML by 
imposing an aberrant epigenetic pattern. 
One of the notable fi ndings of this study was the identifi cation of fi ve methylation signatures 
with no other common morphologic or molecular features, but with distinct clinical outcomes, 
suggesting that these too are unique forms of AML with their own biological characteristics. 
It is particularly signifi cant that these AML subtypes cannot be identifi ed by any available di-
agnostic method, underlining that epigenetic signatures provide a critical layer of additional 
information. Th e fact that these cases included both normal karyotype leukemias as well as 
those with cytogenetic lesions and across multiple FAB subtypes supports a move away from 
defi nitions rooted in standard karyotyping, rather towards a more functional classifi cation 
of AML. Future studies will be required to explore the biological basis of these epigenetically 
defi ned subtypes in the eff ort to develop risk-adapted and molecular targeted clinical trials 
that more accurately refl ect inter-individual diff erences among leukemia patients. However, 
the presence of a strong hypermethylated signature in some of these clusters (clusters 2, 7 
and 15) (Figure 2D). along with their unfavorable prognosis leads us to speculate that these 
patients, as well as those in the CEBPA-silenced cluster, might benefi t from the inclusion of 
hypomethylating agents as part of their therapeutic regime.  
Furthermore, in this study we identifi ed the presence of a common DNA methylation signa-
ture that is detected in the vast majority of cases. Th e nature of the genes found in this com-
mon epigenetic signature, which included tumor suppressors, putative and well-described 
transcription factors, nuclear import proteins, apoptosis-related proteins, and a regulator 
of myeloid cytokines, is highly suggestive of a role in leukemic transformation. In addition, 
we found that this aberrant methylation was accompanied by signifi cant downregulation of 
these genes. Th e fact that these genes are aff ected in a broad fashion, across multiple diff erent 
subtypes of AML leads us to believe that deregulation of these genes is most likely a neces-
sary, though probably not suffi  cient, event during the malignant transformation process of 
hematopoietic cells. 
Finally, the study identifi ed a robust 15-gene methylation classifi er that was predictive of 
overall survival, which was generated in an unbiased manner using a large enough data set to 
perform training, testing and independent validation. Th e methylation predictor was further 
validated as an independent risk factor in a multivariate analysis. Since DNA is stable and 
readily obtained from clinical specimens, we believe that this DNA methylation classifi er 
could serve as a clinically useful biomarker used for decision-making in future clinical trials. 
In conclusion, while epigenetic deregulation has been recognized as a hallmark of cancer for 
some time, the use of epigenomics to further expand our understanding of the biology of 
these diseases has only more recently become feasible in the clinical context. Here we show 
that DNA methylation profi ling is a powerful tool for the clinical stratifi cation of AML and 
to further explore and defi ne the biology of this disease. 
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ABSTRACT
DNA methylation patterns are frequently dysregulated in cancer, although little is known of 
the mechanisms through which specifi c gene sets become aberrantly methylated. Th e EVI1 
locus encodes a DNA binding zinc-fi nger transcription factor that is aberrantly expressed 
in a subset of AML patients (AMLs) with poor outcome. We fi nd that the promoter DNA 
methylation signature of EVI1 AML blast cells diff ers from those of normal CD34+ bone 
marrow cells and other AMLs.  Th is signature contained 294 diff erentially methylated genes, 
of which 238 (81%) were coordinately hypermethylated. An unbiased motif analysis revealed 
that EVI1 binding sites were overrepresented among these aberrantly hypermethylated loci. 
EVI1 was capable of binding to these promoters in two diff erent EVI1 expressing cell-lines, 
whereas no binding was observed in an EVI1 negative cell-line. Furthermore, EVI1 was 
observed to interact with DNMT3A and not with DNMT3B or DNMT1. Among the EVI1 
AML cases, two subgroups were recognized of which one contained AMLs with many more 
methylated genes, which was associated with signifi cantly higher levels of EVI1 than in the 
cases of the other subgroup. Our data point to a role for EVI1 in directing aberrant promoter 
DNA methylation patterning in EVI1 AMLs.
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INTRODUCTION
Patterning of DNA methylation plays a critical role in epigenetic gene regulation during nor-
mal development(1). Aberrant cytosine methylation of gene promoters occurs frequently in 
many forms of cancer, including acute myeloid leukemias (AML)(2). Several tumor suppres-
sor genes, e.g., CDKN2B and CEBPA are found to be abnormally methylated and silenced in 
AML patients(3, 4). Moreover, aberrant distribution of promoter DNA methylation occuring 
in specifi c and distinct patterns has been shown to be a universal feature occurring in all AML 
patients. (5). However, the mechanisms that mediate these aberrant methylcytosine patterns 
have not been defi ned.
Abnormal expression of the EVI1 (ecotropic viral integration-1) gene, as the result of inv(3)
(q21q26.2)/t(3;3)(q21;q26.2) or through other unknown mechanisms, is associated with un-
favorable AML outcome(6, 7). EVI1 encodes a C2H2 zinc fi nger transcription factor, binding 
DNA in a sequence-specifi c manner and functions as a repressor(8-10). Retroviral insertion 
mutagenesis studies suggest that EVI1 deregulation plays a role in leukemogenesis(11). Th e 
mechanism through which EVI1 mediates these eff ects is unknown. Given the function of 
EVI1 as a transcriptional repressor we wondered whether EVI1 might be associated with 
aberrant epigenetic programming in AML patients. In order to test this hypothesis, we 
conducted a large-scale DNA methylation profi ling study in human EVI1 AMLs. A specifi c 
promoter DNA methylation signature is uncovered in EVI1 AMLs and evidence is provided 
that EVI1 contributes to aberrant promoter DNA methylation patterning in those leukemias. 
MATERIAL AND METHODS
Patient samples 
Diagnostic material from 26 AML patients over-expressing EVI1 (EVI1 AML), determined 
using EVI1 real-time quantitative PCR(7), were included based on material availability. All 
patients were enrolled in Dutch-Belgian Hemato-Oncology Cooperative Group trials (avail-
able at http://www.hovon.nl), and provided written informed consent in accordance with the 
declaration of Helsinki. IRB approval was obtained at the Erasmus University Medical Centre. 
Normal CD34+ progenitor cells (CD34+ NBM) were purifi ed from bone marrow specimens 
from 8 healthy donors: 4 acquired from the Translational Trials Development and Support 
Laboratory, Cincinnati Children’s Hospital and 4 purchased from Allcells (Emerville, CA, 
USA). 
Genome wide DNA methylation by the HELP assay 
Blasts and mononuclear cells from AML samples at diagnosis were purifi ed as previously 
reported(12). Th e HELP assay was carried out in the EVI1 AML and CD34+ normal bone 
marrow (NBM) samples as previously published(5). Based on the density of the HpaII/MspI 
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ratios from the 25,626 probe sets in the 26 EVI1 AMLs and 8 CD34+ NBM samples; hyper-
methylation was defi ned as a log2 (HpaII/MspI) < 1 and hypomethylation log2 (HpaII/MspI) 
of a probe set was > 1. Th e HELP data have been submitted to the NCBI Gene Expression 
Omnibus (GEO) repository (GSE18700).
DNA methylation data analysis 
Unsupervised clustering of the HELP data by hierarchical clustering using Pearson correla-
tion distance with Ward clustering method and principal component analysis was performed 
using R.2.8.1(13) and BioConductor(14) using the package MADE4(15). Supervised analysis 
was carried out using a moderated T-test with a signifi cance level of P-value <0.05 aft er cor-
recting for multiple testing using the Benjamini-Hochberg (BH) approach. An absolute dif-
ference in methylation >1.5 between the means of the two populations (meanEVI1 log(HpaII/
MspI) – meanNBM log(HpaII/MspI)) was required to increase the likelihood of detection of 
biologically signifi cant changes in methylation levels. 
Quantitative DNA methylation analysis by MassARRAY EpiTyping 
Technical validation of the HELP data was perf ormed by MALDI-TOF mass spectrom-
etry using EpiTyper by MassARRAY (Sequenom, CA) in 13 randomly selected EVI1 AML 
samples on bisulfi te-converted DNA using a panel of 15 genes using MassARRAY primers as 
previously described(4, 5, 16, 17). Th e correlation between the MassARRAY results and the 
HELP methylation data was calculated using the r value of the regression line
CpG/CG enrichment, gene ontology and regulatory element analysis 
Enrichment of probe sets overlapping with CpG islands or CG clusters(18) in the gene signa-
tures vs. all probe sets of the HELP assay was calculated using the Fisher’s exact test using R 
2.8.1. Gene ontology (GO) analysis was performed using DAVID(19), with the entire HELP 
microarray as the background reference against which enrichment of level 5 GO categories 
was determined. FIRE (Finding Informative Regulatory Elements) was used as described(20), 
to detect motifs in promoter regions i.e., sequences up to 2,000 bp upstream of the TSS de-
fi ned by the UCSC browser 2008(21) , that were able to distinguish between EVI1 AML and 
CD34+ NBM signature genes and a group of 5,000 control sequences.
Chr omatin immunoprecipitation 
Th e chromatin immunoprecipitation (ChIP) was carried out simultaneously in an EVI1 over-
expressing AML SB1690CB cell-line(22, 23), K562 a cell-line with intermediate EVI1 levels, 
and an EVI1 negative MOLM13 cell-line according to manufacturer’s protocol (SimpleChIP 
Enzymatic Chromatin IP Kit, Magnetic Beads, Cell Signaling, Bioke, CA, USA, Catalog 
#9003) using anti-EVI1 (Cell Signaling, #2593) or an equal amount of IgG isotype as negative 
control (Cell Signaling, #2729) or anti-Histone H3 (Cell Signaling, #2650) as positive control. 
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Th ree independent experiments were carried out and according to manufracturer’s proto-
col, in each experiment over 1% of the input from the positive control RPL30 (Histone H3 
binding target) was precipitated (mean 2%, standard deviation 0.78%). Th e amount of im-
munoprecipitated DNA in each experiment is represented as signal relative to the amount of 
input and was calculated with the quantitative real-time PCR results using primers directed 
to promoter regions of FAM83b, IL11RA, MORF4L1, CRHBP, CASP2 and VPREB3 contain-
ing respectively 7, 8, 5, 5, 4, and 5 bp of the fi rst EVI1 binding domain. Th e ChIP primer 
sequences are shown in the Supplement.
EVI1 and DNMT co-immunoprecipitation assays
Th e expression constructs pcDNA-HA-DNMT1, pSVK-HA-DNMT3A and pSVK-HA-DN-
MT3B were a kind gift  of Dr. Stephen Baylin and the latter two constructs were subcloned into 
pcDNA3.1 to generate pcDNA-HA-DNMT3A and pcDNA-HA-DNMT3B. pCMV-empty 
and pCMV-FLAG-EVI1 have been described before(24). We also generated pcDNA-FLAG-
DNMT3A and pCMV-HA-EVI1 to carry out the reciprocal Co- =immunoprecipitation 
(Co-IP) experiments. For Co-IP experiments, HEK293T cells were transfected with 8μg of 
total DNA using FuGENE6 transfection reagents (Roche, Mannheim, Germany). Forty-eight 
hours aft er transfection, FLAG-immunoprecipitations on nuclear extracts were performed 
according to the Nuclear Complex Co-IP kit protocol (Active Motif, Carlsbad, Ca, USA), 
and bound proteins were detected by Western blotting with anti-Flag (Sigma-Aldrich, St. 
Louis, Mo, USA) or anti-HA (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies. 
Co-IPs were carried out in SB1690CB cells with anti-DNMT3A (Abcam, Cambridge, MA) 
and anti-EVI1 (Cell Signaling Technology, Boston, MA). 
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RESULTS
EVI1 AML blasts display a specifi c aberrant promoter DNA methylation signature  
We compared and contrasted the abundance of cytosine methylation at 14,000 gene promot-
ers using the HELP assay in 26 AML patients overexpressing EVI1 (EVI1 AMLs) and in 8 
CD34+ normal bone marrow controls (CD34+ NBM). Th e accuracy of the HELP assay in 
detecting variance in DNA methylation was validated by single locus quantitative EpiTyping 
and the correlation between the two assays was r=0.83 (Figure S1).
Unsupervised analysis using hierarchical clustering (Figure 1A) and principal component 
analysis (data not shown) revealed clear segregation of the 26 EVI1 AMLs from the 8 CD34+ 
NBM controls.  Hierarchical clustering in a previously published cohort of 344 AML pa-
tients(5), revealed that the EVI1 AMLs were almost all contained within two cohorts of pa-
tients defi ned solely based on their epigenetic signatures, but not having any other common 
known cytogenetic or molecular abnormality (Figure S2). Th us, the EVI1 AMLs clustered 
separately from any of the epigenetic clusters with well-defi ned cytogenetic or molecular ab-
normalities, i.e., inv(16), t(8;21), t(15;17), CEBPA-mutant AML, CEBPA-silenced leukemias 
or NMP1 mutant cases (Figure S2).  EVI1 AML leukemia cells thus present with a DNA 
hypermethylation signature that diff ers entirely from that of normal bone marrow progeni-
tors, as well as from those of other genetically well-defi ned AMLs
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Figure 1. EVI1 acute myeloid leukemia patients (EVI1 AMLs) have a unique genome wide methylation profi le 
compared to CD34+ normal bone marrow samples (CD34+ NBM). 
(A) Th e dendrogram represents a hierarchical clustering in 8 CD34+ NBM blasts and 26 EVI1 AMLs. (B) Th e volcano 
plot shows the methylation diff erence comparing the 26 EVI1 AMLs to 8 CD34+ NBM samples with corresponding 
moderated T-test P-value. Probe sets signifi cantly hypermethylated (P<0.001 and methylation diff erence less than 
-1.5) are shown in red, probe sets signifi cantly hypomethylated (P<0.001 and methylation diff erence larger than 
1.5) are shown in green. Signifi cant probe sets that did not have an absolute methylation diff erence larger than 1.5 
are depicted in blue. (C) Th e heatmap shows the methylation levels (Log (HpaII/MspI)) of diff erentially methylated 
genes (rows) in EVI1 AMLs and CD34+ NBM cases (columns). (D) Th e histograms show the percentages of genes 
containing (green) CG clusters and CpG islands and those not overlapping (grey) in all genes on the HELP array and 
in the EVI1 AML diff erentially methylated genes. A Chi-square test P-value is shown per panel.
A supervised analysis (moderated T-test) was next performed in order to more precisely defi ne the nature of aber-
rant epigenetic programming in EVI1 AMLs vs. CD34+ NBM controls. 303 diff erentially methylated probe sets, cor-
responding to 294 unique genes (Figure 1B) were identifi ed as diff erentially methylated in EVI1 AMLs with P<0.001 
(BH corrected P<0.05) and methylation log ratio diff erence >1.5 (corresponding to >25% diff erences in DNA meth-
ylation level).  81% (238/294) of the genes were coordinately hypermethylated in EVI1 AML cases, whereas only 19% 
(56/294) were hypomethylated, compared to CD34+ NBM controls (Figure 1C). 
A signifi cantly greater than expected percent of these probe sets were associated with CpG islands (P<0.0001) and 
CG clusters (P<0.0003) as compared to the distribution of all probe sets on the HELP array (Figure 1D). Of note, 28% 
and 50% of the diff erentially methylated genes did not contain CG clusters or CpG islands, respectively, suggesting 
that DNA methylation beyond these areas may remain important as well(25).
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Unique biological and molecular features of genes metylated in EVI1 AMLs 
From the functional standpoint the EVI1 DNA methylation signature was enriched in genes 
associated with transcription regulation and RNA biosynthetic process (Table S3). Th ree of 
the aberrantly methylated genes in the EVI1 signature (i.e. TOPORS(26), PCDH16(27) and 
CTCFL(28, 29)) have been reported to function as tumor suppressors. Th us, EVI1 AML as-
sociates with a unique set of functionally related and coordinately hypermethylated genes.
To better understand the mechanisms that might contribute to aberrant methylation in 
EVI1 AMLs, we used an unbiased motif analysis algorithm (FIRE(20)), to examine the 
promoter regions in the signature for DNA sequences of potential functional signifi cance. 
Th is approach yielded three motifs signifi cantly over-represented (P<0.05 aft er Bonferroni 
correction) in the 294 diff erentially methylated genes in EVI1 AML compared to a set of 
5,000 randomly selected non-diff erentially methylated promoters (Figure 2A). Two of the 
three over-represented motifs in the EVI1 AML methylation signature contained sequences, 
that overlap with the TGACAAGATAA consensus sequence, that is bound by the fi rst zinc 
fi nger domain of EVI1 (Figure 2A, Figure 2C). A subsequent FIRE motif analysis focusing, 
separately on the 238 hypermethylated and 56 hypomethylated genes revealed two motifs, 
that were highly enriched among the hypermethylated genes and each of these contained 
respectively, 5 bp and 4 bp of the fi rst and second EVI1 zinc fi nger domain binding sequence 
(Figure 2B).
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Figure 2. EVI1 binding sites are over-represented in the hypermethylated promoter regions of EVI1 AMLs and 
EVI1 binds these hypermethylated promoters in vivo. 
(A) Motif analysis of the in EVI1 AML diff erentially methylated genes showed a signifi cant overrepresentation (yel-
low in the heat map color key) of three 7 bp motifs. Per bar each 7 bp optimized motif is shown. Th e unlined 
sequences overlap with the fi rst or second EVI1 binding domain. Th e number of genes that harbored the representa-
tive motifs in their promoter sequences are depicted per bar. (B) Further analysis of the hypermethylated and hypo-
methylated genes reveals two overrepresented motifs in the promoter regions of the hypermethylated genes and one 
overrepresented in hypomethylated genes. (C) A schematic representation of the EVI1 nuclear zinc-fi nger protein, 
with the binding sequence of the fi rst and second EVI1 zinc fi nger domains. Th e overlapping motifs over-represented 
in hypermethylated genes are underlined in respectively blue and green. (D) Quantitative PCR of chromatin immu-
noprecipitation in the EVI1 positive (EVI1+) SB1960CB cell line and the EVI1 negative (EVI1-) MOLM13 cell line 
using EVI1 and IgG antibody. Percentage of amount of input material is shown. Th e mean and standard deviation of 
three independent experiments is shown.
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A role for EVI1 in promoter hypermethylation in EVI1 AML
In order to determine whether the presence of putative EVI1 binding sites indicated that these 
were EVI1 target genes, we fi rst performed HELP analysis on the recently derived human AML 
SB1690CB cell line, carrying a chromosomal 3q26 aberration and overexpressing EVI1(23). 
A highly signifi cant overlap of hyper methylated genes (89%) was found in the SB1690CB 
cell line compared to the hypermethylated genes identifi ed in the EVI1 AML patient samples 
(211/238 genes) (Table S5). Secondly, we performed chromatin immunoprecipitation (ChIP) 
assays on six randomly chosen hypermethylated genes, containing the above mentioned EVI1 
binding sequences. As compared to control antisera, EVI1 antibodies enriched all six genes, 
indicating that EVI1 was indeed bound to these genes (Figure 2D, Figure S3A). Similarly, in 
another cell line expressing EVI1 (K562), ChIP revealed EVI1 binding to the four loci studied 
(Figure S3B). In contrast, these promoters could not be immunoprecipitated in the EVI1 
negative myeloid MOLM13 leukemia cell line (Figure 2D, Figure S3).   
EVI1 interacts with DNMT3A
Th e results implicate EVI1 in promoter methylation. We therefore examined whether 
EVI1 could interact with DNA methyltransferases (DNMTs). Co-immunoprecipitation 
experiments were carried out using FLAG-tagged DNMT1, -3A or -3B and HA-tagged 
EVI1 transduced into 293T cells. FLAG-DNMT3A interacted with HA-EVI1 (Figure 3A, left  
panel), whereas no interaction was observed between HA-EVI1 and FLAG-DNTM1 or -3B 
(data not shown). Similarly, HA-DNMT3A co-precipitated with FLAG-EVI1 in the reverse 
experiment (Figure 3A, right panel). EVI1 is frequently found to be present in nuclear speck-
les. Confocal microscopy revealed that HA-tagged EVI1 co-localized with FLAG-tagged 
DNMT3A within the nuclei of transfected 293T cells, but not with FLAG-tagged DNMT3B 
(Figure 3B).  Most importantly, in SB1690CB cells, endogenously expressed EVI1 protein 
co-immunoprecipitated with DNMT3A (Figure 3C).      Moreover, DNMT3A was found to 
be highly expressed in primary EVI1 AMLs as compared to other AML patients (Figure S4). 
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Figure 3. EVI1 interacts with DNMT3A.
(A) Western blot analysis using anti-FLAG antibodies shows the input of the immunoprecipitation of transfected 
293T cells and the pulldown using anti-HA. (B) Confocal microscopy of 293T cells transfected with HA-tagged EVI1 
(green) and FLAG-tagged DNMT3A and -3B (red). (C) Western blot for EVI1 on lysates from SB1960CB cell-line. 
Th e left  lane shows the input band; the second and third lane show EVI1 staining following immunoprecipitation 
with IgG control (second lane) or anti-DNMT3 (third lane). 
Levels of EVI1 correlated with levels of methylation in EVI1 AMLs
Detailed analysis of the hierarchical clustering (Figure 1A and 1C) revealed that the 26 EVI1 
AML cases could be divided into two distinct subclusters (A and B) each with identifi able 
methylation profi les (Figure 4A). Th e robustness of both subclusters was determined by 
10,000 bootstrap re-sampling. Th e P-values (arbitrary unit: AU values) were more signifi cant 
(<95%) for subcluster B than subcluster A, indicating that methylation profi les in subcluster 
B are more homogeneous (Figure S5). Strikingly, subcluster A contained 7/8 EVI1 AMLs that 
carried 11q23 rearrangements (Fisher’s Exact test P-value 0.009). Most EVI1 AMLs that car-
ried a 3q26 abnormality (7/8) were contained within subcluster B (Fisher’s Exact test P-value 
0.03). Th is cluster was also enriched for cases with -7/7q- chromosomal lesions (8/11), which 
are frequently associated with 3q26 abnormalities (Figure 4A).
Of note EVI1 was expressed at higher levels in subcluster B than in subcluster A (Moder-
ated T-test P-value=0.01, Figure 4B). Supervised analysis revealed 122 signifi cantly diff eren-
tially methylated genes between those two groups (Moderated T-test P<0.001, BH corrected 
P<0.05, and absolute methylation diff erence >1.5).  117 of those 122 (96%) were exclusively 
hypermethylated in the subcluster B (Figure 4C and 4D). 
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In summary, these data demonstrate that, although EVI1 AMLs share a methylation profi le 
that discriminates them from normal marrow blasts, two subgroups can be identifi ed, which 
show a positive correlation between EVI1 transcript levels and methylation levels. Th e fact 
that subcluster B cases frequently carry 3q26 lesions and monosomy 7(30), may be a critical 
determinant in the increased number of methylated genes in those AMLs. 
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Figure 4. Unsupervised analysis identifi ed two epigenetically distinct EVI1 AML subgroups correlating with 
EVI1 relative expression. 
(A) Unsupervised hierarchical clustering with Pearson’s correlation using Ward’s method revealed two EVI1 sub-
clusters i.e., A and B. Th e cytogenetic characteristics are shown per patient; chromosome 3q26 abnormalities (red), 
monosomy 7 or deletion 7q (-7/7q-) (blue) and 11q23 rearrangements (grey). Th e percentages of each characteristic 
are shown per cluster. (B) Median EVI1 relative expression levels and 2SD are shown per subcluster. P-value was cal-
culated using a moderated T-test. (C) Th e volcano plot shows the methylation diff erence of all probe sets (n=25,626) 
(x-axis) comparing the methylation levels of cases in subcluster A with the cases in subcluster B with corresponding 
P-value (-log10 P-value moderated T-test) on the y-axis. (D) Th e heatmap shows the 122 probe sets (110 unique genes) 
diff erentially methylated in subcuster B, when both cluster were compared to each other using a moderated T-test 
(P<0.001 and absolute methylation diff erence >1.5). All genes are hypermethylated in EVI1 AMLs from subcluster B. 
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DISCUSSION
AML patient samples can be classifi ed based on unique DNA methylation signatures(5), but 
the mechanisms that direct coordinated methylation in the diff erent genetically well-defi ned 
AML subsets are unknown. Recruitment of DNMTs to target promoters and subsequent pro-
moter hypermethylation has been proposed as being mediated by the oncogenic transcription 
factor PML-RARA(31) in acute promyelocytic leukemia and AML1-ETO(32) in favorable 
risk AML using cell-line models. However, EVI1 is to our knowledge the fi rst example of a 
transcription factor that may direct a unique recurrent DNA methylation signature in human 
disease.
EVI1 AMLs express a methylation signature that discriminates them from normal marrow 
CD34+ blasts and from other AMLs. Within this diff erential signature ~80% of the genes were 
hypermethylated and ~20% hypomethylated in the EVI1 AMLs as compared to CD34+ NBM 
controls. Moreover, an even stronger hypermethylation signature was observed in the sub-
cluster with the highest EVI1 expression (Figure 4). EVI1 binding sites were overrepresented 
in hypermethylated promoters in EVI1 AMLs. Th ese hypermethylated genes are apparently 
bona fi de target genes since EVI1 was shown to bind to these promoters.  EVI1 could also 
form a complex with DNMT3A, but not with other DNMT family members. Together, these 
results suggest a role for EVI1 in directing de novo DNA hypermethylation in human AMLs 
that overexpress this transforming nuclear protein. 
Knock down of EVI1 in AML models would be an attractive approach to study whether 
genes might become demethylated in the absence of EVI1. However, we observed that knock 
down of EVI1 resulted in an almost complete cell cycle arrest of SB1690CB as well as K562, 
whereas no growth inhibition was observed in the EVI1 negative myeloid cell line MOLM-13 
(data not shown). Th is observation may be of importance for future therapy of this AML 
type, but it does not provide the optimal condition to answer our question, since cell cycle is 
a requirement in order to gradually lose methylation. Th e EVI1 methylation profi le was not 
aff ected following knock down (data not shown). Since EVI1 expression in AML appears so 
tightly regulated by regulatory loci on chromosome 3q21 in case of inv(3)(q21q26.2)/t(3;3)
(q21;q26.2) or by MLL-fusion genes as the result of a chromosome 11q23 aberration, proper 
animal models should be generated to study mechanisms of methylation by EVI1 in a reliable 
manner. 
We previously reported on another AML subtype, i.e., CEBPA-silenced leukemias(4), in 
which the majority of loci were predominantly methylated in the AMLs and not in the CD34+ 
NBMs. One might argue that this is not surprising as aberrant promoter hypermethylation is 
a general event found in many tumors. However, this is not a priori true for AML. CEBPA-
mutant AMLs carry more hypomethylated loci when compared to CEBPA-silenced leukemias 
or to CD34+ normal samples(4, 5). Moreover, CEBPA-silenced leukemias show a very strong 
methylation signature, but it is completely diff erent from that of EVI1 AMLs. In the unsuper-
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vised clustering analysis the CEBPA-silenced cases are grouping together completely separate 
from the EVI1 AMLs (Figure S2). Th us, in EVI1 AMLs a diff erent set of genes is methylated, 
again pointing to a specifi c role for EVI1 in these AMLs. We show that EVI1, which has been 
reported to also interact with histone deacetylases(33) (HDACs), as well as with C-terminal 
binding proteins(34), histone methyl transferases(35) and MBD3/NuRD complex(24), is also 
capable to bind DNMT3A. Th ese fi ndings, together with the observation that EVI1 is capable 
to bind DNA in a sequence specifi c manner and that EVI1 binding motifs are highly enriched 
in hypermethylated loci, support the hypothesis that EVI1 integrates functions in chromatin 
remodeling complexes and DNA methylation to mediate transcriptional repression.  
Treatment with both DNMT and HDAC inhibitors has been shown to reverse aberrant 
epigenetic silencing and induce cell death in various cancer types(31, 36). Th e combination 
of DNMT and HDAC inhibitors has been proposed for therapeutic purposes, although it 
is currently not possible to identify a priori patients likely to respond to this treatment(37). 
Th e fact that EVI1 appears to mediate its gene silencing eff ects both through recruitment 
of HDAC complexes and DNMT3A, suggests that combination therapy with DNMT and 
HDAC inhibitors could be active in these AML cases.
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Figure S1. Validation of HELP methylation levels by MassARRAY Epityper. Dot plot showing correlation between 
log2 (HpaII/MspI) ratios (x-axis) and percentage of methylation as determined by MassARRAY Epityper (y-axis) for 
15 probe sets in 13 randomly selected EVI1 AML patients. Th e correlation coeffi  cient is shown.
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Figure S2. EVI1 AML patients have a distinct genome-wide methylation profi le compared to other recurrent 
molecular and cytogenetic AML cases. Th e correlation plot shows the Pearson correlation of the high variance 
probe set methylation levels between 344 AML patients. Th e 16 clusters that were defi ned by Figueroa et al1., are 
labeled accordingly and the most recurrent cytogenetic or molecular abnormalities, are shown. Clusters #2 and #8, 
have been identifi ed as AML subgroups with unique methylation signatures, without common genetic or cytogenetic 
abnormalities and contain the majority of EVI1+ patients (labeled red for EVI1+ and green for EVI1-).
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Figure S3. EVI1 binds hypermethylated genes containing EVI1 binding sequences. Quantitative PCR of chro-
matin immunoprecipitation in the EVI1 positive (EVI1+) SB1960CB cell line (A) and the K562 cell line (B) and 
the EVI1 negative (EVI1-) MOLM13 cell line using EVI1 and IgG antibody. Percentage of amount of input mate-
rial is shown. Th e mean of two independent experiments is shown. Th e EVI1 binding sequence present in the 
promoter region of the hypermethylated genes is depicted.
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Figure S4. DNMT3A overexpressed in EVI1 AMLs. A gene expression correlation view of 285 AMLs as previ-
ously described2 shows the relative expression of DNMT3A in bars per patient. Focusing on the clusters highly 
over-represented with EVI1 AMLs a trend for DNTM3A overexpression is seen.
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Figure S5. Unsupervised hierarchical clustering using genome wide methylation levels in EVI1 AMLs revealed 
two main clusters. Unsupervised cluster analysis using Pearson’s correlation with Ward’s method revealed two dis-
tinct EVI1 subclusters; A and B. Using 10.000 bootstraps the Approximately Unbiased (AU) and Bootstrap Probability 
(BP) percentages were calculated per tree in the hierarchical clustering to show the tightness per subcluster, i.e. 
higher percentage means tighter cluster. 
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SUMMARY
To diagnose patients with acute myeloid leukemia (AML) in an optimal manner, the com-
bined application of conventional and modern cytogenetics with state-of-the-art molecular 
diagnostics is a requirement. Although at present, the WHO accurately classifi es an array of 
(2008) of human AML patients based on karyotyping combined with molecular diagnostic 
procedures, insight into the molecular defects of human AML is still increasing. As a result 
of that, the classifi cation of AML will be approved in the upcoming years. Th e focus of this 
thesis was to increase our understanding of specifi c subtypes of human leukemia. We focused 
on AMLs with chromosome 3q rearrangements, in particular on patients with an inv(3)
(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 (shortly: (inv(3)/t(3;3)), frequently associated 
with aberrant expression of EVI1, a gene that resides on 3q26.2. Secondly, we wished to elu-
cidate why certain human AMLs showed high EVI1 expression without having chromosome 
3q26 abnormalities. We investigated the importance high EVI1 levels in those leukemias 
and studied the potential to include EVI1 expression analysis in the diagnosis of AML. Th e 
data obtained from the last three chapters increase our understanding of the molecular and 
biological eff ects of EVI1 when aberrantly expressed in AML.
In chapter 2, we compared clinical, cytogenetic and molecular features of AML patients with 
diff erent chromosome 3q rearrangements. We investigated whether AML cases with a 3q 
abnormality respond poor to treatment, whether the new WHO classifi cation group inv(3)
(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 is indeed a specifi c entity separate from the cases 
with diff erent 3q abnormalities involving either the 3q26 or the 3q21 locus. We elucidated 
whether EVI1 expression analysis could be of help to classify the distinct AML subtypes with 
distinct 3q rearrangements. Four groups with 3q abnormalities were identifi ed, i.e. patients 
with (A) inv(3)/t(3;3), (B) balanced translocations involving t(3q26), (C) balanced t(3q21) 
translocations and (D) other 3q abnormalities. Th e inv(3)/t(3;3) cases could be recognized 
as a distinct subgroup; i) they frequently carried a monosomy 7, ii) they oft en carry N-RAS 
mutations, iii) they demonstrated discordant EVI1 and MDS1/EVI1 expression and iv) this 
karyotype was found to be an independent prognostic marker for survival and complete 
remission. Th e cases in the group of patients with remaining 3q abnormalities (D), showed an 
adverse survival outcome as well, but in this set of patients complex and monosomal karyo-
types were highly frequent. Certain cases in group D showed discordant EVI1 and MDS1/
EVI1 expression, very much alike i nv(3)/t(3;3) AMLs. Th ese leukemias showed frequently the 
rare karyotypes, add(3q21), del(3q21), add(3q26) or del(3q26). In fact, detailed FISH analysis 
in these cases revealed the existence of cryptic inv(3)/t(3;3) in the cases that were analyzed.
In chapter 3, we investigated whether EVI1 has a prognostic impact on AML and what the 
relation of MDS1/EVI1 is with high EVI1 expression (EVI1+). Th e expression levels of fi ve 
diff erent EVI1 5’ splice variants were determined. Beside the splice variant EVI1_1C, all vari-
ants were highly expressed in EVI1+ patients. Cases that expressed both, short form EVI1 and 
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the long form MDS1/EVI1 were correlated with 11q23 rearrangements and showed a slightly 
better survival compared to cases with high EVI1, which did not express MDS1/EVI1. We 
uncovered a subset of patients with high EVI1 and low or no MDS1/EVI1 expression without 
karyotopypically recognizable 3q26 abnormalities in which cryptic 3q rearrangements were 
detected using FISH analysis. EVI1 was found to be of prognostic value independently from 
cytogenetic risk, age, monosomy 7 and t(11q23). From this study, we concluded that a com-
bined EVI1 and MDS1/EVI1 Q-PCR should be added to the arsenal of molecular assays to 
classify human AMLs. 
In chapter 4, a comparable study was carried out in pediatric AML patients, in which EVI1+ 
cases could be identifi ed using gene expression profi ling and the quantitative EVI1 specifi c 
PCR assay (Q-PCR). Th e positive correlation between the presence of t(11q23) and aberrant 
EVI1 expression was also found in these pediatric AML patients, in which the frequency of 
the t(11q23) cases is even higher than in adults. Th e prognostic impact of EVI1 in pediatric 
AML was adverse, though not independent from other prognostic markers in pediatric AML. 
Remarkably, no 3q rearrangements were identifi ed in this pediatric AML cohort. 
A novel single Q-PCR approach was established (chapter 5), to measure all the diff erent 5’ 
EVI1 splice variants in one assay. In a large cohort of nearly 1,000 AML cases EVI1 was 
identifi ed as independent prognostic marker for achievement of CR, EFS and RFS. EVI1+ 
patients with intermediate cytogenetic risk, as well as EVI1+ cases that carried t(11q23), 
showed adverse survival response compared to the EVI1- patients in both groups, underlin-
ing that EVI1 screening should be taken into account for routine AML diagnostic work-up. 
Th e importance hereof is demonstrated by the fi nding that EVI1+ patients who received an 
allogeneic SCT showed a signifi cantly better survival compared those receiving autologous 
SCT or chemotherapy alone.
Th e studies from chapter 6 were carried out to understand the clinical, molecular and mecha-
nistic diff erences between EVI1+ and EVI1- AMLs with 11q23 rearrangements. In nearly 
40% of the t(11q23) cases screened (n=83), EVI1 was highly expressed. Th e EVI1+ t(11q23) 
cases showed to represent a distinct group that could be separated from the EVI1- t(11q23) 
cases: i) they expressed a diff erent gene expression profi les leading to separated clustering of 
EVI1+ t(11q23) AMLs from the EVI1- cases; ii) morphologically they were diff erent from 
each other; and iii) EVI1+ t(11q23) cases showed a signifi cantly inferior response to therapy 
than EVI1- t(11q23) cases. In vitro transformation of murine bone marrow cells by MLL-AF9 
lead to the generation of Evi1+ and Evi1- transformed clones. Th e progenitors from the Evi1+ 
clones appeared to carry GMP, as well as immature CMP markers, whereas the Evi1- clones 
were more mature, i.e. only GMPs were found. Cell sorting experiments demonstrated that 
in EVI1+ MLL-AF9 transformed human AML, as well as in transformed mouse bone mar-
row cells, EVI1 expression was aberrant, i.e. the gene was expressed in mature cells, which 
are normally EVI1 negative. In vitro self-renewal of Evi1+ MLL-AF9 transformed myeloid 
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progenitors was inhibited upon EVI1 knockdown, indicating a fundamental role of EVI1 in 
transformation in a subset of MLL-AF9 transformed AMLs. 
In chapter 7 and 8, the research focus was on genome wide methylation levels in AML and 
on the mechanisms of how methylation may be regulated in AML (chapter 7), in particular 
in EVI1 AMLs (chapter 8). We identifi ed in a group of 344 AMLs, unique AML subtypes that 
were characterized by distinctive aberrant DNA methylation signatures. Cases with particu-
lar cytogenetic or genetic aberrations, such as cases with translocations t(8;21) or t(15;17), 
but also leukemias with mutations in CEBPA carried unique DNA methylation profi les. Five 
unique AML subsets without a common molecular or cytogenetic abnormality, but with dis-
crete DNA methylation signatures were identifi ed. In addition, a 15-gene methylation clas-
sifi er was recognized and found independently predictive for survival in AML. In chapter 8, 
we focused on EVI1 AML, which show an aberrant methylation profi le compared to CD34+ 
normal bone marrow. Th e promoters of the aberrantly methylated genes overrepresented 
putative EVI1 binding sites, and EVI1 binding to the promoters of these genes was confi rmed 
in an AML cell line model that carried a 3q26 abnormality. An interaction that was observed 
between DNMT3A and EVI1 made us hypothesize that EVI1 recruits DNMT3A to those 
promoter areas leading to de novo methylation of these regions. 
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GENERAL DISCUSSION AND FUTURE DIRECTIONS
I – 3q26 rearrangements and high EVI1 transcript levels in the diagnosis of AML 
Human AMLs with the specifi c 3q26 rearrangements, inv(3)(q21q26.2)/t(3;3)(q21;q26.2) 
(inv(3)/t(3;3)) represent a unique AML subtype, which show a very poor response to treat-
ment. Th e identifi cation of EVI1+ MDS1/EVI1- cases with cryptic inv(3)/t(3;3), in the group 
of remaining 3q abnormalities, i.e. excluding the inv(3)/t(3;3) or the balanced translocations 
t(3q26) and t(3q21) groups (chapter 2), is a fi nding that stresses that AML patients at diagno-
sis should be analyzed for the presence of this unique abnormality. We propose that besides 
standard cytogenetic analysis using G-banding, the expression of EVI1 should be determined 
in each newly diagnosed AML patient. In the majority of cases this combination of assays 
should be suffi  cient to uncover an AML with an inv(3)/t(3;3) and high EVI1. A Q-PCR 
to determine MDS1/EVI1 expression levels, which are usually low or even absent in these 
AMLs, may confi rm that a patient is indeed of this particular AML subtype. When a patient 
is EVI1 positive and G-banding does not point to the existence of an inv(3)/t(3;3), a MDS1/
EVI1 Q-PCR combined with FISH analysis should be carried out to investigate whether such 
an AML is EVI1+ MDS1/EVI1- and carries a cryptic inv(3)/t(3;3).  
II – Monosomy 7 in EVI1 expressing AMLs with inv(3)/t(3;3) 
More than 60% of human AMLs with an inv(3)/t(3;3) carry a monosomy 7 (chapter 2, 3 
and 5). In fact, no other AML subtype shows such a high correlation with monosomy 7, 
suggesting a causal relation with high EVI1 expression. Th e order of events in primary AML, 
i.e. fi rst aberrant EVI1 expression followed by monosomy 7, or fi rst a monosomy 7 followed 
by aberrant EVI1 expression, is not fully solved yet. However, recent studies of a gene therapy 
trial for granulomatous disease  provided new insights into the putative mechanism of EVI1 
mediated disease progression(1). It was demonstrated that as a result of retroviral insertion 
in the 3q26 locus EVI1 was overexpressed, which associated with abnormal centrosome 
duplication, linking EVI1 activation to the development of genomic instability, monosomy 
7 and clonal progression towards myelodysplasia(1, 2). If aberrant EVI1 expression indeed 
causes monosomy 7 to occur, one would predict that with higher EVI1 levels, the chances to 
obtain a monosomy 7 would increase. Indeed, we found that EVI1 transcript levels are much 
higher in inv(3)/t(3;3) cases with a monosomy 7 than in cases without (Figure 1). 
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Figure 1. Higher EVI1 expression in inv(3)/t(3;3) and monosomy 7 cases compared to inv(3)/t(3;3) as sole ab-
normality.
Th e question remains, why chromosome 7 and not another chromosome is so frequently 
lost in inv(3)/t(3;3) AMLs. Th e most likely explanation would be that loss of chromosome 7 
provides a proliferative advantage to EVI1 over-expressing cells. Th is could mean that, one 
or more critical tumor suppressor genes are located on chromosome 7. In case the expres-
sion of these genes is diminished, the transforming activity by EVI1 is further increased. 
Interestingly, in view of this hypothesis, investigators were able to pinpoint two small regions 
on chromosome 7, that were shown to be selectively deleted in inv(3)/t(3;3) AML cell lines 
without a monosomy 7(3). Possibly one or more genes in those loci may act as tumor sup-
pressor gene with overexpressed EVI1. Array-CGH, deep-sequencing and selective analysis 
of gene expression data of the many inv(3)/t(3;3) EVI1 expressing AML samples available 
should provide insight into this enigma. 
 
III – Mechanism of aberrant EVI1 transcription in AML with 3q26 rearrangement  
How do chromosome 3q26 aberrations lead to high EVI1 expression levels? In case of bal-
anced translocations involving 3q26 that involve other chromosome translocation partners, 
such as in t(3;21) or t(3;12), high EVI1 levels are easily explained by the regulatory control of 
the partner fusion gene. Fusion genes that arise from these translocations are AML1/EVI1(4) 
or AML1/MDS1/EVI1(5) in case of a translocations t(3;21) or ETV6/EVI1(6) or ETV6/MDS1/
EVI1(7) when a translocation t(3;12) is apparent. AML1 and ETV6 are normally expressed 
in myeloid progenitors and consequently, the newly generated fusion genes are expressed 
under the control of the AML1 or ETV6 promoter sequences. EVI1 is highly expressed in the 
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majority of those cases, but depending on the chromosomal breakpoint, i.e. 5’ of EVI1 or 5’ 
of MDS1/EVI1 the fusion partner is either EVI1 or MDS1/EVI1 (chapter 2)
Th e expression of EVI1 and the frequent absence of MDS1/EVI1 in AML with an inv(3)/t(3;3) 
is more complicated. Th e location of diff erent 3q breakpoints in inv(3)/t(3;3) cases have 
been reported previously(8-13). Suzukawa(12) et al., fi rst described that t(3;3)(q21;q26.2) 
and inv(3)(q21q26.2) cases have diff erent breakpoints i.e. 5’ and 3’ of EVI1 respectively. 
Poppe(11) et al., described an even more variable pattern of breakpoints for the t(3;3)
(q21;q26.2) cases, i.e. breaks could occur 5’ and 3’ of EVI1 or even 5’ of MDS1. We performed 
a detailed FISH analysis in a couple of cases (see chapter 2 and chapter 3), showing break-
points 5’ and 3’ of EVI1 as well. We extended this series using multiple probes overlapping 
EVI1 and MDS1, covering the 5’ and 3’ EVI1 region (Figure 2). In 5/9 inv(3)(q21q26.2) cases 
we found that the breakpoints were located either 5’ within the EVI1 locus (#9118), 5’ in 
between EVI1 and MDS1 (#2276, #5288, #6982) or even in the MDS1 gene (#6357) (Figure 
2). Th e sole t(3;3)(q21;q26.2) case (#3q76G), as well as 4 other AMLs with an inv(3) (#6367, 
#2228, #2542, #9212) showed breakpoints, that were 3’ of EVI1. In all cases the expression of 
EVI1 appears to be controlled by regulatory sequences of the RPN1 gene, located on 3q21. 
High EVI1 expression in those AMLs seems to result from a “classical” enhancer type of 
aberrant gene activation, since the insertions of the RPN1 regulatory regions occur either 
3’ or 5’of the EVI1 gene. 
Why do the chromosomal aberrations inv(3)/t(3;3) almost always lead to the dissociative 
pattern of EVI1 and MDS1/EVI1 expression, i.e. high EVI1 expression and no or low MDS1/
EVI1 expression? Th e majority of the inv(3)(q21q26.2) cases have a 5’ EVI1 breakpoint caus-
ing a dissociation of EVI1 or MDS1, which easily explains why only EVI1 is upregulated and 
not MDS1/EVI1. Why MDS1/EVI1 expression is frequently low or even absent in AMLs with 
inv(3)/t(3;3) at the 3’end of EVI1 is unclear. It is possible that the RPN1 regulatory regions 
can only act as an enhancer to the EVI1 promoter and not to the MDS1 promoter. Th is lack of 
activity could be caused by the absence of the required combinations of transcription binding 
motifs in the MDS1 promoter and RPN1 enhancer. Another theory could be, that the MDS1 
promoter is simply to far from the 3’ region of EVI1 (~1 Mbps). However, it has now been 
well established that by looping of the DNA promoters can be co-regulated, even when they 
are separated over a fairly long distance. Th erefore, this latter explanation does probably not 
hold. Array-CGH on a patient sample with a proven 3’ breakpoint showed evidence of copy 
number loss of part of the MDS1 locus (data not shown). As this was a single case, we propose 
that, more AML cases 3’ EVI1 breakpoints need to be analyzed using array-CGH to study 
whether MDS1 is indeed frequently deleted in those samples. Analysis of patient samples 
using tiling arrays that cover the MDS1, EVI1 and RPN1 loci that we have generated should 
help to solve this issue in detail. 
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Th e fact that in inv(3)/t(3;3) AMLs with aberrant EVI1 expression, the RPN1 locus is always 
involved points to an important role for this particular locus to activate EVI1 expression. 
We assume that, when EVI1 translocates to the RPN1 locus or the other way around, this 
RPN1 locus contains the right enhancer at the right time and place in the right cell. Th is 
is underlined by the fact that in human AML with a chromosome 1p36 translocation, the 
PRDM16 gene, which is highly homologous to EVI1 (PRDM3), translocates to RPN1 on 
3q21 as well. In fact, as reported in chapter 2, we found three other very rare translocations 
involving chromosome 3q21, in which the translocated locus is known to contain a PRDM/
EVI1 homologue, i.e. chromosomes 4q21, 6q21 and 11p15, harbouring PRDM8, 1 and 11 
respectively. FISH and Q-PCR should reveal whether in those situations these PRDM genes 
were involved in the translocation and whether their expression has indeed been altered, 
which subsequently would make detection of these rare translocations by Q-PCR fairly easy. 
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Figure 2. FISH analysis of 3q26 rearrangements.
 FISH analysis using RP11 probes depicted aside from each probe. Th e identifi ed 3q breakpoint location is shown per 
case depicted with corresponding patient number. All cases carry an inv(3), identifi ed by FISH, i.e. cryptic (c) or by 
conventional cytogenetic analysis, except 3q76G and 6358, which carry respectively t(3;3) and t(2;3).
IV – Dissociation of MDS1 from EVI1 in inv(3)/t(3;3) AML; transformation by EVI1 
and not MDS1-EVI1
Th e dissociation that occurs between the MDS1 and the EVI1 loci in AMLs with inv(3)/t(3;3) 
causing an overexpression of EVI1 suggests that MDS1/EVI1 does not have the same trans-
forming ability as EVI1. A previously reported RAT-1 fi broblast in vitro soft  agar assay has 
been developed and applied, to study the transforming ability of EVI1(14). Using this assay, 
we addressed the question whether EVI1 and MDS1/EVI1 were equally capable to transform 
RAT-1 cells. Preliminary results from our laboratory showed that in the RAT-1 fi broblast cell 
system, the transformation capacity of EVI1 was larger compared to MDS1/EVI1. MDS1/
EVI1 protein was shown to be as highly as EVI1 was in RAT-1 transduced clones. Th e num-
bers of colonies in EVI1 and MDS1/EVI1 transfected RAT-1 fi broblast aft er 14 days plated 
in soft  agar are shown (Figure 3). Others reported that Evi1 increased the proliferation of 
immature hematopoietic cells(15-20), and disruption of Evi1’s locus impaired proliferation 
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and enhanced spontaneous apoptosis of murine hematopoietic stem and progenitor cells 
through GATA-2 expression(21). Furthermore, EVI1 inhibited programmed cell death in 
response to a variety of apoptotic stimuli(17, 22, 23), and its ectopic expression interfered 
with erythroid and granulocytic diff erentiation(16). Th e role of Mds1/Evi1 was not evaluated 
in those studies. Evi1 accelerated the cell cycle of murine embryonic stem cells (ES)(15), 
whereas Mds1/Evi1 lowered ES cell proliferation(15). Th us, Evi1 and Mds1/Evi1 exhibited 
opposite biological activities as proposed in several reports(15, 24-26). Th ese observations 
underscore that, not only the activation of EVI1 expression, but also the dissociation of the 
MDS1 locus from the EVI1 region is required for transformation of AML with inv(3)/t(3;3).
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Figure 3. EVI1 has increased colony formation capacity compared to MDS1/EVI1 transfected RAT-1 fi broblast 
single clones. (A) Colonies formed in the EVI1 and MDS1/EVI1 (ME) transfected single colonies. RAT-1 fi broblasts 
transfected with P50Mx neomycine and P50Mx zeomycine were used as negative control and the EVI1+ and trans-
forming RAT-1 fi broblast clone 6 (Ecl6) as positive control. Western blot analysis (B) of the clones used for the soft  
agar assay (C). Th e mean number of colonies of one representative duplo experiment are depicted on the x-axis. 
*positive control RAT-1 FL(14), a full length EVI1 transfected RAT-1 clone. **positive control transfected ME clone. 
V – EVI1 and MDS1/EVI1 expression in AML with 11q23 rearrangements  
In a number of AML patients we observed high EVI1 levels, which were not associated with 
aberrations in the 3q26 locus, but frequently with 11q23 rearrangements. Moreover, in those 
cases, besides high EVI1 levels, high MDS1/EVI1 transcript levels were observed as well. 
Since the expression of EVI1 and MDS1/EVI1 is not caused by 3q26 defects, the presence 
of high transcript levels has to be the result of altered transcription regulation, possibly by 
MLL-fusion proteins that are the result of 11q23 rearrangements.
To understand how the expression of EVI1 and MDS1/EVI1 are regulated in those leukemias, 
insight should be obtained about the two promoter regions, i.e. what are critical motifs in 
the promoters, how is expression of EVI1 and MDS1/EVI1 regulated and what could be the 
role of MLL-fusion proteins? We have strong evidence that the MDS1 and EVI1 promot-
ers, which are ~1Mbps separated from each other, are co-regulated. In leukemia without 
a 3q26 abnormality either both transcripts are present or both are absent. In normal bone 
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marrow CD34+ cells both transcripts are detectable and they decline coordinately with 
diff erentiation. In a small number of leukemias where we found that the MDS1 promoter 
was methylated, we observed the EVI1 promoter was methylated as well (data not shown). 
Finally, in CD34/CD38 sorted fractions of EVI1 expressing MLL-rearranged leukemias we 
found co-expression of MDS1/EVI1 in each fraction, i.e. in CD34+/CD38-, CD34+/CD38+, 
CD34-/CD38+ and CD34-/CD38- cells (data not shown). We hypothesize that the promoters 
may be controlled by the same combinations of transcription factor complex(es) and that 
advanced motif analysis, genome alignments across species and 3C/4C experiments will be 
valuable to understand this complicated regulation of transcription. 
Th e question remains why MDS1/EVI1 and EVI1 are so highly expressed in certain MLL-
fusion gene transformed AMLs and not in other AMLs (chapter 2 and 3). In some leukemias 
it may simply be a refl ection of the expression pattern in normal hematopoietic progenitors. A 
low percentage of normal marrow hematopoietic stem and progenitor cells express EVI1 and 
MDS1/EVI1 (ME). It is possible that in certain cases these EVI1+/ME+ cells are transformed 
by MLL-fusion genes. In that case, EVI1+/ME+ expression in these AMLs is not abnormal. 
However, as we demonstrate in chapter 6, EVI1 (also MDS1/EVI1; data not shown) remains 
high in more mature cells, which are normally EVI1 negative. We hypothesize that MLL-
fusion protein may transform myeloid precursors, that are initially EVI1+/ME+ or  EVI1-/
ME-. We hypothesize that in case a cell was already EVI1+/ME+ at the time of transforma-
tion, the MLL-fusion proteins can maintain this high expression, even when a cell partially 
diff erentiates into a cell that should normally become EVI1–/ME–. To prove this hypothesis, 
mouse bone marrow transfection experiments should be conducted in which prior to MLL-
AF9 transduction, the cells are fractionated by sorting into either EVI1+ (LSKs) or EVI1– or 
low (CMP, GMP) precursor fractions. We hypothesize that the MLL-AF9 transformed EVI1+/
ME+ clones will be generated from the LSK fractions and will maintain positive even when 
the cells partially diff erentiate. MLL-AF9 transformed cells from the other sorts will mostly be 
negative for EVI1 and MDS1/EVI1. Another issue to be addressed is, how EVI1 and MDS1/
EVI1 expression is maintained so high in those transformed cells and what the role of MLL-
fusion oncoprotein is herein? MLL-AF9 chromatin immunoprecipitation (ChIP) followed 
by promoter Chip hybridizations or deep-sequencing in combination with EVI1 and MDS1 
promoter-reporter assays should reveal whether there is evidence for a direct role of MLL-
fusion transforming protein in EVI1 and MDS1/EVI1 transcriptional control in these cells. 
VI – Functional diff erence between EVI1 and MDS1/EVI1
We demonstrated that in inv(3)/t(3;3) AML EVI1 and not MDS1/EVI1 is critical for transfor-
mation. High expression of both genes have been reported in MLL-fusion gene transformed 
cells, as well as in experimental models (chapter 6). Replating abilities as determined in an in 
vitro self-renewal assay of cancer stem cells, could be inhibited by knocking down EVI1 and 
MDS1/EVI1. Th us, the role of EVI1 and in particular MDS1/EVI1 in MLL-rearranged leuke-
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mic transformation has to be, at least partially, diff erent from transformation in inv(3)/t(3;3) 
AML. 
Th e two proteins diff er from each other by the absence (EVI1) or presence (MDS1/EVI1) of 
an N-terminal PR domain(27). Th e PR domain is highly similar to the SET domain, a domain 
that is characteristic for the histon methyltransferase superfamily of proteins(28). Th is family 
consists of many diff erent members including e.g. SUV39 or G9a (histone H3K9 methyl-
transferase), proteins which have been demonstrated to interact with EVI1. Interestingly, 
another protein with a SET domain is MLL itself, which has H3K4 histone methyltransferase 
activity(28-30). 
MLL possesses histone methyltransferase activity (H3K4) through the SET domain(31), 
forming a complex that associates with the promoter of target genes such as HOXA9. Th e 
SET domain is lost in MLL fusions, emerging another mechanism the acquisition of alterna-
tive unique histone methyltransferase activity by partner proteins(32). It is possible that in 
t(11q23) AML cases expressing EVI1 and MDS1/EVI1, the PR alias SET domain of the latter 
one is taking over the function of the MLL-SET domain, thereby maintaining gene activa-
tion through H3K4. ChIP-chip or ChIP-seq experiments should reveal whether MLL target 
genes are also bound by MDS1/EVI1 and whether the presence of MDS1/EVI1 aff ects histon 
modifi cation such as H3K4 methylation on putative target genes, e.g. HOXA9 or MEIS1. 
Protein interaction studies should be carried out to investigate whether MLL-fusion proteins 
form an active complex with MDS1/EVI1.  
VII – Methylation mechanisms in EVI1 AML
In this thesis, genome wide methylation profi ling was carried out on a large cohort of AML 
patient samples. Ideally, this would give insight into the genes that are aberrantly methylated 
in specifi c AML subtypes. What is the defi nition of aberrant? In chapter 7 we compared 
the methylation signatures of CD34+ normal bone marrow control samples to those of the 
complete cohort of AML patient samples. We identifi ed a set of 45 genes that was almost 
always diff erentially methylated in any AML. Many of those appeared to be silenced and may 
thus function as tumor suppressor genes in AML. Th e question is, how to proceed and study 
the role of these genes in myeloid development? Which genes should we focus on? Th e fact 
that, we only identifi ed 45 genes methylated, that in essence may represent tumor suppressor 
genes, should make it possible to rapidly screen the eff ect of knocking down each of those in 
appropriate hematopietic models in vitro. 
Besides these 45 genes identifi ed, the relevance of genes selectively methylated per AML sub-
group may be of interest as well. AML groups with recurrent abnormalities such as transloca-
tions t(8;21), inv(16)/t(16;16) or t(15;17), but also leukemias with CEBPA double mutations, 
each carried a unique methylation signature. Th ese fi ndings suggest that certain methylated 
genes, particularly associate with certain AMLs with unique molecular abnormalities. It may 
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also point to unique mechanisms of DNA methylation in the diff erent molecularly defi ned 
AMLs. In this thesis we therefore we focused on EVI1 AMLs solely (chapter 8). 
We particular studied the methylation patterns in these EVI1 AMLs, and wondered how 
methylation of specifi c sets of genes may occur in these AML. We showed that EVI1 AMLs 
express a unique methylation signature, that separates them from other AMLs and from 
normal marrow CD34+ cells. Since DNMT3A can bind to EVI1 and EVI1 binding motifs 
highly enriched in the methylated genes, we hypothesize that DNMT3A may be recruited 
to putative EVI1 target genes. DNA methylation at the dinucleotide CpG in regulatory 
regions is a hallmark of stable transcriptional silencing(33). Major epigenetic modifi cations 
also include other processes, such as histone de-acetylation and methylation which are oft en 
closely coupled to DNA methylation(34) and recruitment of transcription factor repressor 
complexes. EVI1 has been shown to interact with histone de-acetylases (HDACs), as well as 
to histone methyl transferases, SUV39H1 or G9a. Moreover, it has been demonstrated that. 
EVI1 binds to MBD3 a member of the histone deacetylation complex (NuRD) and to CtBP1, 
an interaction that leads to strong transcriptional repression of target genes. Th us, our data 
point to a central role for EVI1 in epigenetic silencing. 
EVI1 expressing AMLs are very diffi  cult to cure and therefore these patients may benefi t 
from novel tailored forms of treatment. Knockdown of EVI1 in cell line models showed that 
proliferation of those leukemias could be abolished almost completely (chapter 6). Th ese 
fi ndings point to a critical role of EVI1 in proliferative behavior of those tumors. Improving 
our knowledge of the function of EVI1 and how it interacts with each of the earlier mentioned 
partner proteins is invaluable for the development EVI1 specifi c drugs. 
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Leukemie of bloedkanker is een ziekte van het beenmerg, de plaats waar bloedcellen worden 
aangemaakt. Er zijn veel verschillende typen bloedcellen, welke allemaal een specifi eke func-
tie in het lichaam hebben. Bij leukemie heeft  één cel type de overhand genomen en de andere 
(gezonde) cellen verdrongen. In dit proefschrift  is onderzoek gedaan naar een bepaalde vorm 
van leukemie, namelijk acute myeloïde leukemie (AML). Cellen die zich eigenlijk zouden 
moeten ontwikkelen tot granulocyten kunnen dat niet meer, vermenigvuldigen zich onger-
emd en overwoekeren het beenmerg en bloed. Eigenlijk is AML niet één ziekte maar een 
verzameling van aandoeningen. Wanneer we naar de cellen kijken onder de microscoop ziet 
de ziekte er vaak wel hetzelfde uit, maar op basis van andere eigenschappen blijken er grote 
verschillen te zijn. Hierdoor zijn sommige patiënten beter te behandelen dan anderen. AML 
wordt onder andere veroorzaakt door fouten in het DNA (mutaties). In de afgelopen twee 
decennia is er veel onderzoek gedaan naar deze genetisch afwijkingen in AML. Wij weten 
nu dat sommige mutaties geassocieerd zijn met een goede prognose, terwijl bij andere afwi-
jkingen de vooruitzichten minder goed gesteld zijn. Het is daarom voor de behandeling van 
AML belangrijk om de verschillende vormen van deze ziekte goed te kunnen onderscheiden. 
In het verleden werd AML voornamelijk onderverdeeld op basis van morfologisch ei-
genschappen (microscopisch onderzoek) en chromosomale afwijkingen (cytogenetisch 
onderzoek) van de leukemie cellen In de nieuwe classifi catie van de “World Health Organiza-
tion” (WHO) worden zowel cytogenetische als moleculaire methoden (gen mutatie en gen 
expressie onderzoek) succesvol gecombineerd. Echter het einde is nog lang niet in zicht en de 
kennis over de genetische afwijkingen in AML neemt nog steeds toe. De indeling van AML 
patiënten zal dus ook in de nabije toekomst steeds verder verbeteren.
Het doel van dit proefschrift  was om de moleculaire inzichten van bepaalde groepen AML 
patiënten verder te vergroten. De nadruk van het onderzoek lag bij patiënten met afwijkingen 
op de lange arm van chromosoom 3 (3q); zoals AML patiënten met een inv(3)(q21q26.2) 
of t(3;3)(q21;q26.2); RPN1/EVI1 afwijking (afgekort inv(3)/t(3;3)). Deze afwijkingen zijn 
gecorreleerd met hoge expressie van EVI1, een oncogen dat gelokaliseerd is op chromosoom 
3q26.2. Daarnaast, hebben we onderzoek gedaan naar de AMLs die geen cytogenetisch 
detecteerbare chromosoom 3q26 afwijkingen bezaten, maar wel een hoge EVI1 expressie 
(EVI1+ AMLs) hadden. EVI1 expressie niveaus werd bepaald in grote series patiënten met 
AML. Het belang om de EVI1 expressie analyse te includeren in de diagnostische routine 
van AML patiënten werd onderzocht in de hoofdstukken 2 tot en met 5. In de laatste drie 
experimentele hoofdstukken (6 tot en met 8) wordt ingegaan op de vraag welke rol EVI1 
heeft  in AML. 
In hoofdstuk 2, hebben we de klinische, cytogenetische en moleculaire karakteristieken 
van patiënten met verschillende chromosoom 3q afwijkingen vergeleken. Vier groepen van 
AML patiënten met 3q afwijkingen werden bestudeerd; patiënten met (A) inv(3)/t(3;3), (B) 
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gebalanceerde 3q26 afwijkingen, (C) gebalanceerde 3q21 afwijkingen, en (D) alle andere 3q 
afwijkingen. Er werd onderzocht hoe deze verschillende patiënten reageerden op behandel-
ing. Daarnaast werd onderzocht of de nieuw gedefi nieerde WHO groep van AML patiënten 
met een inv(3)/t(3;3) zich onderscheidt van de AML groepen met andere 3q afwijkingen. De 
EVI1 expressie waarden van de verschillende 3q groepen werden onderling vergeleken. De 
inv(3)/t(3;3) patiënten behoren tot een unieke groep, omdat ze; i) vaak één chromsoom 7 
hebben verloren, ii) frequent N-RAS mutaties hebben en iii) een hoog EVI1 en laag MDS1/
EVI1 expressie patroon vertonen. MDS1/EVI1 is een fusie van de twee genen MDS1 en 
EVI1, die aan elkaar grenzen op chromosoom 3q26. De aanwezigheid van een inv(3)/t(3;3) 
was een signifi cant onafh ankelijke prognostische parameter, en voorspelt een lage kans op 
complete remissie en een verminderde overlevingskans. Ook de groep patiënten met AML 
met resterende 3q afwijkingen (groep D) toonde een ongunstige overleving. De slechte prog-
nose van deze laatste groep kon deels verklaard worden door de aanwezigheid van andere 
chromosomale afwijkingen, vooral het zogenaamde complexe karyotype, waarvan bekend is 
dat het een slechte respons op therapie voorspelt. In deze groep werden ook regelmatig ver-
borgen inv(3)/t(3;3) afwijkingen gevonden. Deze afwijkingen konden worden aangetoond 
door middel van chromosomale fl uorescentie in situ hybridisatie (FISH), waarmee specifi ek 
EVI1 op chromosoom band 3q26, RPN1 op chromosoom band 3q21 en veranderingen in het 
patroon van deze twee genen zichtbaar kunnen worden gemaakt.
In hoofdstuk 3 onderzochten we de prognostische waarde van de expressie van EVI1 en 
MDS1/EVI1 mRNA transcripten in AML. De expressie van vijf verschillende EVI1 varianten 
werd bepaald. Behalve variant EVI1-1C, kwamen alle varianten hoog tot expressie bij EVI1+ 
AML. AML patiënten met zowel hoge EVI1 als MDS1/EVI1 expressie, bleken vaak een 
chromosoom 11q23 translocatie te hebben. Bij deze translocaties wordt het MLL gen, dat op 
chromosoom 11q23 ligt, gefuseerd is met het gen van het getransloceerde chromosoom. AML 
patiënten met hoge EVI1 en MDS1/EVI1, toonden een enigszins gunstigere overleving dan 
de patiënten met hoog EVI1 en laag MDS1/EVI1 expressie patroon. Deze laatste patiënten 
behoorden meestal tot de inv(3)/t(3;3) groep. Bij een aantal patiënten zonder cytogenetisch 
zichtbaar chromosoom 3q26 defect, maar met hoge EVI1 en lage MDS1/EVI1 expressie, 
identifi ceerden wij verborgen inv(3)/t(3;3) afwijkingen, door middel van EVI1 specifi eke 
FISH. Hoge EVI1 expressie manifesteerde zich als een onafh ankelijke prognostische factor 
voor ongunstige overleving in deze groep AML patiënten. 
Een zelfde onderzoeksbenadering werd in hoofdstuk 4 gevolgd bij kinderen met AML. In 
deze studie werd zowel gebruik gemaakt van een genoom brede gen expressie analyse als 
moleculaire methoden om EVI1 expressie te meten. De positieve correlatie tussen hoge EVI1 
en MDS1/EVI1 expressie met 11q23 chromosomale afwijkingen en de trend van ongunstige 
overleving werd ook bij kinderen met AML gevonden. Bij kinderen met EVI1+ AML werden 
geen (cryptisc he) chromosomale 3q26 afwijkingen gevonden.
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In hoofdstuk 5 hebben we een nieuwe moleculaire test ontwikkeld om de expressie van alle 
EVI1 gen varianten in één experiment bij AML te kunnen bepalen. In een groep van ~1.000 
AML patiënten werd EVI1 expressie bepaald. Hoge EVI1 expressie werd geïdentifi ceerd als 
prognostische marker, voor het bereiken van een complete remissie, het voorspellen van de 
response op therapie en het krijgen van een recidief. Binnen de groepen met een intermediair 
cytogenetisch risico profi el of met 11q23 chromosomale afwijkingen, hadden patiënten met 
EVI1+ AML een slechtere overleving dan EVI1- patiënten. Verder bleken de EVI1+ patiënten, 
die tijdens hun behandeling een allogene stam cel transplantatie hebben ondergaan, een 
signifi cant betere overlevingskans te hebben dan de patiënten die een autologe stam cel 
transplantatie of alleen chemotherapie kregen. Deze bevindingen onderstrepen het nut om 
EVI1 bepaling op te nemen in de diagnostiek van AML.
In hoofdstuk 6 onderzochten we de klinische, moleculaire, phenotypische en mechanistische 
verschillen tussen EVI1+ en EVI1- AML patiënten met een chromosoom 11q23 translo-
catie (t(11q23)). Bij 40% van de t(11q23) gevallen bleek dat de EVI1 expressie hoog was. 
De EVI1+ t(11q23) AML patiënten kunnen op basis van de volgende bevindingen worden 
onderscheiden van de EVI1- t(11q23) patiënten: i) ze hebben een verschillend gen expressie 
profi el, ii) de morfologie van de twee groepen is verschillend, en iii) EVI1+ t(11q23) patiënten 
hebben een ongunstiger ziektebeloop vergeleken met EVI1- t(11q23). MLL-AF9, het fusie 
gen dat ontstaat bij translocatie t(9;11), bleek na transfectie beenmerg cellen uit een muis te 
transformeren tot cellen die zich in kweek (in vitro) ongeremd vermenigvuldigen. Hierbij 
ontstonden zowel Evi1+ als Evi1- getransformeerde klonen. In de Evi1+ klonen was een kleine 
maar signifi cante populatie van onrijpe voorloper cellen detecteerbaar, de zogenaamde 
“common myeloid progenitors”. De voorloper cellen van de Evi1- klonen waren juist rijper. 
In de Evi1+ klonen, was Evi1 expressie ook aantoonbaar in de meer uitgerijpte cellen. Dit 
abnormale Evi1 expressie patroon werd ook waargenomen in cellen van AML patiënten met 
een MLL fusie gen, maar niet in gezonde rijpe beenmerg cellen van een muis of mens. Wan-
neer Evi1 werd uitgeschakeld in Evi1+ MLL-AF9 cellen, met een “knockdown” techniek, werd 
de vermenigvuldiging van de getransformeerde cellen weer teruggedrongen. EVI1 speelt dus 
een belangrijke rol in de transformatie van een subset van MLL-AF9 AMLs. 
In hoofdstuk 7 en 8 werd onderzoek gedaan naar genoom brede methylering in AML. DNA 
methylering kan leiden tot de uitschakeling van genen. In kanker cellen kan de expressie van 
zogenaamde “tumor supressor” genen door methylering worden onderdrukt. In 344 AML 
patiënten (hoofdstuk 7) werden unieke DNA methylerings profi elen gevonden waarmee 
verschillende AML subgroepen konden worden herkend. AML met bijvoorbeeld CEBPA 
mutaties of een translocatie t(8;21) vertonen ieder een eigen methylerings profi el. Er werden 
ook vijf AML patiënten groepen onderscheiden die elk een uniek methylerings profi el had-
den, maar waar geen bekende overeenkomstige cytogenetische of moleculaire afwijking kon 
worden aangetoond. Daarnaast, werd een set van 15 gemethyleerde genen onderscheiden, 
welke in combinatie een voorspellende waarde hadden op de overleving van AML. We con-
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cluderen dat DNA methylatie optreedt in een specifi eke set van genen in AML. Daarnaast 
kunnen unieke methylerings patronen worden gedefi nieerd bij verschillende AML groepen. 
Wat de rol is van deze verschillende genen bij leukemie ontwikkeling moet verder worden 
onderzocht. In hoofdstuk 8 werd aangetoond dat de EVI1 AML patiënten ook een specifi ek 
methylerings profi el hebben. Dit profi el verschilt sterk van het profi el in vergelijkbare ge-
zonde onrijpe beenmerg cellen. In de promotor regio’s van deze afwijkend gemethyleerde 
genen werden sequenties gevonden waarvan bekend is dat EVI1 daar specifi ek aan kan 
binden. In zogenaamde chromatine immunoprecipitatie experimenten werd de interactie 
van EVI1 met deze promotoren aangetoond. De complex vorming tussen EVI1 en de DNA 
methyl transferase DNMT3A die wij vervolgens aantoonden suggereert dat, EVI1 het enzym 
DNMT3A rekruteert naar deze specifi eke promotor regio’s. We veronderstellen op basis van 
deze bevindingen dat deze interactie kan leiden tot methylering van deze promotoren. 
In de afsluitende discussie in hoofdstuk 9 worden de belangrijke bevindingen uit het proef-
schrift  in een bredere context behandeld en in perspectief geplaatst. 
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and bioinformatics. Kena Figueroa, I still remember our time in the lab, always on R project 
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on the so beloved Apple computers. Your determination and enthusiasm kept me going. 
I am positive you’ll be a good PI. Th e remaining Melnick lab; Leandro Cerchietti and Rita 
Shaknovich, thanks for the laugh and good fun during Halloween in the lab.
De fellow Ph-D studenten; Saman Abbas, Su Ming Sun, Sophie Corthals, Annemarie 
Meenhuis, Karishma Palande, Elnaz Farahbakhshian, Renee Beekman, Eric Vroegindeweij, 
Simone Talens, Mathijs Sanders, Rastislav Horos, Kerim Hoorweg, allen veel succes met het 
afronden van jullie promotie. Bedankt voor de leuke tijd in het lab.
Resterende (ex-) collega’s van de 13e kan ik natuurlijk niet vergeten om te bedanken voor 
hun hulp, praatje en plezier; Menno Dijkstra en Onno Roovers; lab-dag rules, Marieke von 
Lindern, Stefan Erkeland, Mojca Jongen-Lavrencic, Annemiek Broyl en Jurgen Haanstra.
Jan van Kapel; de man van de apparatuur, van de computers en van het installeren van pro-
gramma’s, maar ook voor een praatje over mannen, vakanties, en natuurlijk weer mannen. 
Jan, ik zal je missen als mijn computer weer eens vastloopt. 
Zonder de gegevens van het HOVON-data center en de HOVON centra was een groot deel 
van het onderzoek in dit proefschrift  niet mogelijk geweest. Wim van Putten, dank voor de 
correcte up-to-date patiënteninformatie en statistische ondersteuning.
De secretariële ondersteuning op de afdeling hematologie was altijd behulpzaam en ook voor 
mijn staven snel; Ans Mannens en Monique Mes, we Skypen!, Jeanne Vlasveld en Nathalie 
van Dommelen. Egied Simons verrichtte mooi werk door van 9 Word bestanden en veel 
Powerpoint presentaties een geheel proefschrift  te maken, voor u ligt het resultaat.
Mijn twee paranimfen, Marije Havermans en Manon van der Velde, bedankt dat jullie samen 
met mij deze dag tot een succes willen maken. Marije, ik wil jouw speciaal bedanken voor al 
je werk en vele colony assays, muizen proeven, en je altijd enthousiaste humeur, ook wanneer 
er wel eens niet iets goed ging, wat zeer zelden het geval was. Je bent een slimme meid en ik 
weet zeker dat je het EVI1 onderzoek samen met Eric een stap verder zal brengen! Manon, ik 
vind je een schat! Wie had ooit kunnen denken dat we als huisgenoten, totaal vreemden van 
elkaar, 5 jaar later zulke goede vriendinnen zijn!
Na het leven als onderzoeker achter een computer in een ‘grijs’ lab, hetgeen ik zeker mis, 
werk ik nu met een leuke groep arts-assistenten in het IJsselland Ziekenhuis, ook hen wil ik 
bedanken, daar zij mij door mijn eerste periode als onwettende arts-assistent hebben heen 
gesleurd, en me veel praktische kennis hebben aangeleerd. 
Als laatste, maar niet geheel onbelangrijk, de thuisbasis; mijn ouders, Willem en Lucille, dank 
voor de steun in alle jaren, een luisterend oor en het Skypen in NYC, zonder jullie had dit 
proefschrift  er zeker niet gelegen. Mijn broer Niel, ik heb nog steeds je SPSS boek hier in de 
kast liggen, ik geloof dat ik het nu niet meer nodig heb. Hopelijk doet Feyenoord het volgend 
jaar beter. David, can you believe how we met in Austria? I am looking forward to our next 
weekend and holidays, I am sure we’ll go skiing together next time in Austria ;)
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Abbreiations 
ABBREVIATIONS
AML Acute myeloid leukemia
ALL Acute lymphoblastic leukemia
ATRA All-trans retinoic acid
BAALC  Brain and acute leukemia gene, 
cytoplasmic
BAC  Bacterial artifi cial chromosome
BMT Bone marrow transplantation
CBF Core binding factor
CBFB Core binding factor beta gene
CEBPA   CAAT/enhancer binding protein 
alpha gene
CGH  Comparative genomic hybridiza-
tion
CLP  Common lymfoid progenitors
CML  Chronic myeloid leukemia
CMP  Common myeloid progenitor
CtBP  C-terminal binding protein
CR Complete remission
DFS  Disease-free survival
DNA  Deoxyribonucleic acid
DNMT  DNA methyltransferase
EFS  Event-free survival
ERG   v-Ets erythroblastosis virus E26 
oncogene homolog gene
EVI1  Ecotrpoic viral integration site 1
FAB  French-American Britisch 
FISH  Fluorescent in situ hybridization
FLT3-ITD   FMS-like tyrosin kinase 3 (gene) 
internal tandem duplication 
FLT3-TKD  FLT3-tyrosine kinase domain
GEP Gene expression profi ling
GMP   Granulocytic myeloid progenitor
HDAC Histone deacetylase
HELP   HpaII Enriched Ligated mediate 
PCR assay
HOVON   ‘Stichting Hemato-Oncologie voor 
Volwassenen Nederland’
HSC  Hematopoetic stem cells
IDH1 Isocitrate dehydrogenase 1
KRAS   v-ki ras2 Kirsten rat sarcoma viral 
oncogene homolog
MBD3 Methyl-CpG binding domain 3
MDS1   Myeloid dysplastic syndrome gene 1
MEP   Megakaryocyte erythrocyte 
precursor
MLL   Myeloid/lymfoid or mixed lineage 
leukemia
MLL-PTD   MLL partial tandem duplication
MN1 Meningioma 1 gene
MP Methylation profi ling
MYH11 Myosin, heavy chain 11 gene
NPM1  Nuceophsomin 1
NRAS   Neuroblostoma RAS viral (v-ras) 
oncogene homolog
OS  Overall survival
PCR  Polymerase chain reaction
PR domain Prositive regulatory domain
PML Promyelocytic leukemia
Q-PCR   Quantitative real-time reverse 
transcription PCR
RARA  Retinoic acid receptor, alpha gene
RPN1 Ribophorin 1 gene
RNA Ribonucleic acid
RFS  Relapse-free survival
SKY Spectral karyotyping
SNP  Single nucleotide polymorphism
SMAD3  Similar mothers against decapen-
taplegic homolog 3 gene
SUV39H1  Histone H3 lysine 9-specifi c histone 
methyltransferases H1
WBC  White blood cell count
WT1 Wilm’s tumor 1
WHO World heath organization
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Figure 1. Distribution of cytogenetic characteristics and survival according to 3q aberrant AML groups. 
Distribution of 3q abnormalities (all ages, panel A) and overall survival (only 15-60 years of age, panel B) of 3q 
abnormal AML classifi ed as inv(3)/t(3;3) (group A), balanced t(3q26) (group B), balanced t(3q21) (group C), and 
remaining 3q abnormalities (group D). A corresponding log-rank P value per comparison to the non-3q cytogeneti-
cally abnormal (CA) reference group is shown.remaining 3q abnormalities (group D). A corresponding log-rank P 
value per comparison to the non-3q cytogenetically abnormal (CA) reference group is shown.
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Figure 4. Fluorescent in situ hybridisation (FISH) of chromosome 3q26 and 3q21 loci reveal hidden 3q26 aber-
rations.
BAC clone localization from centromere (Cen) to telomere (Tel) (A). A metaphase from EVI1+ patient #28 revealed 
a cryptic inv(3)(q21q26) (inv3) and a normal chromosome 3 (nor3) using EVI1 (RP11-82C9) and MDS1 (RP11-
141C22) (B) and RPN1 (RP11-456K4) BAC clones (C). 
C
olor Section
231
Chapter 4
 
70
75
80
85
90
95
100
221884_at
226420_at
Cluster 1Cluster 2
2sdmedian
expression
-2sd
Figure 1. Hierarchical clustering using the gene expression of the 3 probe sets representing EVI1 in 228 pediatric 
AML samples reveals a subclustering of 24 EVI1+ cases. 
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Figure 1. Distribution of cytogenetic abnormalities among EVI1+ AML (n=148). 
*Occurring in a non-complex karyotype and not associated with inv(3)/t(3;3). **Among the EVI1+ with a normal 
karyotype, 66% of this group carried the NPM1wt/FLT3-ITDneg/CEBPAwt genotype
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Chapter 7
Figure 1. DNA methylation segregates AML patients into 16 groups. 
Heatmap representation of a correlation matrix in which each patient’s DNA methylation profi le is correlated with 
that of the other patients in the dataset. Patients are ordered according to the unsupervised analysis (hierarchical 
clustering) results, so that highly correlated patients are located next to each other. Parallel bars on the right of the 
heatmap have been used to indicate the principal cytogenetic and molecular fi ndings for each patient. Cluster mem-
bership and cluster feature summaries are described on the left  of the heatmap.  
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Figure 2. Distinct DNA methylation signatures defi ne each of the 16 clusters. 
Heatmap representation of the aberrant DNA methylation signatures of specifi c clusters compared to a cohort of 
normal CD34+ hematopoietic cells obtained from healthy donors. Each row of the heatmap represents one probe 
set of the HELP array, and each column represents an AML patient (denoted by light brown bars) or a healthy donor 
(denoted by dark brown bars). (A) DNA methylation signatures for clusters with recurrent translocations, (B) DNA 
methylation signatures associated with abnormalities of CEBPA, (C) DNA methylation signatures for clusters pre-
senting NPM1 mutations, (D) DNA methylation signatures for the 5 epigenetically defi ned clusters. 
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Figure 3. DNA methylation captures clinically signifi cant diff erences among AML patients. 
(A) Left : Kaplan-Meier curves for overall survival for the favorable risk clusters 1 (inv(16)) and 4 (CEBPA-dm), 
and the novel epigenetically defi ned clusters. For plotting simplicity curves for clusters 3 (t(8;21)), cluster 5 and 
cluster 15 were not included in the plot. Figure S3 shows a Kaplan-Meier plot including all the clusters in the overall 
survival analysis.  Right: Kaplan-Meier curves for overall survival for the favorable risk clusters 1 (inv(16)) and 4 
(CEBPA-dm), and the NPM1 clusters. For plotting simplicity curves for clusters 3 (t(8;21)), and NPM1 cluster 14 
were not included in the plot. Figure S3 shows a Kaplan-Meier plot including all the clusters in the overall survival 
analysis. (B) Kaplan-Meier curves for overall survival (left ) for the fi ve novel clusters. On the right: Table summa-
rizing the multivariate Cox proportional hazards regression model, using cluster 1 (inv(16)) as the referent cluster. 
Additional Kaplan Meier plots are shown in Figure S3. 
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Figure 5. 45 genes are consistently aberrantly methylated in AML. 
(A) Heatmap representation of the common 45-gene signature consistently aberrantly methylated in AML. Each row 
represents a probe set from the HELP microarray and each column represents a sample. (B) Boxplots of gene expres-
sion levels in 4 representative genes from the 45-gene common epigenetic signature demonstrating downregulation 
of expression in the AML samples compared to normal CD34+ cells  Th e list of genes is shown in Table S4. 
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Figure 1. EVI1 acute myeloid leukemia patients (EVI1 AMLs) have a unique genome wide methylation profi le 
compared to CD34+ normal bone marrow samples (CD34+ NBM). 
(A) Th e dendrogram represents a hierarchical clustering (i) and a principal component analysis (ii) in 8 CD34+ 
NBM blasts and 26 EVI1 AMLs. (B) Th e volcano plot shows the methylation diff erence comparing the 26 EVI1 
AMLs to 8 CD34+ NBM samples with corresponding moderated T-test P-value. Probe sets signifi cantly hypermethyl-
ated (P<0.001 and methylation diff erence less than -1.5) are shown in red, probe sets signifi cantly hypomethylated 
(P<0.001 and methylation diff erence larger than 1.5) are shown in green. Signifi cant probe sets that did not have an 
absolute methylation diff erence larger than 1.5 are depicted in blue. (C) Th e heatmap shows the methylation levels 
(Log (HpaII/MspI)) of diff erentially methylated genes (rows) in EVI1 AMLs and CD34+ NBM cases (columns). (D) 
Th e histograms show the percentages of genes containing (green) CG clusters and CpG islands and those not overlap
C
olor Section
237
1st Znf Domain 2nd Znf Domain
-COOHNH2-
TGACAAGATA AGATAA
A
Hypermethylated
genes
Hypomethylated
genes
91
170
87
42
10
15
45
6
Differentially methylated genes
50
179
149
C
-20 20Over-representationUnder-representation
B
D
EVI1-
MOLM13
EVI1 specific hypermethylated genes 
Anti-EVI1 IgG
EVI1+ 
SB1690CB
0.00%
0.10%
0.20%
0.30%
0.40%
0.50%
FAM83b CRHBP VPREB3 IL11RA
0.00%
0.10%
S
ig
na
l r
el
at
iv
e 
to
 in
pu
t (
%
)
Anti-EVI1 IgG
Figure 2. EVI1 binding sites are over-represented in the hypermethylated promoter regions of EVI1 AMLs and 
EVI1 binds these hypermethylated promoters in vivo. 
(A) Motif analysis of the in EVI1 AML diff erentially methylated genes showed a signifi cant overrepresentation (yel-
low in the heat map color key) of three 7 bp motifs. Per bar each 7 bp optimized motif is shown. Th e unlined 
sequences overlap with the fi rst or second EVI1 binding domain. Th e number of genes that harbored the representa-
tive motifs in their promoter sequences are depicted per bar. (B) Further analysis of the hypermethylated and hypo-
methylated genes reveals two overrepresented motifs in the promoter regions of the hypermethylated genes and one 
overrepresented in hypomethylated genes. (C) A schematic representation of the EVI1 nuclear zinc-fi nger protein, 
with the binding sequence of the fi rst and second EVI1 zinc fi nger domains. Th e overlapping motifs over-represented 
in hypermethylated genes are underlined in respectively blue and green. (D) Quantitative PCR of chromatin immu-
noprecipitation in the EVI1 positive (EVI1+) SB1960CB cell line and the EVI1 negative (EVI1-) MOLM13 cell line 
using EVI1 and IgG antibody. Percentage of amount of input material is shown. Th e mean and standard deviation of 
three independent experiments is shown.
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Figure 3. EVI1 interacts with DNMT3A.
(A) Western blot analysis using anti-FLAG antibodies shows the input of the immunoprecipitation of transfected 
293T cells and the pulldown using anti-HA. (B) Confocal microscopy of 293T cells transfected with HA-tagged EVI1 
(green) and FLAG-tagged DNMT3A and -3B (red). (C) Western blot for EVI1 on lysates from SB1960CB cell-line. 
Th e left  lane shows the input band; the second and third lane show EVI1 staining following immunoprecipitation 
with IgG control (second lane) or anti-DNMT3 (third lane). 
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Figure 4. Unsupervised analysis identifi ed two epigenetically distinct EVI1 AML subgroups correlating with 
EVI1 relative expression. 
(A) Unsupervised hierarchical clustering with Pearson’s correlation using Ward’s method revealed two EVI1 sub-
clusters i.e., A and B. Th e cytogenetic characteristics are shown per patient; chromosome 3q26 abnormalities (red), 
monosomy 7 or deletion 7q (-7/7q-) (blue) and 11q23 rearrangements (grey). Th e percentages of each characteristic 
are shown per cluster. (B) Median EVI1 relative expression levels and 2SD are shown per subcluster. P-value was cal-
culated using a moderated T-test. (C) Th e volcano plot shows the methylation diff erence of all probe sets (n=25,626) 
(x-axis) comparing the methylation levels of cases in subcluster A with the cases in subcluster B with corresponding 
P-value (-log10 P-value moderated T-test) on the y-axis. (D) Th e heatmap shows the 122 probe sets (110 unique genes) 
diff erentially methylated in subcuster B, when both cluster were compared to each other using a moderated T-test 
(P<0.001 and absolute methylation diff erence >1.5). All genes are hypermethylated in EVI1 AMLs from subcluster B.
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